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The aim of this thesis was to improve the detection method of electrochemical solution-
based DNA diagnostics. Electrochemical solution-based detection lacks in sensitivity 
compared to surface-immobilised techniques or fluorescent probes, however benefits from 
cheaper equipment and materials, and lower levels of user-input required. Improvements 
in electrochemical signal upon detection of DNA would allow for improved sensitivity of the 
probes and therefore more useful diagnostic devices. To achieve this, it was hypothesised 
that the incorporation of several ferrocene labels onto oligodeoxynucleotides could offer 
improved electrochemical performance. 
The synthesis of a library of ferrocene-based nucleotides is discussed in Chapter 2, with a 
view to increasing the possible increase in electrochemical signal analysed via differential 
pulse voltammetry that can be achieved via the introduction of multiple ferrocene units on 
a single strand. This was achieved through the conjugation of ferrocene onto 2’-
deoxyuridine utilising the copper-catalysed azide-alkyne cycloaddition, followed by solid 
phase synthesis of oligonucleotides to allow the introduction of up to five ferrocenes on a 
single oligonucleotide strand. The digestion of two DNA sequences was studied with S1 
nuclease, showing an increase in signal is possible in a single-stranded assay. 
Chapter 3 expands on this methodology, next synthesising ferrocene labels with increased 
sensitivity vs.  those developed in Chapter 2. This was achieved through the introduction of 
two ferrocenes onto a single nucleotide, followed by incorporation into a clinically relevant 
DNA sequence, allowing the synthesis of oligonucleotides containing ten ferrocene units. 
The probes were again treated with S1 nuclease displaying increased sensitivity measured 
via differential pulse voltammetry over the traditional 5’-labelling method, as well as the 
probes developed in the previous Chapter. 
Chapter 4 details the incorporation of the probes previously developed into diagnostic 
assays, using both T7 exonuclease and lambda exonuclease to digest the novel probes. The 
internal labelling strategy was shown to be active towards T7 exonuclease digestion, 
however this did not offer improved digestion properties compared to traditional methods. 
The use of multiplex detection system was suitable for the detection of two clinically 
relevant DNA sequences simultaneously, while also offering insight into the mechanistic 
properties of T7 exonuclease.  The incorporation of internal labels enabled the use of 











B generic nucleobase 
Boc tert-butyloxycarbonyl 
bpy 2,2'-bipyridyl 
BSA bovine serum albumin 
Bz benzoyl 
cDNA complementary DNA 
Cp cyclopentadiene or cyclopentadienyl 
Cp* 1,2,3,4,5-pentamethylcyclopentadiene 
or 1,2,3,4,5-pentamethylcyclopentadienyl 
CPG controlled pore glass 
CT Chlamydia trachomatis 
CuAAC copper-catalysed azide-alkyne cycloaddition 
CV cyclic voltammetry 
dA 2'-deoxyadenosine 







DMF-DMA dimethylformamide dimethyl acetal 
DMTr 4,4'-dimethoxytrityl 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DPPA diphenylphosphoryl azide 
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FRET Förster resonance energy transfer 
h hours 
HIV human immunodeficiency virus 
HPLC high performance liquid chromatography 
x 
 
HRMS high resolution mass spectrometry 
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i-Pr iso-propyl 
IR infra-red 
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LOD limit of detection 
M Molar 
MB methylene blue 
MBG molecular biology grade 
m-CPBA 3-chloroperoxybenzoic acid 
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MP melting point 
Ms methanesulfonyl 
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NAAT nucleic acid amplification test 
NBS N-bromosuccinimide 
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NG Neisseria gonorrhoeae 
NMR nuclear magnetic resonance 
NTC no template control 
ODN oligodeoxynucleotide 
PCR polymerase chain reaction 
Ph phenyl 
PNA peptide nucleic acid 
POC point-of-care 
POCT point-of-care test 
p-TSA para-toluenesulfonic acid 
qPRC quantitative polymerase chain reaction 
RNA ribonucleic acid 
rt room temperature 
S1 S1 nuclease 
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SNP single nucleotide polymorphism 
ssDNA single-stranded deoxyribonucleic acid 
ST synthetic target 
STI sexually transmitted infection 
T7 T7 exonuclease 
TAMRA 5-carboxytetramethylrhodamine 
TBAB tetrabutylammonium bromide 
TBAF tetrabutylammonium fluoride 
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TLC thin layer chromatography 
















Sensing, in its broadest definition, is defined as the detection of an analyte to give a signal 
or response to its presence. The analyte varies from physical properties to chemical or 
biological substances, and the signal can be an optical, electrical, or physicochemical 
readout. Sensors are used in almost every aspect of modern life – computers rely entirely 
on them, as well as many medical devices being heavily reliant. 
A biosensor is a device that uses biological components in combination with a label which 
gives a physicochemical readout. Biosensors have been commercialised to allow for the 
detection of chemical weapons and explosives,1,2 waste water analysis,3 glucose sensing in 
diabetic patients,4 and bacterial and viral analysis5, amongst many other uses. 
Pathogen detection is important in many industries, including food production, clinical 
diagnosis, environmental analysis, and defence, amongst others. For public health, the 
detection focusses on food, water treatment (both supply and waste streams), and clinical 
settings for direct impact on the wider health of the population. 
1.1. Pathogen Detection Methods 
Conventional techniques for pathogen detection include microscopy, culture, and serology.6 
Culture remains the gold standard for the diagnosis of many pathogens. When conducted 
correctly it gives unequivocal results, however the growth of the desired pathogens are 
subject to potential failures and cross contamination. For some microorganisms, culture is 
not a suitable option due to either the difficulty or speed at which the organisms grow, or 
the associated danger with growing the organisms (e.g. Treponema pallidum, HIV, 
Mycobacterium tuberculosis, Coxiella burnetii).7 Microscopy is operationally simple, 
however lacks sensitivity and results could be interpreted subjectively. The development of 
molecular recognition techniques allowed for the development of equally as reliable, but 
quicker and simpler to conduct methods of diagnosis, which will be detailed herein. 
A biosensor relies on biomolecular recognition, and although the binding event of a target 
such as an antibody or protein is highly specific, they normally do not directly result in a 
measurable output without chemical modification. Biosensors relying directly on binding 
biological materials therefore usually require separation steps to ensure accurate readouts. 
Such techniques include Western blots and enzyme-linked immunosorbent assays (ELISA). 
1.1.1. Immunoassays 
ELISAs remain one of the most extensively used diagnosis methods. Its success draws from 
the specificity of antibodies, whereby the antigens are signalled by enzymatically labelled 
antibodies.8  The most common form for the diagnosis of pathogens is a “sandwich” ELISA 
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(Figure 1.1), which captures the antigen between two antibodies, one of which is 
immobilised onto a surface. The second antibody is labelled with an enzyme, commonly 
horseradish peroxidase or alkaline phosphatase, which then reacts with the substrate to 
produce a signal. Any non-specifically bound materials are washed away, so unless the 
target is present, the enzyme will not turnover any signal. Extensive research into the field 
of ELISAs has led to the development of colourimetric,9 fluorescent,10 and electrochemical 
versions.11 ELISAs have also been used outside the detection of pathogenic materials, most 
famously in lateral-flow assays for the detection of the hormone human chorionic 
gonadotropin for pregnancy tests. ELISAs can be used as standalone biosensors, or in 
combination with other molecular techniques such as PCR or signal amplification methods, 
leading to high selectivity and specificity for a range of analytes. 
 
Figure 1.1 Capture “sandwich” ELISA 
Western blots are a similar immunoassay, whereby proteins in a sample are separated by 
gel electrophoresis, then incubated with a labelled antibody. The label then reacts with a 
substrate to produce a signal (usually fluorescent or colourimetric) which can be detected 
by a device. Western blots are considered by many to be the gold standard for the detection 
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of HIV.12 Although highly selective and specific, ELISAs and Western blots are rarely found 
outside of clinical laboratories, and as such, HIV and pregnancy tests are the only ELISAs to 
have been widely implemented in decentralised settings. 
The only other widely implemented biosensor for medical applications is the home blood 
glucose monitor, used by millions of diabetics worldwide. The device uses the enzyme 
glucose oxidase, which catalyses the reaction of glucose into hydrogen peroxide, which is 
then oxidised at the electrode surface (Scheme 1.1). This produces an electric current which 
can be measured and is proportional to the serum glucose concentration, therefore allowing 
the user to quantify their blood glucose level. Home glucose monitors are still plagued by 
inconsistencies in results, with the International Organisation for Standardization (ISO) 
allowing for large margins of error compared to laboratory results.13 ISO ensures 
commercial equipment are standardised across a given industry, updating its database to 
mirror chemical, biological, and technical advances. 
 
Scheme 1.1 Schematic of glucose detection in a home glucose monitor 
These three techniques are all enzyme-based, exploiting the high specificity of the active 
sites. A major drawback of antigen-based immunoassays and non-amplification tests for 
pathogen detection is the window period associated with infection. For example, HIV can go 
undetected in a newly infected patient for up to three months, while during this window 
period the patient’s immune system is developing a detectable level of antibodies. Until this 
point, the pathogen cannot be detected, therefore leading to many false negatives. 
1.1.2. Nucleic Acid Amplification Tests 
Nucleic acid amplification tests (NAATs) bypass the window period by amplifying low levels 
of pathogenic RNA or DNA to a detectable level, thus the pathogen can be diagnosed as soon 
as, or very soon after, the initial infection has occurred. NAATs are one of the most reliable 
and widespread techniques available for biomolecular diagnostics due to their reliability 




Scheme 1.2 Enzymatic amplification of nucleic acid 
NAATs are commonly used for the detection of bacteria in both clinical and agricultural 
settings, with a range of research and commercial tests available for common foodborne 
infections such as E. coli, and sexually transmitted infections including C. trachomatis and N. 
gonorrhoeae.16–19  
NAATs on clinical samples are conducted via three main steps: extraction, amplification, and 
detection. A sample is first collected and the target DNA must be isolated. For whole blood 
samples, this usually requires a purification technique, whereby the bacteria are separated 
from the rest of the complex matrix. For urine and swabs, this is a simple lysis, usually 
through salt/water treatment. By varying the osmotic pressure, the cells are forced to swell 
and burst, releasing genetic material. As bacterial DNA is not enclosed inside a nucleus, the 
DNA is released directly into the lysate. This DNA is then available to be amplified via 
amplification techniques. 
The most well-known amplification technique is the polymerase chain reaction (PCR), 
which uses DNA polymerases to extend DNA primers. Other nucleic acid amplification 
techniques have been developed, but none of the isothermal techniques have reached the 
same level of success as the polymerase chain reaction.20 PCR was developed in the 1980s 
by Mullis et al. and used to identify sickle cell anaemia.21 PCR has since been extended for 
use in DNA sequencing, gene analysis, disease diagnosis, and pathogen detection. 
In a standard PCR cycle (Scheme 1.3), double-stranded DNA (dsDNA) is first heated and 
denatured to give two strands of complementary single-stranded DNA (ssDNA). Upon 
cooling, short primers with complementary sequences anneal to the beginning of the target 
sequence, indicating the section of DNA to be amplified. Using the ssDNA as a template, a 
DNA polymerase then extends the two existing single strands via the incorporation of 
deoxynucleoside triphosphates (dNTPs), with the polymerase catalysing the nucleophilic 
attack of the existing 3’-hydroxyl of the DNA primer into the α-phosphate of the 
complementary dNTPs, yielding two new copies of dsDNA. The thermal cycling is repeated 
with the new dsDNA for the required number of cycles, such that each cycle effectively 
doubles the number of copies present (assuming 100% efficiency). The amplicons are 
5 
 
detected via gel electrophoresis, or are treated with labelled DNA probes to allow for 
specific detection of the amplicons. 
 
Scheme 1.3 Polymerase chain reaction cycle 
In the early days after the discovery of PCR, the experiments were time intensive and 
labourious. The enzymes first used were not stable upon heating which is an essential step 
to denature the DNA. This required the user to manually transfer fresh enzymes to the 
sample after each cycle, however the discovery of Taq polymerase, a thermostable DNA 
polymerase, led to the development of quicker and more reliable PCR methods.22 When first 
invented, PCRs were performed using hot and cold water baths, which the user would have 
to move the PCR tubes between. Since then, driven by the discovery of Taq, thermal cycling 




Quantitation of DNA can be achieved through real time (quantitative) PCR (qPCR). This was 
first developed using 32P labelled primers,23 and later simplified with the use of fluorescent 
probes such as DNA intercalators or oligonucleotide probes.24 In this variation, a second, 
fluorescent probe is added to the solution containing a fluorophore-quencher tethered to 
the same probe (Scheme 1.4).25 Upon extension of the DNA primers, the fluorophore is 
released into solution due to the dual polymerase and exonuclease action of the enzyme 
used. The fluorescence is no longer quenched, thus resulting in a switch-on signal. qPCR has 
been used for applications where the amount of DNA is indicative of a genetic condition, or 
the success of treatment via gene expression (e.g. cancer diagnostics).26,27 It has also been 
used to quantify bacteria such as C. diff and MRSA, and bacteria responsible for infections 
such as meningitis, pneumonia, and anthrax.28 
 
Scheme 1.4 Real-time quantitative PCR cycle 
Amplification tests allow for sensitive analysis of complex matrices. Coupled with modern 
detection methods, nucleic acid analysis allows for multiplex detection of biologically 
relevant samples with high precision and accuracy. Detection methods have advanced since 




1.2. Nucleic Acid Labelling Strategies 
Biomolecular recognition events (e.g. duplex formation) do not usually result in a 
measurable change in physicochemical properties. As such, a range of methods utilising 
different labelled probes have been developed to enable the detection of the recognition 
event. Detection and qualitative analysis of DNA has developed at a tremendous rate since 
the elucidation of the structure of DNA in 1953.29 The structure of DNA is formed from three 
parts, the nucleobase, ribose, and phosphate backbone, together forming a single nucleotide 
unit. The phosphodiester linkages chemically bond single nucleotides to each other, 
allowing long fragments of DNA to be created. Watson-Crick base pairing (Figure 1.2) allows 
formation of a double helix, whereby adenine (A) pairs with thymine (T), and guanine (G) 
pairs with cytosine (C) via H-bond acceptors and donors located on the nucleobases, as well 
as van de Waals forces and π- π interactions.30 
 
Figure 1.2 Watson-Crick base pairing of canonical nucleobases 
The formation of the double helix of dsDNA creates two grooves, namely the major and 
minor, indicating the smaller and larger spaces between the phosphate backbone formed in 
the helical structure. The two strands of DNA are antiparallel, such that one runs 5’-3’ while 
its reverse complement runs 3’-5’ (Figure 1.3). 
 
Figure 1.3 DNA numbering nomenclature 
Nucleases are enzymes that catalyse the hydrolysis of the phosphodiester backbone to yield 
a hydroxylated and a phosphorylated section. Dependent on the specific nuclease, they can 
act in either a 5’-3’- direction or a 3’-5’- direction. Exonucleases cleave from the terminus of 
the oligonucleotide strand, whereas endonucleases cleave at internal phosphate groups. 
Most nucleases have a very specific set of conditions under which they will cleave DNA, with 
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selectivity for single or double stranded, DNA or RNA, restriction sites, and phosphorylation 
determining whether an enzyme will digest target DNA.2 
The knowledge formed a basis of understanding of how DNA interacts with itself, and as 
such allowed for the intelligent design of DNA probes and sensors. Presently, biochemists 
have a range of labelling strategies available for detection methods, each with their benefits 
and drawbacks. These external labels are based on a range of functionality and can be 
chosen to suit the end-user’s specific requirements. As such, labelling strategies of nucleic 
acids has drawn much attention, such that the selective introduction of labels can now be 
achieved with relative ease. 
Oligonucleotide synthesis is common practice with many companies set up solely for the 
production of oligonucleotides. These oligonucleotides can range from small DNA primers 
only a few base pairs long, to sequences containing hundreds of nucleotides. As well as 
making simple oligonucleotides based on only the canonical bases, many manufacturers 
offer custom oligonucleotides which can be functionalised in a range of ways. After gene 
sequencing, oligonucleotides based on the target sequence can be synthesised to allow for 
detection.  
Oligonucleotides are typically synthesised via the phosphoramidite method, allowing for 
the inexpensive synthesis of nucleic acids with defined sequences. Solid-phase synthesis is 
not limited to 2’-deoxynucleosides, as this method can be used for the synthesis of RNA, or 
modified nucleic acids such as locked, branched, or peptide nucleic acids. 
In the phosphoramidite method, first developed in the 1980s by Caruthers et al., the desired 
oligonucleotide is built from protected nucleoside monomers.31 The 5’- hydroxyl position is 
protected with the acid-labile 4,4’-O-dimethoxytrityl (DMTr) protecting group to prevent 
polymerisation of the oligonucleotide, and the 3’-OH is activated through the use of 
nucleoside phosphoramidites. Solid phase synthesis of oligonucleotides is usually 
performed from the 3’-end to the 5’-end. The first stage of oligonucleotide synthesis is 
attaching the first base onto the solid-support, typically controlled pore glass (CPG), after 
which point the desired sequence can be built through a series of couplings, oxidations and 
washes (Scheme 1.5). The first nucleobase is subjected to trityl deprotection (a), through 
treatment of the solid-supported base with acid, (typically dichloroacetic acid) to yield the 
nucleophilic 3’-OH. The next base is activated through treatment of the phosphoramidite 
with a tetrazole catalyst, displacing DIPEA, creating a more electrophilic site for the 3’-OH 
to attack (bi).  
The growing oligonucleotide is treated with acetic anhydride to cap any unreacted 5’-OH 
residues (bii), followed by oxidation of the phosphite to the phosphate with elemental 
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iodine (biii), and the nucleic acid is again subjected to the cycle until the desired sequence 
is achieved. The nucleic acid is then cleaved from the solid-support and any protecting 
groups present (e.g. amide protecting groups of exocyclic amines, or cyanoethylphosphate 
groups) are cleaved through treatment with concentrated ammonia (c). The crude 
oligonucleotides are then purified via HPLC to give the desired oligonucleotide either as a 
lyophilised powder or as an aqueous solution. Both are stable and can be stored at –20 °C 
for extended periods of time without decomposition. 
 




Broadly speaking, there are four ways in which to label oligonucleotides. These are end, 
sugar, phosphate, or base labelling (Figure 1.4). 
 
Figure 1.4 Modification sites of oligonucleotides 
Synthesis of labelled units is generally conducted via the phosphoramidite method, which 
involves protection and activation of the label as the DMTr phosphoramidite (Scheme 1.6).32 
This is achieved through treatment of the nucleoside with 4,4’-dimethoxytrityl chloride (1) 
in pyridine to first yield the 5’-protected nucleoside, followed by activation of the 3’-OH 
residue with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (2).  
 
Scheme 1.6 General method for conversion of labelled nucleosides to the DMTr phosphoramidite 
The location of introducing the label must be considered, as for the label to have potential 
as a successful probe, it must not impair the chemical or biological function of DNA. As such, 
labelling must not interfere too much with electronics to continue to allow for base pairing 
and π-π stacking, or change the shape of the unit to not obstruct enzymatic activity or α-
helix formation. Non-canonical bases are more diverse in size and shape, however sacrifice 
base-pairing for improved fluorescent properties. External fluorophores or redox active 
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moieties allows for fine-tuning of the measured property, without confinements of base-
pairing ability, which would significantly affect the properties of any label. 
1.2.1. End-capping 
End-capping is the simplest method in which to label oligonucleotides. Traditional 
oligonucleotide synthesis occurs in the 3’- to 5’- direction, and as such, when the final base 
is installed, the oligonucleotide can simply be treated with a phosphoramidite of the desired 
label (Scheme 1.7).33 This caps the oligonucleotide, which is then subjected to oxidation to 
give the P(V) species, and this can then be cleaved from the support and purified via the 
normal process. 3’-labelling can also occur in this manner if the oligonucleotide is bound to 
the solid-support in the opposite direction. 
 
Scheme 1.7 5'-end capping of oligonucleotides 
While offering a reliable method to synthesise custom sequences, the incorporation of 
custom labels can be prohibitively expensive, as oligonucleotide manufacturers often 
require minimum quantity orders. In addition, the introduced label must not include any 
acidic or enolisable protons due to the treatment of the oligonucleotide with high 
concentrations of basic reagents, which would cause probe decomposition, and can limit the 
generality of the labels. 
Labels can instead be incorporated enzymatically, with the introduction of 5’- and 3’- labels 
being possible with the use of ligases or kinases.34 It is not always a practical solution, 
however, as setting up protocols for enzymatic incorporation of labels can be difficult and 
expensive, particularly if conducted on small scales. Depending on the final application of 
the probes they may also be required to undergo further purification using methods such 
as membrane filtration, spin column chromatography, or HPLC, further adding to costs. 
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3’-labelling can be achieved by treatment of the desired oligonucleotide sequence with 
labelled dNTPs and enzymes such as Klenow or T4 DNA polymerase.35,36 T4 DNA 
polymerase synthesises DNA in the 5’-3’ direction and also has 3’-5’ exonuclease activity, 
which is exploited to allow for synthesis of labelled probes. The enzyme will cleave bases 
from the 3’-end, then replace with dNTPs containing the desired labels. Care must be taken 
to avoid long reactions because the enzyme will revert to exonuclease activity and degrade 
the newly labelled DNA after all dNTPs have been exhausted. T4 polymerase has found 
applications in radiolabelling, sequencing, and more recently, electrochemical detection.37,38 
The enzyme poly(A) polymerase will add a single adenosine unit, which can then undergo 
cleavage to leave a 32P labelled phosphate residue at the 3’- end for use as a radiolabel.39 
This can also be applied to RNA labelling with transferase and dNTPs, which only extend in 
the presence of 3’-OH, and as such can be used to incorporate a single labelled base.40–42 
Modification at the 5’-end of DNA can also be achieved through enzymatic methods. T4 
polynucleotide kinase can be employed which undergoes a forward and exchange reaction, 
adding 32P to 5’-OH DNA. This methodology was used to allow T4 polynucleotide kinase to 
label substrates to give non-nucleosidic bases at the 5’-end.43 
Chemical labelling can also be achieved with the diimide coupling agent N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (Scheme 1.8).44 This allows a 
wide range of labels to be incorporated and does not rely on potentially sensitive enzymatic 
conditions, however labelled oligonucleotides require purification after the reactions to 
ensure only desired probe is isolated. 
 
Scheme 1.8 Carbodiimide coupling of phosphates 
1.2.2. Phosphate modification 
Radiolabelling was the first instance of introducing labels directly onto DNA probes and was 
achieved through phosphate modification. Other phosphate modifications have since been 
developed to introduce electrochemical and fluorescent labels directly onto the phosphate 
backbone. Labelling of phosphate linkages can lead to unpredictable and undesirable 
biological properties due to diastereomer formation.45 In an unmodified oligonucleotide, 
the two non-bridging oxygens are resonance stabilised leading to equal negative charges, 
however introduction of substituents in the non-bridging position leads to the formation of 
a new stereogenic centre and a pair of diastereomers, which can be difficult to separate. The 
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unnaturally shaped diastereomer may lead to significant destabilisation in the duplex due 
to the change in angle of Watson-Crick base pairing and as such, phosphorous-modified 
oligonucleotides are generally more stable to nucleases, and have found applications in the 
modification of therapeutic agents.46 
Phosphate modification of ODNs through the introduction of alkyne moieties allows for the 
highly regioselective copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction to 
occur. This strategy was simplified by Krishna and Caruthers, who described the 
development of a new phosphoramidite building block with the replacement of one of the 
non-bridging oxygens with ethyne (Scheme 1.9).47 This was then used to create ODNs, and 
the alkyne was functionalised during solid-phase synthesis via CuAAC chemistry, utilising 
the copper (II) sulfate and sodium ascorbate (NaAsc) catalyst system. It was shown that the 
Tm of duplexes formed were higher than those with standard linkers, and the duplex was 
significantly more stable to digestion by exonuclease enzymes. 
 
Scheme 1.9 Ethynyl modified phosphates for phosphate modification 
Duplex destabilisation from phosphate modification can be counteracted by using α-
anomeric ribose. Chaix et al. described the use of the modified α-oligonucleotides (Scheme 
1.10), allowing for substitution on the phosphate without causing destabilisation of the 
duplex.48 
 
Scheme 1.10 α-oligonucleotides for improved dsDNA stability 
1.2.3. Sugar modification 
The ribose moiety is another position in which to label DNA. Incorporation of labels in the 
2’-position of ribose has been used extensively to avoid substitution of the nucleobase. 
Modification of the ribose moiety is usually carried out on gram-scale, synthesising the 5’-
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O-DMTr phosphoramidites and incorporating the modified units during solid-phase 
synthesis. This methodology has been followed to successfully introduce fluorescent and 
electrochemical labels.49 Introduction of a label directly to the ribose moiety usually occurs 
in the 2’- position to allow for standard 5’- 3’- connectivity in an oligonucleotide (Scheme 
1.11).  
 
Scheme 1.11 General 2’-modification of ribonucleosides 
The reaction of unprotected ribose allows for deprotonation and subsequent treatment 
with an appropriate electrophile. Regioselectivity, however, is far from ideal and 
substitution reactions tend to give ratios of 2:1 in favour of the 2’-product. 
 The conjugation of ferrocenyl alkyl bromide 4 to adenosine 3 via nucleophilic substitution 
was achieved by Meade et al. (Scheme 1.12),50 and although the reaction requires separation 
from the regioisomeric by-product, it offers a method to functionalise ribose without the 
need for further protecting group strategies. 
 
Scheme 1.12 2’-O- electrochemical substitution of ribose 
Yamana et al. first introduced fluorescent labels into the ribose moiety of nucleosides.51 
These were incorporated into the 2’-position of ribose through substitution of 
dibutylstannylenes with alkyl bromides (Scheme 1.13). It was shown that the introduction 
of the anthraquinone (AQ) unit resulted in improved stability of the oligonucleotide upon 





Scheme 1.13 Introduction of fluorophore via nucleophilic substitution 
Simultaneous protection of the 5’- and 3’- hydroxyls was achieved with siloxane protecting 
groups (Scheme 1.14), which allowed Usman and co-workers to synthesise 2’-modified 
uridines for incorporation into ribozymes.52 Ribozymes are often unstable in biological 
media due to the widespread existence of RNases. Modification at the 2’-position allowed 
for the synthesis of catalytically active RNA for use as ribozymes, with increased resistance 
to nuclease activity. This was achieved through the substitution of 2’-hydroxyls via 
deoxygenative allylation reactions.  
 
Scheme 1.14 5’,3’-O protecting strategy 
Amide couplings remove regioselectivity issues if there is an amine residue in the 2’- 
position instead of the hydroxyl. Amide couplings have been used to introduce fluorophores 





Scheme 1.15 Sugar labelling through amide coupling 
1.2.4. Non-nucleosidic units 
Non-nucleosidic units have also gathered much attention, which can either be achieved 
through replacing a single nucleotide such that there is a gap in the bases when 
oligonucleotides are synthesised, or by replacing the ribose with a label, onto which the base 
is conjugated (Figure 1.5). 
 
Figure 1.5 Non-nucleosidic labelling strategies 
Pyrene has been extensively studied as a nucleoside mimic, as it readily forms fluorescent 
excimers. Langenegger and Häner developed non-nucleosidic pyrene units,55,56 where the 
pyrene was introduced as a non-nucleosidic unit, replacing both the base and the ribose 
(Scheme 1.16) via the synthesis of non-nucleosidic DMTr phosphoramidite 5. The single-
stranded DNA had a single fluorescence emission, however upon duplex formation and 
intramolecular π-π stacking with a second pyrenyl unit, the pyrenes exhibited a second 
fluorescence emission. 
 
Scheme 1.16 Interstrand stacking of non-nucleosidic pyrene units 
Serinol has been employed as a ribose mimic.57 The 1,3-diol mimics the 5’,3’- hydroxyl 
linkage in ribose and can be used to enable substitution of a single nucleobase.  The units 
17 
 
are synthesised via amide couplings to install the serinol unit, which are then protected and 
activated using standard DMTr phosphoramidite chemistry to incorporate in solid-phase 
ODN synthesis. Around the same time, Asanuma et al.58 and Tucker et al.59 developed 
serinol-modified DMTr phosphoramidites 6 and 7 for incorporation into oligonucleotides 
to detect for deletion mutations and SNPs (Figure 1.6). The introduction of DNA 
intercalators allowed for the detection of mutations via structural changes induced in the 
oligonucleotide, which cause changes in the emission spectra, attributed to a change in base 
pairing of the oligonucleotides. 
 
Figure 1.6 Non-nucleosidic fluorescent phosphoramidites 
Non-nucleosidic units have also been studied via the replacement of the ribose moiety with 
redox active units. Tucker et al. reported the use of ferrocenyl thymidine as a replacement 
for two nucleobases.60,61 Ferrocene thymidine 8 was incorporated into automated nucleic 
acid synthesis, coupling eight units together. The single-stranded ferrocene nucleic acid was 
shown to have UV absorption as expected and a single, reversible oxidation at 212 mV (CV, 
vs. Ag/AgCl).  Duplex formation of the strand with complementary sequences was not 
studied. 
 
Figure 1.7 Ferrocenyl-thymidine 
1.2.5. Base labelling 
Much research has been carried out on the synthesis of modified nucleobases. Canonical 
bases are not inherently fluorescent, and as such the introduction of labels allows for 
18 
 
discrimination and detection of sequences. Generally, the introduction of fluorescent labels 
onto canonical bases involves ring fusion or substituent addition (Figure 1.8)62 and through 
the introduction of extended π-systems the inactive bases can be made to fluoresce. The 
purine skeleton can be influenced readily, with the introduction of a single aromatic ring 
allowing fluorescence. Due to their comparatively smaller size, pyrimidine units tend to 
require a higher level of substitution to create fluorophores.  
 
Figure 1.8 Possible modification sites of cytidine and guanine 
Uridine is the most commonly chosen nucleoside to attach an external label. The pyrimidine 
bases are easier to handle due to their reduced polarity compared with the purine bases. 
This allows easy synthesis of 5-halogeno pyrimidines, which can then be subjected to cross-
coupling reactions to introduce the desired label.  
After incorporation of the desired label onto a nucleobase, three main methods exist to 
introduce the nucleoside into a nucleic acid strand, namely direct, post-synthetic 
modification, and enzymatic incorporation. Each have their advantages and disadvantages 
associated however suitability is highly dependent on the end-user and scale at which the 
labelled DNA is required to be synthesised. 
Enzymatic incorporation is the simplest, whereby labelled nucleosides are incorporated via 
modified dNTPs. This cheap method allows for the synthesis of long DNA strands, allows 
incorporation of many labelled units, and can be carried out in most laboratories with 
standard biology equipment. It does, however, limit the type of label that can be 
incorporated as they must not inhibit the enzyme’s activity. The DNA obtained after 
enzymatic synthesis is difficult to use as DNA probes, due to the requirement for separation. 
As such, these are typically used as signalling probes, for example in nick translation 
reactions, or PCR, to indicate level of completion of the reaction. 
Modified dUTPs have been used to introduce ferrocene onto the base stack of DNA via 
enzymatic incorporation (Scheme 1.17).63 The ferrocene unit was introduced through 
coupling of ferrocenyl acids and amine functionalised nucleoside triphosphates activated 
by HBTU. The labelled dUTP 9 was shown to have been successfully incorporated into DNA 
by the enzymes T4 polymerase and Klenow fragment, with data indicating a minor 
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destabilisation of the duplex and reduction in Tm. 9 was also shown to be a suitable 
substitute for dTTP in PCR, allowing for the synthesis of long DNA fragments. 
 
Scheme 1.17 Synthesis of ferrocenyl dUTPs 
The conjugation of ferrocene onto nucleotides has been studied by several groups. Having 
a conjugated π-system allows for the charge transfer between the base and the ferrocene, 
therefore modifying its redox properties.64 This label was synthesised from 5-iodo-2’-
deoxyuridine 10 utilising the Heck reaction to yield the desired nucleoside 11, which was 
then incorporated into the desired oligonucleotide sequence via the phosphoramidite 
method according to standard procedures. 
 
Scheme 1.18 Heck reaction between ferrocene and 5-iodo-2’-deoxyuridine 
The conjugation of ethynylferrocene directly to uridine was also attempted,64 however 
concurrent with previous studies by Yu et al.,65 the Sonogashira cross-coupling does not 
proceed cleanly, instead yielding a mixture of the desired product 12 and the cyclisation by-
product 13. Under basic conditions, the iminolate of uridine forms slowly, which cyclises 
with the activated alkyne (Scheme 1.19). The yield of the cyclised product increases with 




Scheme 1.19 Undesired cyclisation of ferrocene and uridine under basic conditions 
Cross-couplings of ferrocene and nucleosides have also been carried out “on-column”, such 
that 5-iodo-2’-deoxyuridine is incorporated as a modified dT unit.66 The DMTr 
phosphoramidite of 5-iodo-2’-deoxyuridine was incorporated into an oligonucleotide 
sequence, and the solid-phase synthesis was temporarily paused. At this point the resin was 
subject to Sonogashira cross-coupling, yielding the redox active nucleobase (Scheme 1.20). 
The reagents and catalysts for the Sonogashira reaction were washed away, and 
oligonucleotide synthesis was continued according to the standard coupling/washing 
procedure. 
 
Scheme 1.20 “On-column” ferrocene cross-couplings 
1.2.6. Post-synthetic modification 
Post-synthetic modification is achieved by the introduction of a functional handle during 
oligonucleotide synthesis. This sequence is constructed and purified in the usual method, 
and after the desired sequence has been made and cleaved from the resin, the nucleoside is 
functionalised with the label of choice. Although more expensive than enzymatic 
incorporation, it allows site-specific introduction of labels, as the location of functional 
handles can be controlled more. Additionally, it allows possibly the widest range of 
functional group tolerance of the three methods, as the ODN is not subject to further 
removal from resins, or deprotection of various protecting groups required during solid-
phase synthesis. The major drawback of this method is the significant purification challenge 
posed, as incomplete functionalisation, particularly in cases where multiple functional 
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handles exist, would result in complex mixtures of products with very similar solubility 
properties. 
The first enzymatic methods used was nick translation, which was used to incorporate 
radiolabelled  dNTPs.67 In this method, the enzyme locates the nick (a gap in the dsDNA 
duplex) and extends the nucleoside while simultaneously digesting the complementary 
strand, therefore incorporating the labelled dNTPs. Other enzymatic methods include using 
modified dNTPs during PCR, however enzymatic methods yield mixed products which have 
target DNA already present and as such cannot easily be used to detect DNA without further 
purification. 
 “Click” chemistry was defined by Sharpless as any reaction that is high yielding, 
stereospecific, produces minimal waste, does not require chromatography, and can be 
carried out under mild conditions (e.g. low temperatures, low-boiling solvents).68 The 
regioselective, copper-catalysed version of Huisgen’s azide-alkyne cycloaddition,69 was 
discovered simultaneously by Meldal et al. and Sharpless et al. and is the most well-known 
“click” reaction (Scheme 1.21).70,71 Its applications span chemical and biochemical synthesis, 
allowing unprecedented access to a range of materials in highly specific, high yielding 
reactions. 
The CuAAC is a strong candidate for post-synthetic modification, as it is biocompatible and 
can be carried out in aqueous solutions, thus allowing the oligonucleotides to be suspended 
in buffers and introducing the label at a later point. Click chemistry has been widely utilised 
in DNA modification due to its lack of reactivity with functional groups naturally found in 
DNA. The CuAAC has been used to functionalise nucleic acid oligomers, employed as a DNA 
crosslinking agent, supramolecular structure formation tool, phosphate surrogate, and as a 
surface immobilisation technique.72 
 
Scheme 1.21  Copper catalysed azide-alkyne cycloaddition 
The CuAAC of alkyne-functionalised oligonucleotides has been used to introduce several 
labels on the DNA backbone. The introduction of a number of alkynes on the backbone of 
DNA allows access to highly functionalised oligomers via post-synthetic modification 
(Figure 1.9).73 Treatment of ODNs with six consecutive alkyne moieties afforded 
functionalised products in quantitative yields. This allowed for the conjugation of glucose, 
coumarin, and fluorescein azides onto the oligonucleotide. Comparison of flexible and 
inflexible alkyne moieties showed that using the flexible alkyne 15 allowed for quantitative 
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incorporation of azide labels such as glucose, biotin, and coumarin, however when using 
rigid structure 14, the CuAAC reaction was inhibited, resulting in incomplete conversion to 
desired product. Two sequences were used as PCR primers, each containing two free 
alkynes sites. These primers allowed for the synthesis of PCR products up to 2000 bp long, 
giving access to clickable PCR amplicons. 
 
Figure 1.9 Alkyne functional handles on 2’-deoxyuridine 
DNA CuAAC chemistry can also be achieved by introducing different protecting groups, so 
that multiple labels can be introduced onto a single strand post-synthetically (Scheme 1.22). 
The modular deprotection of alkynylsilanes can be exploited to introduce different labels in 
a site-specific manner when multiple functional handles are present. Carell et al. developed 
their previous DNA CuAAC strategy and used silyl protecting groups to modify the reactivity 
of alkynyl ODNs, allowing for the introduction of a range of fluorescent and biologically 
relevant labels.74 By using this methodology, the desired label could be incorporated 
regioselectively, thus yielding the desired labelled sequence. 
 
Scheme 1.22 Sequential CuAAC reactions on oligonucleotides 
The CuAAC has proven itself as a useful tool for functionalising DNA, pre- and post- 
oligonucleotide synthesis. It can be utilised to introduce labels on the sugar, phosphate, and 
base, as well as being used to functionalise other nucleic acids such as PNA.  
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1.3. Nucleic Acid Detection Methods 
The development of a range of labelling techniques has allowed for the design of different 
detection methods. Dependent on the type of label used, the applications can vary widely, 
with each detection method having its associated benefits and drawbacks. Further 
development has allowed the applications to move from the laboratory benchtop, to field-
based point-of-care (POC) diagnostics. 
1.3.1. Radiolabelling 
Labelling of DNA was first achieved through the introduction of radioisotopic labels to 
isolate complementary RNA and DNA.75 These were detected through hybridisation with 
agar DNA columns and the level of radioactivity was measured to calculate the amount of 
radioisotope incorporated. Incorporation of labelled fragments is usually achieved by 
enzymatically introducing 32P labelled triphosphates at the 5’- and 3’- ends.67,76 Labelled 
nucleic acids are typically detected through radiography film, positron emission 
tomography, or via Cherenkov radiation. 
Radiolabelling of compounds has drawn much interest for in vivo imaging, whereby 
incorporating β- or γ- emitters onto an oligonucleotide allows for imaging via positron 
emission tomography to assess cell uptake of antisense oligonucleotide therapeutics 
(Scheme 1.23).77,78  
 
Scheme 1.23 Radiolabelling of oligonucleotides 
1.3.2. Colourimetric and fluorescent detection 
Colourimetric biosensors are easy to interpret and do not require expensive machinery.79 
The ease of this detection method is exemplified by home pregnancy tests. A simple blue 
strip indicates pregnancy, which is unequivocally interpreted by the user.  Colourimetric 
DNA sensors, however, have not achieved such success. Chee et al. developed colourimetric 
DNA arrays to analyse gene expressions.80 The probes were labelled with a red protein, and 
the target with green fluorescein, and the red and green light intensity was compared upon 
hybridisation of the oligonucleotides. A decrease in intensity indicates the location of a SNP, 




Colourimetric detection has not found widespread implementation in DNA diagnostics due 
to its limited sensitivity, however fluorescent molecules have allowed for the development 
of a huge range of detection methods. These range from non-specific interactions with any 
dsDNA, to highly sensitive probes for single nucleotide polymorphism detections. The high 
sensitivity of fluorescent-based detection methods allows for the detection limits down to a 
single molecule, allowing for early detection when pathogenic material is low, or for 
detection of highly toxic substances at low concentrations. 
A fluorophore is a compound that absorbs and re-emits light when irradiated at the correct 
wavelength of light. Such compounds typically contain conjugated aromatic rings or 
extended π-systems. The excitation of an electron to a higher energy state and subsequent 
relaxation allows the electron to emit the energy in the form of light, if the excitation beam 
and the HOMO-LUMO gap are sufficiently close in energy. The absorption and emission 
spectra can be analysed and the emission intensity is directly related to the concentration 
of fluorophore present according to the Beer-Lambert law, therefore fluorescence is an 
excellent choice for quantitative techniques.81 Organic compounds that emit coloured light 
can be used for many applications such as dyes and solar cells. High molar extinction 
coefficients of highly conjugated aromatic compounds allow the dyes to be used in low 
concentration, whilst yielding high signals. 
DNA intercalators are small, usually highly conjugated, aromatic compounds, which insert 
between the base pairs in the double stranded form of a nucleic acid (Figure 1.10). This is 
mainly due to π-π stacking, an attractive force involved in chemical and biological 
recognition events, as well as DNA binding and protein structure.82 Upon intercalation, the 
rigidity of the intercalator is increased, thus extending its π-system allowing an increase in 
quantum yield of the fluorescence. 
 
Figure 1.10 Ethidium bromide DNA intercalation 
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Intercalators were first identified as a tool for visualising DNA in the 1960s.83 It was 
discovered that upon treatment of DNA in high concentrations of salt, ethidium bromide 
(EB) forms a fluorescent complex with the DNA. In the absence of DNA, ethidium bromide 
is mildly fluorescent, however introduction of dsDNA or RNA results in a large increase in 
the quantum yield, and a change in the absorption spectrum. There is clear interaction 
between EB and nucleic acids, as shown by the isosbestic point upon mixing of EB with DNA 
or RNA. It was also found that EB and DNA form a complex in the single-stranded state, but 
this was attributed to the ionic attraction between the cationic EB core and the negatively 
charged phosphates. As a result, fluorescent detection of DNA while using intercalators 
gives relatively high background signals due to the ssDNA interactions. 
Intercalators have been used extensively in gel electrophoresis, where the DNA is separated 
based on charge and size. Since the introduction of EB into DNA detection, other 
intercalating dyes have been developed which have improved fluorescence properties over 
EB, which are largely designed around EB’s core phenanthridine structure, as well as 
acridine, and cyanine based dyes.84 Gel electrophoresis, however, has inherent drawbacks 
due to the length of time required to achieve results. Gels are referenced against DNA of 
known length, and as such the readout gives a value of size alone. The implications, 
therefore, are limited specificity, with little possibility of multiplexing amplification tests to 
detect for multiple targets simultaneously. 
 
Figure 1.11 Structures of common DNA intercalators (Top left, clockwise, SYBR green, ethidium bromide, 
Ru(bpy)2(dppz), methylene blue) 
EB, 17, and SYBR green, 16, are dyes that bind to dsDNA. Both are common biological 
reagents that are used to stain DNA. For example, tracking the progress of PCR assays in the 
absence of any labels is achieved through gel electrophoresis. Rasmussen et al. used SYBR 
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green to quantify the progress of PCR. By monitoring the fluorescence during melting, the 
double stranded DNA is denatured, dramatically reducing the fluorescence.85 The 
temperature at which this occurs, and the amount the fluorescence decreases by can then 
be attributed to the amplification product and the user can then quantify the amount 
present. 
As well as organic fluorophores, organometallic complexes have been used to indicate the 
presence of dsDNA. Hartshorn and Barton used ruthenium bipyridyl/dipyridophenazine 
(18) complexes to indicate the presence of dsDNA.86 In aqueous solutions the complex does 
not photoluminesce. However, upon introduction of dsDNA, the probe’s luminescence 
increases by a factor of 104 as the metal complex intercalates to dsDNA and turns on the 
luminescence. 
Asanuma et al., used internally labelled oligonucleotides, where the insertion of a pyrene 
phosphoramidite on both sides of a base was used to discriminate between wild type and 
deletion mutagenic DNA.58 In the presence of the wild type, the probe and target hybridise 
fully and the pyrene intercalates, thus reducing the fluorescence to very low intensities 
(Figure 1.12). In the target with a single nucleotide deletion, the probe has a 3-unit 
mismatch, which sits outside the duplex, increasing the fluorescence by a significant 
amount. The deletion portion was increased to two base pairs and the system still shows a 
significant increase in signal upon hybridisation with mutagenic DNA. 
 
 
Figure 1.12 Detection of deletion mutations by fluorescence 
DNA intercalators suffer from high background signals, as ssDNA hybridisation is still a 
major contribution to overall signal. As such, probes in which the labels are covalently 
attached are more favourable. 
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To create a switch, a quencher molecule is sometimes added to turn off the fluorescence. 
These molecules are chosen so the energy of the HOMO-LUMO gap of the quencher matches 
that of the fluorescence. If the molecules are sufficiently close to each other, in both space 
and energy, Förster resonance energy transfer (FRET) will occur, and the quencher will 
relax to the ground state, releasing the energy as heat, thus no (or very little) fluorescence 
happens (Scheme 1.24). When the distance between the fluorophore and quencher is 
increased, FRET can no longer happen and the energy will be released as light. 
 
Scheme 1.24 Förster resonance energy transfer 
Folding-based biosensors are another method which can be used to detect pathogenic DNA. 
Molecular beacons were first developed by Tyagi and Kramer, exploiting the highly specific 
nature of DNA binding.87 As with many other biomolecular recognition events, the binding 
of complementary DNA (cDNA) does not result in easily measurable changes of its 
physicochemical properties. The introduction of a label onto oligonucleotide probes allows 
for the detection of the binding event. Molecular beacon probes are based on hairpin 
structures, whereby a single oligonucleotide is labelled at opposite ends with a fluorophore 
and quencher, relying on proximity of the labels to each other (Scheme 1.25). 
 
Scheme 1.25 Molecular beacons 
These probes consist of a loop of DNA capped in the 5’- and 3’- ends with a naphthalene 
fluorophore and an azobenzene quencher. The probe has a self-complementary section at 
both ends which force the formation of the hairpin in the absence of cDNA, bringing the 
fluorophore and quencher in proximity to each other. However, upon introduction of cDNA, 
the probe unfolds and binds to the target DNA, allowing the naphthalene to fluoresce freely. 
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Whitcombe et al. described the use of self-probing amplicons that fluoresce upon 
amplification of the target sequence.88 In this example, the primers used to indicate the start 
of the PCR product were also the probes, labelled with fluorescein at the 5’- end and a methyl 
red quencher on the oligonucleotide 30 base pairs away (Scheme 1.26). The primers also 
included a hexaethylene glycol monomer adjacent to the methyl red, which inhibits the 
action of the polymerase to ensure the extension products are not copied. The first PCR cycle 
extends the primer, and the product is subjected to another round of denaturing. The target 
now contains a complementary sequence to itself, so upon cooling the probe folds and 
anneals to the target sequence. This increases the distance between the fluorophore and 
quencher (cf. molecular beacons), allowing the real-time production of signal to be detected. 
 
Scheme 1.26 Self-probing amplicons 
Livak et al. exploited the exonuclease action of Taq polymerase to digest probes with 
fluorophores and quenchers attached.89 Upon extension of the primer, the probe is digested, 
releasing fluorescein into solution, leaving a sufficient distance between the quencher to 
allow fluorescence to occur. The group investigated the effect of distance between the 
fluorophore and quencher, using distances of as low as 2, and as large as 26 base pairs. Even 
with a distance of 26 base pairs between them, the fluorescence was still quenched. Upon 
hybridisation (and digestion), the intensity of the fluorescence increased dramatically. 
However, when the fluorophore and quencher are only two base pairs away from each 
other, the enzyme does not release a small enough fragment to allow the quenching to stop. 
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Many organic molecules exist that have a range of absorption and emission spectra, which 
allows for multiplex capability for the detection of several targets in a single test. Lee et al. 
used two fluorescein compounds to discriminate between two alleles of the gene 
responsible for cystic fibrosis.90 The labels, with a difference in max of roughly 20 nm, were 
attached to an oligonucleotide with quenchers. Both probes were then subject to PCR with 
mutagen, wild-type, both mutagen and wild type, and blanks, demonstrating that the two 
can be differentiated in the same solution. 
1.3.3. Electrochemical detection 
Application of fluorescent DNA detection is usually confined to research laboratories due to 
the expensive nature of the machinery, although recently more devices are being integrated 
into point-of-care settings. Although many examples of detection via fluorescence are 
common in the literature and fluorescent detection is more widespread, electrochemical 
detection methods possess advantages over optical methods, and as such these methods are 
still of great interest to further develop. 
Electrochemical detection holds many advantages over their fluorescent counterparts. 
Fluorescence uses bulky, precise devices that require calibration, often including lasers, 
meaning the cost of the devices is often extremely high and the equipment is difficult to 
transport due to the need for calibration and the sensitivity of the machine.91 Conversely, 
electrochemical detection can be made significantly cheaper given the robustness of the 
equipment. No lasers are required, immediately reducing the cost, and the machines can be 
made from cheap materials – metal wiring, circuit boards, and computer chips, all of which 
are mass produced and as such a potentiostat can now be custom built for a low cost. 
Electrodes are easily screen-printed and potentiostats can be miniaturised, allowing rapid 
point-of-care detection of pathogens to be an affordable technology. Analysis of samples is 
quick, taking only a number of seconds and can be conducted on turbid samples, reducing 
the need for purification. Detection of DNA can be achieved with or without the use of 
amplification techniques such as PCR. 
The last three decades has seen a dramatic increase in publications in the field of 
electrochemically-labelled nucleic acids (Figure 1.13), leading to the development of a 
number of techniques now available for reliable, sensitive, and rapid detection of nucleic 




Figure 1.13 Publications per year on electrochemistry of nucleic acids. Numbers taken from Web of Science 
query for (electrochem* AND DNA) OR (electrochem* AND nucleic acid*). 
1.3.3.1. Surface-immobilised detection methods 
Electrochemical detection of DNA is typically achieved through adsorption onto an 
electrode surface and the presence of target DNA will elicit a structural or electronic change 
in the probe, therefore leading to a change in signal (Scheme 1.27). To create 
electrochemical sensors, the nucleic acid is first synthesised, and immobilised on an 
electrode, which are typically made from carbon, indium tin oxide (ITO), or gold. The 
electrode surface is washed to remove any non-specifically bound DNA from the surface, 
ensuring that only the desired, correctly bound probes remain. 
 
Scheme 1.27 Typical electrode surface immobilised DNA detection 
There is a sensitivity battle to be considered when using surface-immobilised techniques. 
An increase in probe density allows for a higher signal due to increased number of redox 
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active sites available, however increasing the number of probes on the surface of the 
electrode too far also results in a decrease in sensitivity. Too high a probe density on the 
electrode surface would inhibit hybridisation events, as it would limit the amount of target 
DNA that can fit between the probe strands. As such, blocking layers such as 
mercaptohexanol are deposited simultaneously to ensure that the correct spacing of DNA is 
achieved. The adsorption of thiol-capped DNA to a gold surface can be controlled by 
changing the concentration of DNA, and varying the buffer and mercaptohexanol 
concentration, allowing uniformity of the DNA layers deposited.92 
Label-free amperometric detection of nucleic acids can be achieved via the use of guanine-
free probes (Scheme 1.28).93 Guanine can be replaced with inosine, a naturally occurring 
nucleoside which still binds to C residues but has different Eox, therefore inosine in the probe 
and any G residues in the target can be discriminated. Detection either occurs through direct 
oxidation from the probe on a carbon electrode, or via the redox cycling of Ru(bpy)3Cl2 using 
ITO electrodes. The number of guanosine residues shows a linear relationship with current, 
and as such the sequence and number of repeat units can be determined.   
 
Scheme 1.28 Ruthenium oxidation of guanosine residues 
Label-free detection of DNA can also be achieved through redox-active DNA intercalators 
(Figure 1.14).94,95 DNA intercalators have been used in electrochemical detection of DNA, 
however, concurrent with fluorescent based intercalators, discrimination between ssDNA 
and dsDNA is not perfect and as such high backgrounds are often observed. Takenaka et al. 
developed the diimide derivative 20 to detect for DNA methylations in PCR amplicons. The 
capture probes were immobilised on gold electrodes and the current upon hybridisation 




Figure 1.14 Takenaka’s ferrocenyl diimide 
Other DNA intercalators have been studied, exploiting the charge transfer through DNA to 
anthraquinonemonosulfonic acid. This allowed Gooding and Wong to discriminate between 
cDNA, and C-A or G-A single mismatches.96 The distorted charge transfer between 
complementary and mismatched DNA resulted in a shift in reduction potential of the 
anthraquinone moiety. 
Labelled nucleic acids have attracted more attention than label-free methods due to their 
increased sensitivity and lower oxidation potentials required to achieve oxidation of 
probes. The first electrochemical labels to be covalently attached to DNA were Os(VIII) 
species. In the developed conditions, osmium undergoes cyclisation reactions with 
pyrimidine residues in regions of dsDNA which had been distorted (i.e. SNPs or deletion 
mutations).97,98 
Covalent electrochemical labelling of DNA can be achieved with a range of labels including 
acridine,99 anthraquinone,51 and ruthenium based metal complexes.86 This field, however, 
is dominated by derivatives of two molecules: methylene blue, and ferrocene. Methylene 
blue is a charged species, and as such has inherently superior aqueous solubility over 
ferrocene, however through conjugation of the labels to oligonucleotides, both have been 
used extensively in nucleic acid detection assays. 
Plaxco et al. developed Kramer’s fluorescent hairpin methodology into an amperometric 
electrode-based system.100,101 The immobilised ssDNA was 5’-capped with a ferrocene label, 
and the probe has a self-complementary sequence, bringing the ferrocene label adjacent to 
the electrode in the absence of DNA, thus allowing oxidation to occur (Scheme 1.29). Upon 
introduction of cDNA, the self-complementary section is displaced by formation of the more 
stable duplex, increasing the distance between the ferrocene and the electrode, thus 




Scheme 1.29 Signal-off electrochemical molecular beacons  
Grinstaff et al. further developed the displacement assay into a signal-on assay.102 The 
introduction of a spacer unit allowed for the incorporation of electrochemically active 
labels, which would be off in the absence of cDNA (Scheme 1.30). Upon introduction of 
cDNA, the spacer has enough flexibility to allow the label to come close enough to the 
electrode, therefore allowing oxidation to occur. 
 
Scheme 1.30 Switch-on electrochemical detection 
Sessler et al. further developed the displacement assays into a ratiometric detection method 
(Scheme 1.31).103 By using an internal control, the signal intensity of the label could be 
quantified, and therefore the amount of DNA present. In this method, ferrocene was bound 
to the 3’- end of DNA, capped with a thiol linker, and immobilised on a gold surface. In the 
ssDNA state, methylene blue is in proximity to the electrode, then cDNA forces a 
conformational change, unfolding the probe. The ferrocene label remains the same distance 
from the electrode, so the integral of the MB peak can then be determined and referenced 




Scheme 1.31 Ratiometric electrochemical detection of DNA 
Surface immobilised strategies can also be used to detect for single nucleotide 
polymorphisms (SNPs) through charge transfer from DNA to hybridised electrochemical 
labels. A single mismatch does not significantly affect the structure of a DNA helix, but does 
interfere with Tm,104 and charge transfer due to the interruption of the extended π-
system.105–107 Electrochemical DNA intercalators can be paired with surface-immobilised 
probes, and in the presence of a SNP, the charge transfer switches off (Scheme 1.32).108,109   
 
Scheme 1.32 Methylene blue/ferricyanide cycle via DNA charge transfer 
In the presence of cDNA, the redox couple methylene blue/leucomethylene blue (LB) results 
in the expulsion of LB into solution as this can no longer intercalate, LB then reduces the 
ferricyanide in solution, allowing the reformed MB to intercalate and the complete cycle can 
be analysed by CV to give a fully reversible two-electron voltammogram. Upon introduction 
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of mismatched DNA, the charge transfer along the base stack is inefficient and as such the 
MB cannot be reduced, so no current is generated. 
Recently, Yamana et al. reported the introduction of a ferrocenyl uridine into surface 
immobilised probes to detect mismatches for DNA.64 The introduction of an ethene unit 
between ferrocene and the nucleobase allowed for the charge transfer between the 
nucleobase and ferrocene (Scheme 1.18, Section 1.2.5). Upon hybridisation with DNA, the 
level of charge transfer would change, resulting in a change in the current generated 
depending on whether fully complementary or mismatched DNA was present (Scheme 
1.33). 
 
Scheme 1.33 Detection of SNPs via charge transfer 
1.3.3.2. Solution-based detection methods 
Solution-based detection of DNA using electrochemical labels has not drawn as much 
attention as surface-immobilised strategies because of their comparatively reduced 
sensitivity, and while there are several examples in the literature of ferrocene-labelled DNA 
being used to study duplex formation and stability, the methodology has seldom been 
expanded into a full detection assay. 
Surface-immobilised capture probes have advantages over solution-based detection, as the 
probe and label are forced into proximity to the electrode. Unmodified electrodes rely on 
efficient transport of the label from solution to the surface, and can be subject to fouling, 
therefore increasing risk of false-positives. Unmodified electrodes do however present an 
opportunity for use of disposable electrodes, as significantly cheaper materials can be used 
than those required for immobilised techniques. 
Solution-based detection of DNA hybridisation has been achieved through the introduction 
of ferrocene units at the 5’-end and as non-nucleosidic units (Figure 1.15).110,111 The 
modified oligonucleotides were studied at 25 µM, and were hybridised with complementary 
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sequences and detected in phosphate buffer (pH 6.8). Upon hybridisation with fully cDNA, 
no change in CV of the ODNs was observed, however hybridisation with complementary, 
but shorter sequences gave increased CV area by 45%, which was attributed to increased 
availability of the ferrocene at the electrode surface. The probes generated current in the 
range of 10-7 A, however this value was not baseline corrected and as such the actual 
sensitivity of these probes is likely to be significantly lower. 
 
Figure 1.15 5’- and non-nucleosidic ferrocenyl DNA 
Solution-based detection of ferrocenyl peptide nucleic acids (PNA) was developed by 
Metzler-Nolte et al. whereby the ferrocene was conjugated at the N-terminus to develop a 
set of probes 21–24 with different oxidation potentials (Figure 1.16).112 The CV of these 
probes was studied, showing a shift in oxidation potential between the different PNA 
conjugates due to the different connectivity. The probes generated large current in the 
range of 10-6 A, however the redox behaviour of these probes was studied at 800 µM, which 
in a diagnostic assay would be unsuitably high. 
 
Figure 1.16 Multiplex ferrocene PNA conjugates 
Hsing et al. developed PNA derivatives for solution-based electrochemical detection.113 This 
detection strategy elegantly utilised the uncharged nature of PNA and by modification of the 
ITO electrode surface with positively charged poly(allylamine hydrochloride) (PAH), 
allowed for the design of both signal-on and signal-off strategies (Scheme 1.34).  
When using the unmodified surface, the neutral PNA is attracted to the negatively charged 
ITO electrode, allowing efficient electron transport and therefore allowing oxidation to 
occur at the electrode surface. Upon introduction of cDNA, the negatively charged 
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phosphate repels the duplex from the electrode surface, increasing the distance and 
therefore switching off electron transfer and any current generated. The electrode surface 
was then modified with PAH, forming a positively charged monolayer on the ITO surface. 
The single-stranded PNA probe is repelled by the electrode surface, such that it is off in the 
absence of cDNA. Upon introduction of the negatively charged cDNA, the duplex is attracted 
to the surface, allowing ferrocene oxidation to resume. The probes were studied at 1 or 0.1 
µM, and hybridisation with cDNA allowed for clear differentiation at 10-10 A. The 
hybridisation event of cDNA with the probe gave a detection limit of 40 fmol.  
 
Scheme 1.34 Immobilisation free detection of DNA 
In collaboration with Atlas Genetics, previous work from this group focussed on the 
development of solution-based detection using 5’-ferrocenylated probe 25 (Scheme 
1.35).114–117 This was hybridised with synthetic complementary target to yield hybridised 
dsDNA 26, which was then treated with T7 exonuclease, which exhibits double-strand 
specific activity. As such, the unhybridised probe 25 remains intact in the absence of cDNA, 
only producing digestion products, and therefore redox active products, when 
complementary DNA is present. The probes were studied at 1 µM, resulting in a signal 




Scheme 1.35 Solution-based T7 exonuclease detection of DNA by ferrocene labelled probes 
The limited sensitivity of solution-based detection can be overcome by coupling the reaction 
with efficient nucleic acid amplification techniques such as PCR, however still lacks in 
sensitivity compared to surface-immobilised methods. The use of surface-immobilised 
techniques has not found widespread use in point-of-care diagnostics largely due to the cost 
associated with the electrodes and the extended procedures required to immobilise probes 
onto the surface. Solution-based detection which relies on enzymatic digestion can be 
conducted with relative ease and speed compared to surface-immobilised techniques, 
allowing for disposable diagnostic tests to be conducted in short timeframes. 
1.4. Aims 
The benefits of electrochemical DNA detection over fluorescent detection devices has not 
yet been fully explored, and could allow for significantly cheaper diagnostic tests as well as 
enhanced information that can be gained from a single test. The current limitations of 
electrochemical detection are either the cost and labour associated (surface-immobilised 
methods), or the sensitivity of the devices (solution-based). The aim of this thesis was to 
develop a nucleic acid labelling strategy which would allow for increased sensitivity of the 
probes. 
To achieve this, it was hypothesised that a range of ferrocene azides should be synthesised 
for use in the copper-catalysed azide-alkyne cycloaddition to conjugate the ferrocene label 
to a nucleobase, followed by incorporation of the substituted nucleoside into an 
oligonucleotide sequence using solid-phase synthesis (Figure 1.17). In theory, this could 
allow for the introduction of multiple redox active sites on a single oligonucleotide probe, 
and upon enzymatic digestion the probes could generate a higher electrochemical signal 
due to the effective increased concentration of the ferrocene label. 
 
Figure 1.17 Proposed route towards ferrocene oligonucleotides 
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S1 nuclease was to be employed as a nuclease to digest the labelled oligonucleotides in a 
proof-of-concept experiment to confirm whether the probes containing multiple ferrocenes 
are still active towards nuclease digestion. 
It was also hypothesised that further increases in electrochemical signal could be achieved 
via the use of a reductive amination strategy, to double the concentration of ferrocene 
without an increase in substitution of the oligonucleotide probe (Figure 1.18). 
 
Figure 1.18 Possible increase in electrochemical signal via increased substitution through reductive 
amination reaction 
These probes were also to be digested via S1 nuclease digestion to determine their 
susceptibility towards enzymatic digestion. 
If the probes exhibit a suitable level of enzymatic susceptibility, the probes are to be 
incorporated into a dsDNA assay to study their digestion properties and determine whether 
the increased substitution of the oligonucleotide probes can offer improved electrochemical 
signals compared to traditional labelling methods using T7 exonuclease. Improvement of 
electrochemical signal could allow for lower quantities of probe to be used in diagnostic 
assays, and reduce the time required to run an assay due to potential improved sensitivity 
and limit of detection. Finally, the new labelling strategy could be used to explore the 





2. Design, synthesis, and testing of mono-ferrocenylated 
nucleosides 
2.1. Introduction 
Ferrocene was first reported by Kealy and Pauson in 1951,118 and its structure was 
elucidated a year later by Wilkinson and co-workers.119 The organometallic compound is air 
and moisture stable and undergoes a one-electron oxidation, and the ferrocene core can 
tolerate a range of organic chemistry reaction conditions. It is relatively stable to both acidic 
and basic conditions, and the cyclopentadienyl (Cp) rings can be manipulated through SNAr 
and SEAr chemistry, as well as undergoing selective deprotonations to synthesise a host of 
highly functionalised cores. Ferrocene cores can be synthesised from iron (II) chloride with 
functionality pre-installed through the use of functionalised Cp rings. These properties have 
enabled ferrocene to be applied in many areas of chemistry, including responsive 
materials,120 asymmetric ligands,121 electrochemical references,122 petrochemicals,123 and 
pharmaceuticals,124 and extensively as a redox label in DNA detection.125 
Electrochemical detection is typically conducted via voltammetric analysis. One of the 
fundamental principles that allows ferrocene to be used in such applications is its 
controlled, yet variable, oxidation potential. By manipulating the oxidation potential of the 
iron centre and forcing a change upon recognition of an analyte, a reaction can be 
monitored. It is possible to develop switches where the probe has a discrete Eox in the 
absence or presence of the analyte.126 This is known as ratiometric analysis, whereby the 
integral of the two peaks are compared and therefore quantify the amount of probe present 
(Figure 2.1). This is a form of duplex detection, which is the simultaneous detection of two 
signalling moieties. 
 
Figure 2.1 Ratiometric analysis of two distinct electrochemical species 
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Substitution of the Cp rings enables modification of the oxidation potential, and therefore 
allowing for multiplexing capabilities for electrochemical applications. The introduction of 
electron-donating groups on the Cp rings puts more electron density onto the iron core, 
therefore making it easier to lose an electron, making the oxidation potential more negative. 
The opposite is also true with electron withdrawing groups, where the electron density is 
moved away from the Cp rings, therefore less density on the iron centre, leading to a higher 
oxidation potential. 
Deprotonation of ferrocene and quenching with an electrophile is one of the most simple 
and general ways in which to create substituted ferrocenes. A variety of functionality can be 
installed, allowing for a range of reactions to be performed. For example, quenching 
lithioferrocene with DMF yields ferrocenecarboxaldehyde. The aldehyde can then be 
subjected to standard carbonyl chemistry. This strategy allows for further derivatisation of 
ferrocene along a single carbon chain. 
It is desirable to introduce multiple substituents on the ferrocene core, which are typically 
substituted in 1,2- or 1,1’- patterns. 1,2-substitution generates chiral ferrocenes via planar 
chirality. The first chiral ferrocenes synthesised were resolved via the formation of 
diastereoisomeric salts,127 however later methods developed allowed for asymmetric 
lithiation,128,129 and therefore direct access to enantiomerically enriched samples. These 
methods of lithiation rely on the formation of more stable conformers, whereby one 
orientation of the auxiliary will be disfavoured due to steric clash. Kagan et al. further 
developed the strategy to generate removable, chiral auxiliaries therefore allowing further 
modification after introduction of stereochemical information (Scheme 2.1).130 
 
Scheme 2.1 Origin of stereochemical control in Kagan’s chiral ferrocene 
1,3-substitution patterns have been synthesised through the diacetylation of ferrocene,131 
however this was not developed as a regioselective reaction and the products require 
separation from their 1,1’-regioisomers. The use of sulfide as a directing group allows for 
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meta-selective deprotonation,132 and subsequent quenching with electrophile, generates 
much improved yields. Oxidation of the directing group to the corresponding sulfoxide, 
followed by lithium-sulfoxide exchange allowed for access to 1,3-substituted ferrocenes in 
much improved selectivities and yields (Scheme 2.2). This strategy has, however, received 
significantly less attention over the years than the 1,2-derivatives and as such are scant 
literature references in comparison to 1,2-counterparts. 
 
Scheme 2.2 1,3-substitution of ferrocene 
Di-lithiation allows access to regiospecific 1,1’-substituted ferrocenes. This intermediate 
can be quenched with a range of electrophiles. Extensive studies by Sanders and Mueller-
Westerhoff developed general strategies towards mono- and di-lithiated species (Scheme 
2.3).133 To access the mono-lithiated species, a mixture of t-BuLi and KOtBu are employed, 
whereas di-lithiation occurs through treatment of ferrocene with n-BuLi and TMEDA. 1,1’-
bromination provides access to asymmetrically substituted Cp rings through subsequent 
stoichiometry-controlled lithium-halogen exchange. 
 
Scheme 2.3 Mono- and di-lithiations of ferrocene 
Modification of the electronics of the Cp rings allows for multiplex capability to allow for 
detection of multiple targets in a single sample. Major modifications are achieved through 
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direct substitution of the Cp ring. For example, increasing the electron density through 
replacement of one Cp for pentamethylcyclopentadiene (Cp*) results in a large shift 
compared to the unsubstituted version. Electron poor derivatives can be created through 
substitution of the ring with groups such as halogens or sulfoxides. 
Minor modification of the oxidation potential can be achieved through varying the chain 
length attached to the ferrocene.134 Increased hydrophobicity of the ferrocene can increase 
the oxidation potential by up to 100 mV, allowing for fine-tuning of the ferrocene after the 
rough oxidation potential has been achieved through substituent incorporation. 
The majority of electrochemical DNA detection is achieved through surface modification of 
gold electrodes. Whilst offering higher sensitivity than their screen-printed counterparts, 
the increased cost of gold electrodes poses a significant stumbling block for widespread use 
of electrochemical DNA diagnostics. Electrochemical detection has huge benefits over 
fluorescent detection, however they cannot live up to their full potential if the materials 
continue to be prohibitively expensive. 
As such, solution-based, screen-printed electrodes offer a cheaper alternative and could 
allow for widespread use of such electrochemical DNA devices. However, solution-based 
DNA detection often suffers from low sensitivity of probes, although there are several 
examples in the literature where, when combined with amplification techniques, solution-
based detection is a suitable alternative to surface-immobilised versions. 
It was hypothesised that through the introduction of multiple redox active units along an 
oligonucleotide backbone, the signal could be increased significantly and improve the 










Scheme 2.4 Proposed increase in signal from multi-internal labelling 
Upon conjugation of multiple units of the same redox label, the signal could be amplified 
due to increased concentration of the signalling molecule. The CuAAC reaction has been 
used extensively in DNA modification, and allows for late-stage modification, which could 
allow for general conditions to synthesise a range of redox active nucleosides. Through late-
stage functionalisation, the required connectivity of the nucleosides can be installed (e.g. 
activating and protecting groups), before the desired ferrocene is installed. This allows for 
the incorporation of ferrocenes with varying redox potentials without significant deviation 
from a general synthesis. 
 
Scheme 2.5 Retrosynthetic analysis of target nucleic acid  
Given the potential application of these probes is for diagnostic assays, the probes are 
required to be synthesised with high purity. As such, the phosphoramidite method, rather 
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than enzymatic incorporation of dNTPs was chosen. It was also deemed necessary to 
incorporate the redox active label prior to solid-phase synthesis, to ensure complete 
conjugation of the ferrocene to the oligonucleotide, and remove any requirements for 
additional purification. 
As such it was decided to investigate the synthesis of a library of ferrocenyl azides, and 
conjugate these directly to alkyne-modified 2’-deoxynucleosides. This would allow for the 
incorporation of these labels in a sequence-specific manner, allowing evaluation of possible 




2.2. Nucleobase modification 
Due to the easier chemical modification of purine nucleobases, 2’-deoxyuridine was chosen 
as the initial nucleoside to modify, as the Watson-Crick pairing is the same as thymidine, but 
possesses a vacant 5-position in which to introduce functionality. To this extent, initial 
investigations focussed on the introduction of an alkyne moiety in the 5-position of the 
purine bases. 
2.2.1. Uridine substitution 
It was initially investigated to construct the substituted uridine from uracil, installing both 
the alkyne and N-glycosidic bond. The initial reactions were conducted, showing successful 
incorporation of both the alkyne moiety and successful installation of the glycosidic bond. 
To ensure the correct β-anomer is synthesised during the formation of the glycoside, ribose 
must still possess the 2’-OH be used to assist with neighbouring group participation. As 
such, after the formation of the desired nucleoside, the 2’-hydroxyl residue must be 
removed to enable use of the monomer in DNA (Scheme 2.6). 
 
Scheme 2.6 Synthesis of 2’-deoxynucelosides 
To achieve this, the radical Barton-McCombie deoxygenation reaction was to be attempted 
to form the desired 2’-deoxuridine core.135 However, this introduces additional steps in a 
reaction that is not typically high yielding, and as such, it was sought to use the pre-formed 
nucleosides as starting material. 
5-iodo-2’-deoxyuridine, although expensive as a starting material (£5/g in a moderate 
length linear synthesis, cf. uracil at £0.40/g), was purchased and used as starting material 
for the introduction of the required functionality. The cross coupling between 5-iodo-2’-
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Table 2.1 Cross-coupling screening reactions 
After attempting several procedures (Table 2.1) it was found the procedure reported by 
Cristofoli et al. gave the desired compound in the highest yield.141 It was found that thorough 
deoxygenation of the system was required to enable high yielding reactions, with moisture 
sensitivity not a concern (Scheme 2.7). The reaction was scaled up to 20 mmol, with no 
significant reduction in yield (73%). 
 
Scheme 2.7 Sonogashira cross-coupling of nucleoside 
The nucleobase must be activated for solid phase synthesis, and nucleophilic sites that 
would result in unwanted polymeric products need to be protected. DMTr 
phosphoramidites are standard coupling reagents used in solid phase synthesis.32 As such, 
the 5’-hydroxyl group must be protected in such a way that allows for deprotection under 
mild conditions. The tritylation of nucleosides is ubiquitous in the literature and as such, a 
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range of general procedures were available from which to choose.143 The key findings from 
this were that to maximise yields, the uridine should be azeotroped with anhydrous 
pyridine prior to use, and ensure that only freshly distilled pyridine is used as solvent. 
 
Scheme 2.8 5’-O protection of 2’-deoxyuridine 
Removal of the TMS group to afford the desired 5-ethynyl-5’-O-DMTr-2’-deoxyuridine was 
attempted via potassium carbonate in methanol.144 This yielded the desired final compound 
in a 39% yield, however it was found that the use of TBAF in THF proved more reliable with 
higher yields and as such was the chosen method (Scheme 2.9).145 
 
Scheme 2.9 Alkyne deprotection 
Upon successful synthesis of 27, one of the key intermediates for the CuAAC had been 
generated. This intermediate allows for the inclusion of any azide that has moderate acid 
and base stability. Attention was turned to other nucleosides to increase the labelling 
versatility of the ferrocenyl nucleosides.  
2.2.2. Cytidine substitution 
2’-deoxycytidine was investigated as a new coupling partner. In contrast to 5-iodo-2’-
deoxyuridine, 5-halo-2’-deoxycytidines were prohibitively expensive for use as a starting 
material, either as the iodide or bromide, and as such the direct iodination of cytidine was 
investigated. 
The use of elemental iodine and m-CPBA afforded the desired compound in 38% yield after 
column chromatography.146 Due to the high polarity of the product, very polar solvent 
mixtures were required, which included the addition of ammonia and water the mobile 
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phase. Due to the high proportion of immiscible aqueous and organic solvents, this resulted 
in difficult separation from by-products. Recrystallisation conditions were investigated 
however no suitable conditions were found. The reaction was also difficult to reproduce, as 
following the reaction via TLC showed no conversion to desired product when attempting 
the reaction on other occasions. 
 
Scheme 2.10 Iodination of 2’-deoxycytidine with m-CPBA as oxidant 
In the presence of a mixture of iodine, iodic acid, carbon tetrachloride, acetic acid and water, 
2’-deoxycytidine was able to cleanly undergo iodination in the 5-position (Scheme 2.11).147 
The reaction mixture was quenched with water, and co-evaporated with methanol until the 
reaction was colourless. This removed much of the iodine from the mixture, allowing the 
desired product to be successfully recrystallised from water, adjusted to pH 10 with 1M 
NaOH. 
 
Scheme 2.11 Iodination of 2’-deoxycytidine with HIO3 as oxidant 
Although neither yield from the reaction was particularly high, the iodic acid reaction 
resulting product was of a higher purity by 1H NMR spectroscopy and as such was chosen 
as a more suitable method for the preparation of this starting material. 
The installation of an alkynyl group was then attempted. As was found with the uridine 
derivative, there are many examples in the literature to install the ethynyl moiety. After 
attempting several methods, however, it was found that the isolation of 30 was particularly 
difficult due to its highly polar nature. Crude 1H NMR spectroscopy showed success for 
several sets of conditions, however it was difficult to isolate 30 in high purity. Finally, a set 
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of reaction and purification conditions were found which provided 30 in high purity and 
reasonable yield (Scheme 2.12).148 
 
Scheme 2.12 Sonogashira cross-coupling of 2’-deoxycytidine 
After the successful synthesis of the alkynylated 2’-deoxycytidine, the protection of the 
exocyclic amine and 5’- hydroxyl was attempted. The amine must be protected due to the 
phosphoramidite coupling method, as the exocyclic amine is nucleophilic. The amine would 
therefore couple with the incoming phosphoramidite. This would create a base that would 
be conjugated via the nucleobase rather than the ribose, hence causing problems with 
Watson-Crick binding. 
5’-O-DMTr protection was attempted under the same conditions as the uridine derivative. 
Crude TLC and 1H NMR spectroscopy indicated conversion to the desired product, and after 
work-up and purification the desired spot was isolated, however the product was not stable, 
showing decomposition to a number of spots by TLC and growing of a large number of peaks 
present in 1H NMR analysis (Scheme 2.13). 
 
Scheme 2.13 Attempted protection of 2’-deoxycytidine 
It was therefore attempted to telescope the reaction, and protect both the hydroxyl and 
amine groups before purification by first installing the DMTr group, followed by acyl 
protection of the exocyclic amine (Scheme 2.13). Crude TLC indicated the 5’-OH reaction 
proceeded with full conversion. The reaction was quenched with MeOH to remove any 
remaining DMTrCl, and the crude mixture was subjected to protection with either acetyl or 
DMF protecting groups. Unfortunately, although the first protection of the alcohol appeared 
to proceed without issue, the introduction of a second protecting group was not fruitful. On 
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addition of either acetyl chloride, acetic anhydride, or DMF-DMA, crude TLC indicated a 
large number of new spots, many of which were fluorescent under long-wavelength UV 
light. Purification via silica gel chromatography was attempted, however highly polar 
mixtures of apolar solvents and MeOH did not give suitable separation. Water and/or 
ammonia was added to the eluents to improve separation, and although this helped to 
isolate single spots by TLC, upon analysis by NMR it was found that once again, the product 
was not clean. As such, investigations towards the synthesis of an alkynyl substituted 
cytidine were terminated. 
2.2.3. Purine bases 
After the unsuccessful synthesis of the alkynyl cytidine derivative, it was attempted to 
functionalise both 2’-deoxyadenosine (dA) and 2’-deoxyguanosine (dG). As was the case 
with halogenated cytidine, 8-halogenated dG and dA were prohibitively expensive. As a 
result, the direct halogenation of both was required and a number of literature methods 
were attempted.  
The bromination of guanosine was first attempted, and the first conditions attempted 
proved successful. The  was treated with N-bromosuccinimide in a mixture of acetonitrile 
and water, evaporated to dryness and recrystallised from acetone at –20 °C for 48 hours.149 
This provided the desired product in a good yield, with no further purification required. 
 
Scheme 2.14 Bromination of 2’-deoxyguanosine 
The bromination of adenosine was also attempted, however this required a more thorough 
investigation. After the success of guanosine with NBS, this was repeated on the adenosine 
substrate, however no conversion to desired product was observed. Elemental bromine was 
then employed on the substrate, as a literature search showed that many methods utilise 
aqueous bromine in acidic sodium acetate buffer. Of the many procedures reported, most 
vary slightly in concentration of buffer used or in work-up procedure. After attempting 
several literature conditions, it was found that bromine in pH 4.0 sodium acetate/acetic acid 
1.0 M buffer was suitable, however it was important to run the reaction at a low 
concentration of 2’-deoxyadenosine of 0.05 M and ensure that the reaction was run in the 
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absence of light. The desired product was isolated via co-extraction of acetic acid and the 
product with CH2Cl2. 
 
Scheme 2.15 Bromination of 2’-deoxyadenosine 
After the successful isolation of the pyrimidine bases, the Sonogashira cross-couplings were 
attempted. Literature procedures for the cross-coupling with Pd(II) species were followed, 
however crude TLCs showed no conversion, or very weakly fluorescent new spots forming. 
In cases where the reaction did show new spots by TLC, it was attempted to isolate the new 
product via silica gel chromatography. 
 
Scheme 2.16 Attempted cross-coupling of 2’-deoxyguanosine 
In a similar manner to 2’-deoxycytidine, the pyrimidine nucleosides were incredibly polar 
and it was difficult to isolate new spots. After some attempts, conditions were found which 
resulted in crude 1H NMR and MS indicating desired product, however upon purification, 
only trace amounts of low purity were obtained. Upon introduction of Pd(0) species, the 
reactions resulted in the formation of highly fluorescent species for both dG and dA. Due to 
the strongly coordinating nature of the purines and their increased number of coordinating 
atoms compared to the pyrimidines, the adenosine and guanosine is likely getting too 
strongly adsorbed to the silica and can no longer be isolated because of the strong H-
bonding array that is formed with the solid phase.  
Due to the difficulties encountered during protection of the cytidine derivative, it was 
decided that while it was desirable to include additional nucleobases in the study, in the 
interest of time the route towards redox active pyrimidines would be abandoned. 
Disappointingly, this resulted in the isolation of deoxyuridine as the only modified 
nucleoside. This somewhat limits the biological targets that can be selected to those that are 
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rich in adenosine (due to the A-T binding), however it was still possible to conduct a 
thorough investigation into the effects of internal labelling on enzymatic digestion. 
2.3. Ferrocenyl azide library development 
With access to the patents and intellectual property of Atlas Genetics, their library of 
ferrocene compounds was studied to find a suitable ferrocene label to conjugate to the 
uridine. The key decisions to make were regarding the length of the linker to tether the 
ferrocene, and the desired oxidation potential of the substrate. As the following studies 
were a proof-of-principle investigation, it was decided that an unsubstituted ferrocene 
would be used with no additional functionality on the cyclopentadiene rings. The length of 
the linker to be used was also of importance, as the additional aromatic triazole formed in 
any click reaction between the base and the ferrocene would add additional length to the 
linker. It was hypothesised that too short a linker may disrupt base pairing of the 
nucleobases, however too long a tether made allow the ferrocene to wrap back around and 
interfere with the binding of DNA to double strands. As such, it was decided to use a simple 
ferrocene linker, 3-ferrocenylpropan-1-ol, 38. 
 
Scheme 2.17 Synthesis of 3-ferrocenylpropan-1-ol 
To achieve this, ferrocenecarboxaldehyde was first subjected to the Horner-Wadsworth-
Emmons reaction. The resultant enone was isolated quantitatively after a quick work up 
and trituration with hexane. The enone of the resulting product was hydrogenated, again 
resulting in quantitative conversion and isolation of clean ferrocenyl ester. Finally, the ester 
was reduced and purified to prepare the desired compound in an 83% yield (Scheme 2.17). 
It was then necessary to convert the alcohol into the corresponding azide. This was first 
attempted via the use of diphenylphosphoryl azide (DPPA). This did not, however, lead to 
desired product. The DPPA did indeed undergo electrophilic attack from the nucleophilic 
oxygen, however the reaction did not proceed past the intermediate phosphinate, as the 
resulting azide nucleophile did not displace the phosphinate to give desired product. It was 
thought that additional azide source in the form of sodium azide could help the reaction to 





Scheme 2.18 Attempted direct azidation of ferrocenyl alcohol 
A two-step reaction was instead investigated, whereby the alcohol would first be converted 
into a suitable leaving group and then undergo nucleophilic substitution. The first leaving 
group that was utilised was a tosylate. The alcohol was treated with tosyl chloride and 
triethylamine, however leaving the reaction overnight at 40 °C resulted in no new 
compounds being formed via TLC analysis. The temperature was further increased to 60 °C, 
after which point new spots began to appear via TLC. A work-up was carried out and the 
new spot was isolated, however it was found that while the tosylate had indeed been formed 
in situ, the resulting product was more reactive than the tosyl chloride, and as such the 
remaining alcohol attacked the tosylate intermediate 40 to yield the dimer 41. The reaction 
was repeated in higher dilution and increased equivalence of tosyl chloride, however the 
dimer was still formed as the major product. 
 
Scheme 2.19 Tosylation of ferrocenyl alcohol 
The installation of a bromide leaving group was therefore investigated. This was achieved 
through the Appel reaction, treating the alcohol with carbon tetrabromide and 
triphenylphosphine. No evidence of the ferrocenyl dimer 41 was observed by TLC or 1H 
NMR analysis. 
 
Scheme 2.20 Bromination of ferrocenyl alcohol 
The initial reaction gave the desired product in a 73% yield, however conducting the 
reaction in anhydrous solvent and cooling for the addition of PPh3 increased the yield. The 
work-up procedure was further improved after trituration of the reaction mixture with 
hexanes to precipitate out the phosphine oxide formed in the reaction, enabling the desired 
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compound to be isolated quantitatively. This compound was found to be light sensitive - if 
the vial was stored on the bench for two days, a powdery, brown residue began to form 
around the glass. The decomposing mixture could, however, be passed through a silica plug 
to clean the remaining material and then be used in further reaction without issues. 
A suitable method to convert the bromide to the azide was then investigated. Sodium azide 
was employed as the azide source. Initial conditions used sodium azide in a CH2Cl2:H2O 
mixture with TBAI as a phase transfer and nucleophilic catalyst, however the product was 
only isolated in 40% yield, and due to safety concerns during potential scale up of mixing 
chlorinated solvents and azide species, other methods were investigated. Literature 
searches of the conversion primary bromides into azides gave new conditions of using an 
excess of sodium azide in ethanol under reflux, which again only gave the product in 50% 
yield. Considering the reaction is a simple SN2, it would be expected to undergo conversion 
to product in higher yields and as such further methods were investigated. 
The third method that was attempted also used an excess of sodium azide in a 1:1 mixture 
of acetone/water (Scheme 2.21). Stirring at room temperature overnight gave no 
conversion, however heating the mixture to 70 °C dramatically increased the rate of the 
reaction, and after heating for 2 hours no starting material remained. After a simple work-
up and filtration through silica, the desired ferrocenyl azide 39 was obtained in 95% yield.  
 
Scheme 2.21 Conversion of ferrocenyl bromide to azide 
2.3.1. Substituted ferrocenes 
Through changing the electron density on the ferrocene ring, the oxidation potential can be 
finely tuned. By introducing electron-donating or electron-withdrawing groups, the number 
of signals that can be incorporated in the range of the electrodes is increased due to the 
small peak width of the ferrocene based system. This allows for the simultaneous detection 
of different DNA targets via the conjugation of labels with different oxidation potentials to 
different probe sequences. 
The research carried out by Atlas Genetics has previously identified a range of substitution 
patterns with varying oxidation potentials that are suitable for multiplexing. As such, the 
goal in this chapter was not to identify a multiplex capability, but to investigate whether 
incorporating “mass-spectrometry labels” would be applicable. As such, electrophiles with 
isotopic patterns visible in mass spectrometry were chosen to allow for the enzymatic 
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digestion products of probes to be studied via mass spectrometry, with the goal of making 
the digested oligonucleotides easier to identify due to the isotopic pattern present. This 
could, in theory, provide insight to action of various chosen enzymes, and therefore inform 
the optimal labelling sequence of probes. 
To modulate the oxidation potential of ferrocene, the functionality on the cyclopentadiene 
rings must be modified. The use of 1,1’-dibromoferrocene as starting material allows for the 
introduction of two different functional groups through lithium-halogen exchange, yielding 
1,1’-disubstituted ferrocenes. The aldehyde handle on a ferrocene is particularly useful, as 
this allows a range of chemistry to be carried out immediately after functionalisation, as 
utilised with the formation of the first ferrocenylazide label through the Horner-
Wadsworth-Emmons reaction. It can also be reduced to the alcohol and the benzylic alcohol 
can then be etherified though the Lewis-acid catalysed substitution with diols. 
To this extent, 1,1’-dibromoferrocene was synthesised according to the literature 
procedure.133 Additionally, the reaction is easier to conduct on a large scale (100 mmol) 
allowing stocks of starting material to be synthesised (Scheme 2.22). Despite having largely 
different electronic properties, halogenated ferrocenes are difficult to separate by 
chromatography. An elegant method of purification developed by Long and co-workers 
exploited the differing oxidation potentials by using iron (III) chloride solution to oxidise 
any remaining unreacted and mono-brominated ferrocene.150 The desired product was then 
recrystallised from hot methanol to remove any unreacted tetrabromoethane. 
 
Scheme 2.22 Synthesis of 1,1’-dibromoferrocene 
1,1’-dibromoferrocene was then converted into 1’-bromoferrocenecarboxaldehyde through 
treatment of the dibromide with n-BuLi, followed by quenching with DMF to yield the 
desired aldehyde. 
 
Scheme 2.23 Lithium-halogen exchange and quenching of dibromoferrocene 
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This aldehyde itself has enough functionality to affect the oxidation potential of ferrocene, 
however it is desirable to introduce a range of functionality to allow for further multiplexing 
capability. As such, the aldehyde was protected as the 1,3-dioxolane to allow for further 
lithium-halogen exchanges to occur. 
 
Scheme 2.24 Acetal formation of ferrocenecarboxaldehyde 
With the protection of the electrophilic site complete additional substitution could now be 
performed. To synthesise the substituted ferrocenes, the standard electrophilic substitution 
was carried out via lithium-halogen exchange followed by quenching with the desired 
electrophile. The reactions must be carried out in a thoroughly deoxygenated Schlenk flask, 
otherwise the reaction often failed or gave very low yields, resulting in either the protonated 
species, or unidentified decomposition products. The reaction is simple to track, as after 
deprotonation with n-BuLi, the FcLi precipitate forms as it is insoluble in THF at low 
temperatures. This is indicative of a successful lithium-halogen exchange and as such can 
be used as an early indication of the success of the reaction. Work up with sodium hydroxide 
and purification via silica gel chromatography then generated the newly substituted 
ferrocenes in good, reproducible yields.  
 
Scheme 2.25 Electrophilic substitution of ferrocenyl acetal 
The telescoped chain extension was employed to extend the alkyl chain of these derivatives 
(cf. the synthesis of 3-ferrocenylpropan-1-ol 38), however subjecting 1’-
bromoferrocenecarboxaldehyde 45, and the stannyl derivative 48 to this reaction resulted 
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in complete protodehalogenation and protodestannylation, and as such this route was 
deemed not suitable for substituted ferrocenes. 
Due to the unsuitability of the Horner-Wadsworth-Emmons reaction, the acetals were 
converted to the corresponding alcohol. To increase the chain length, the pseudobenzylic 
alcohol can be subjected to the ytterbium (III) triflate catalysed etherification. This protocol 
was first applied to benzylic substrates,151 where the ytterbium acts as a Lewis acid catalyst 
forming a stable benzylic carbocation, followed by nucleophilic substitution by excess diol. 
The reaction can be conducted on ferrocenyl methanols with varying lengths of diols.134 
The reaction was applied to 1’-bromoferrocenecarboxaldehyde, first reducing the aldehyde 
with sodium borohydride, followed by treatment of the resultant alcohol with ytterbium 
(III) triflate (Scheme 2.26). 
 
Scheme 2.26 Etherification of 1’-bromoferrocenecarboxaldehyde 
The substituted 1,3-dioxolanes were subjected to the same reaction, however upon 
deprotection it was found the aldehydes were particularly unstable, and as such the reaction 
was telescoped from the deprotection through to the chain extension (Scheme 2.27). Each 
step showed full consumption of starting material to a single spot by crude TLC, and as such 
was used without further purification at each stage. 
It was found that the tributylstannane underwent a significant degree of 
protodestannylation during the telescoped procedure. A single spot was observed when 
carrying out TLC for the reduction to yield the intermediate alcohol 52, however upon 
extension of the chain, the Rf of the stannyl and protio species separated, and as such it was 
possible to separate the two products by silica gel chromatography at the final step. 
 
Scheme 2.27 Etherification of substituted ferrocenes 
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The conditions for conversion of the ferrocenyl alcohol to the azide developed previously 
were attempted on 53, 54, and 55, however it was found that the conversions to the 
corresponding bromides via and Appel reaction were unsuccessful. These ferrocenyl 
alcohols were, however, successfully converted into the corresponding azides via a one-pot 
mesylation and nucleophilic substitution reaction (Scheme 2.28). 
 
Scheme 2.28 Azidation of substituted ferrocenyl alcohols 
2.3.2. Conjugation of ferrocene to 2’-deoxyuridine via the copper-catalysed azide-alkyne 
cycloaddition 
After the successful synthesis of a small library of ferrocenyl azides, the conjugation of these 
to the uridine was investigated. First, a test CuAAC reaction was carried out with simple 
alkynes to investigate the suitability of the ferrocenes with alkyne substrates (Scheme 2.29). 
According to literature procedures, the copper (II) sulfate and sodium ascorbate catalyst 
system was used, employing 10 mol% catalyst loading. Using 1-azido-3-ferrocenylpropane 
39, this was conjugated to both trimethylsilyl acetylene and propargyl alcohol with great 
success, showing that the ferrocene system is indeed stable under the conditions. 
 
 
Scheme 2.29 Test CuAAC reactions with ferrocene 
Having shown the ferrocene is stable under CuAAC conditions, it was then attempted to 
conjugate the ferrocene directly to the nucleoside. This was achieved by combining the 
ferrocene and the protected alkyne in the presence of copper (II) sulfate and sodium 
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ascorbate. The reaction proceeded slowly, with the formation of a new spot occurring after 
only 2 hours. The spot continued to grow, and after stirring overnight at rt, the product was 
found to have precipitated out of solution to leave a yellow slurry. The reaction was 
subjected to a simple aqueous work-up to remove the salts and quick column to remove any 
unwanted starting materials remaining to generate the desired product in a 48% yield. 
 
Scheme 2.30 Conjugation of ferrocenyl azide to nucleoside 
After the successful synthesis of the ferrocenylated deoxyuridine, it was then attempted to 
protect the 5’-hydroxyl group. Following standard literature procedures for tritylation, the 
nucleoside was treated with DMTrCl in pyridine. After 18 hours at room temperature, there 
was no indication of the formation of desired product, and crude 1H NMR showed only 
starting materials. 
 
Scheme 2.31 Attempted tritylation of ferrocenyl nucleoside 
DMTr protection occurs via an SN1 reaction, leaving the stable benzylic carbocation 
intermediate. It is plausible that due to the bulky ferrocene in the 5-position of the uridine, 
this could block the large planar trityl cation and therefore no protection would occur. As 
such, the order of reactivity was changed, and it was decided to swap the protection and 
tritylation. Additionally, this would reduce the number of steps required after conjugation 
of the ferrocene. The DMTr protection was therefore carried out on the free alkyne 
substrate, and the CuAAC was then performed on the protected nucleoside. By carrying out 
the reaction in this order it was possible to synthesise the redox active protected nucleoside 




Scheme 2.32 CuAAC with pre-installed 5’-protecting group 
The library of ferrocenylazides was applied to this reaction such that a range of ferrocenyl 
uridines were synthesised (Scheme 2.33). 
 
Scheme 2.33 Library of substituted ferrocenyl nucleosides 
Under the CuAAC reaction conditions, the derivative 66 was not stable, instead yielding the 
protodestannylated species 64. The yield of all reactions was disappointingly low at under 
50% for all three, likely due to ferrocene decomposition, as evidenced by the brown colour 
of the aqueous layer upon work-up, and staining of the silica upon purification. 
2.3.3. Phosphoramidite activation of redox active nucleosides 
The final stage of chemical synthesis for the ferrocenyl uridines was to convert the 3’- 
hydroxyl into the phosphoramidite, ready for solid-phase oligonucleotide synthesis. This 




Scheme 2.34 Phosphoramidite formation of ferrocenyl 2’-deoxyuridine 
The reaction proceeded smoothly, with indications of a successful reaction from DIPEA·HCl 
precipitation after only a few minutes, and a new spot forming by TLC after 10 minutes. 
Upon aqueous work-up and standard column chromatography, the new spot was isolated. 
Upon analysis, it was apparent that two products had been isolated. Diastereomers are to 
be expected as the molecule has multiple stereogenic centres, including a newly formed 
stereogenic phosphorous centre, which was formed with no stereocontrol. This would, in 
itself, lead to a complicated 1H NMR as the diastereomers could not be separated in the 
eluent systems trialled, but the 1H NMR spectrum was particularly crowded, and the 31P 
NMR spectrum showed both a P(III) and a P(V) species, with the P(V) peak at 10 ppm being 
the major product. Phosphoramidites are known to readily oxidise to the phosphoramidate, 
and as such the reaction was repeated, however great care was taken to remove risk of 
oxidation. 
All solvents used had argon bubbled through prior to use, including work-up and column 
solvents. The laboratory did not have air-free purification techniques, therefore the column 
was set up such that a nitrogen flow was used instead of traditional bellows, and secondary 
needle was attached to the spout of the column to ensure no additional oxygen entered the 
system. Additionally, as the compounds are coloured and the Rf of the starting material and 
product were significantly different, it was possible to collect directly into a round-bottom 
flask and evaporate solvents with minimum exposure to air. This level of care allowed the 
desired product to be isolated without any trace of the P(V) species. 
As the ferrocenylthymidine phosphoramidite had been synthesised successfully, it was 
necessary to also synthesise a 5’-label of a similar size and substitution pattern to compare 
digestion properties of 5’-labelling vs. internal labelling. To this extent, it was chosen that 3-
ferrocenylpropan-1-ol 38 was to be converted into the corresponding phosphoramidite 69. 




Scheme 2.35 Phosphoramidite formation of 5’- label 
The non-nucleosidic phosphoramidites are significantly more stable than nucleoside 
derivatives, however caution was also taken to ensure the desired product was isolated as 
solely the P(III) species. 
Due to low yields and small scale of the other ferrocenyl nucleosides 64-67, they were not 




2.4. S1 digestions of mono-ferrocene oligonucleotides 
S1 Nuclease is a single-strand specific endonuclease, having activity in the 5’-3’ direction. It 
cleaves DNA and RNA to release 5’-phosphorylated mono and oligonucleotides (Scheme 
2.36).152 S1 nuclease was chosen as a proof-of-concept digestion protocol, to investigate in 
a simple reaction whether the current could be increased. This would allow desired probe 
sequences to be synthesised and tested, without relying on PCR protocols or cDNA 
hybridisation. 
The S1 assays have a lower level of complexity than double-stranded digestions as there are 
fewer components. This was used as a check to see whether the ferrocene attached to the 
oligonucleotide would inhibit enzymatic activity. If these probes did not digest under S1 
nuclease conditions, then their applicability to a full assay would be in doubt. 
 
Scheme 2.36 S1 nuclease activity 
2.4.1. Internal Control sequence selection 
The sequence chosen was based on Atlas Genetics’ internal control (IC) probe sequence, 
which is used in their detection assays to confirm the result of the test. The IC sequence is a 
23mer with 5 dT residues. It was decided to substitute the thymidine units for the modified 
ferrocenyluridine 68 in a sequential manner, from the 5’-end towards the 3’-end. This 
resulted in the design of six probes (Table 2.2). One probe was designed as a control (IC-C), 
to compare the internal labelling strategy to the 5’- labelling. The dT residues were then 
substituted for 68 in a stepwise manner. 
The synthesis of these probes was conducted by ATDbio, who were provided with roughly 
100 µmole of phosphoramidites 68 and 69 for the synthesis of the various probes. The 
probes were synthesised via the phosphoramidite method and purified and analysed via 
HPLC. HPLC-MS traces confirmed the successful inclusion of all ferrocene units (Appendix 





IC-C 5’Y-GCA CGA TCC CTT TCC TAA AGA CG-3’ 
IC-1 5’-[p]-GCA CGA Um144CC CTT TCC TAA AGA CG-[p]-3’ 
IC-2 5’-[p]-GCA CGA Um144CC CUm144T TCC TAA AGA CG-[p]-3’ 
IC-3 5’-[p]-GCA CGA Um144CC CUm144Um144 TCC TAA AGA CG-[p]-3’ 
IC-4 5’-[p]-GCA CGA Um144CC CUm144Um144 Um144CC TAA AGA CG-[p]-3’ 
IC-5 5’-[p]-GCA CGA Um144CC CUm144Um144 Um144CC Um144AA AGA CG-[p]-3’ 
Table 2.2 Internal Control oligonucleotide sequences. [p] = phosphorylated. 
 
Figure 2.2 Key for Table 2.2 
The synthesis of these probes was conducted by ATDbio, who were provided with roughly 
100 µmole of phosphoramidite for each probe. HPLC-MS traces confirmed the successful 
inclusion of all ferrocene units, however coupling efficiencies were not provided by the 
company. 
The multi-labelled probes were then subjected to S1 nuclease digestion to investigate their 
possible increased signal. It was decided not to attempt to optimise the reaction buffer, and 
as such all S1 digestions were conducted according to the supplier’s protocol.153 
The background oxidation of the probes was first investigated (Figure 2.3). When 
comparing background oxidations, the 5’-labelled probe IC-C results in a higher signal than 
the mono internally labelled probe IC-1. When the ferrocene building block is incorporated 
on the 5’-end, it is hypothesised it can access the electrode surface more readily, hence 
leading to oxidation at the surface. When this is moved internal to the oligonucleotide, this 
is not as easily accessible due to formation of secondary structures, therefore a 
comparatively reduced current.  
This effect is not continued throughout, however, as substitution for additional ferrocene 
units leads to an increase in current. The effective concentration of ferrocene is increasing 
and as such leads to an increase in current. The additional ferrocene units could also disrupt 
the formation of secondary structures, resulting in the ferrocene cores being more available. 
There is correlation between number of ferrocenes and current generated, such that the 
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background rate of the penta-labelled probe IC-5 has the highest background. The increase 
in current for the internally labelled probes exhibits a linear relationship. 
 
Figure 2.3 IC probes (6 µM), pH 4.5 NaOAc buffer, 37 °C, 30 minutes. 
The digestion of the probes was then investigated to assess their applicability in a diagnostic 
assay. It is believed the intact probe is too large to generate a significant level of current, as 
the size of the probes means limited diffusion will occur and upon introduction of S1 
nuclease the 3’- O-P bond is cleaved therefore realising smaller nucleosides, which are able 
to diffuse to the electrode and undergo redox cycling. 
Initially, the probes were studied by DPV after treatment with S1 nuclease for 15 minutes. 
The IC-C, IC-1, and IC-2 probes showed full digestion in 15 minutes at 37 °C. This is clearly 
seen in the voltammograms as both an increase in current and a shift in Eox occurs. For the 
IC-C probe, the background Eox is centred around 190 mV, which shifts to 100 mV upon 





Figure 2.4 IC-C, S1 nuclease (10 U), pH 4.5 NaOAc buffer, 37 °C, 15 minutes 
All internally labelled probes exhibited a similar shift in oxidation potential, such that the 




Figure 2.5 IC-1, S1 nuclease (10 U), pH 4.5 NaOAc buffer, 37 °C, 15 minutes 
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The Eox of all the internally labelled probes comes at the same potential for the digested 
probes indicating that the same species is being oxidised. The incorporation of five 
ferrocene units has an effect on the current generated, but the electronic environment of 
the different units remains constant, or at least very similar, in all probes. 
Probes IC-3, IC-4 and IC-5 did not digest within 15 minutes. This was observed on the 
voltammograms, where the spectrum is no longer a single peak. This can be attributed to 
the intact probe as the secondary peak, observed as a shoulder, comes at the same oxidation 
potential as the background (Figure 2.6). 
 
Figure 2.6 IC-4, S1 nuclease (10 U), pH 4.5 NaOAc buffer, 37 °C, 15 minutes 
The digestion time was increased to 30 minutes at 37 °C for all probes to allow for full 
digestion. This allowed the IC-3, IC-4, and IC-5 probes to digest, confirmed by the absence 
of a secondary peak, to the extent that only a single probe was observed in the 
voltammogram. 
Having established suitable digestion conditions for all probes, the experiments were 
repeated to obtain a spread of data. Due to the variable nature of the screen-printed 
electrodes, the value from one scan to another can vary significantly, and as such the runs 




Figure 2.7 IC probes (6 µM), pH 4.5 NaOAc buffer, S1 nuclease (10 U). 37 °C, 30 minutes 
Upon digestion the internally labelled probe IC-1 resulted in an increased signal compared 
to the 5’-labelled probe IC-C. This is hypothesised to be mainly due to increased solubility 
of the probe in the aqueous medium, as the probe is conjugated directly to the nucleobase 
which will improve its solubility. Introducing multiple ferrocenyl units resulted in an 
increase for two and three ferrocenyl units, however no significant increase in signal was 
observed when four or five units were incorporated.  
Theoretically, the maximum signal that could be generated for IC-5 is 5 times the current of 
the IC-1, as if full digestion has occurred the concentration will be 5 times as high. To 
investigate this further, IC-1 was studied at 30 µM to determine whether the higher labelled 
probes were inhibiting enzyme activity, or the high ferrocene concentration could have 
caused an electrode overload (Figure 2.8). 
The background rates were studied at the higher concentration of 30 µM. Increasing the 
background concentration did not result in a fivefold increase in background. Upon 
digestion, the increased concentration of IC-1 resulted in a large increase in signal. This 
indicated that there is no overload occurring at the electrode, and that the lower signal can 
be attributed to reduced digestion. From the voltammograms, it is clear that there was no 
undigested probe present, as there was no secondary peak or shoulder. This suggests the 
probe is still being fully digested despite the increased substitution. 
If the digested products are smaller, i.e. mono or di nucleotides, it will result in a higher 
signal. It is possible that the size of the products digested is different, resulting in the lower 
signal. S1 nuclease may digest the probe to a suitable degree to lower its oxidation potential 
such that only a single peak is observed, however leave the probe large enough so it is 




Figure 2.8 IC internally labelled concentration studies IC-1 (6 µM and 30 µM) and IC-5 (6 µM), S1 nuclease (10 
U), pH 4.5 NaOAc buffer, 37 °C, 30 minutes. 
It was hypothesised that there is no real benefit from having more than three labels on the 
IC sequence. The increased background rate, but lack of increase in digested signal, results 





2.4.2. CT sequence selection 
It was postulated that the proximity of the substituted thymidine units to each other could 
be inhibiting the enzymatic activity leading to lower signal of the probes than what was 
expected. Due to the proximity of the thymidine residues in the IC sequence, it was difficult 
to spread the labels out and as such, it was desirable to move to a sequence in which the Um 
could be separated. As such, the C. trachomatis (CT) sequence used by Atlas Genetics in their 
assays was chosen as a suitable probe.154 As such, six more probes were designed and 
synthesised, this time focussing on increasing the number of nucleotides between each 
label. 
Probe Sequence 
CT-mC 5’Y - CTG TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
CT-1 5’-[p]-CUm144G TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
 CT-2 5’-[p]-CUm144G TCC GCUm144 GGT TCT TCC TTA CT-[p]-3’ 
CT-3 5’-[p]-CUm144G TCC GCUm144 GGT TCT TCC TTA CUm-[p]-3’ 
 CT-4 5’-[p]-CUm144G Um144CC GCUm144 GGT TCT TCC TTA CUm-[p]-3’ 
CT-5 5’-[p]-CUm144G Um144CC GCUm144 GGT TCT TCC Um144TA CUm144-[p]-3’ 
Table 2.3 Chlamydia trachomatis oligonucleotide sequences. [p] = phosphorylated. 
These probes were subjected to the same digestion protocol with S1 nuclease (Figure 2.9). 
The background rate of these probes follows a similar trend to the IC equivalents, showing 
a slight decrease in signal for the mono internally labelled probe CT-1 vs.  CT-C, and then a 





Figure 2.9 CT probes (6 µM), pH 4.5 NaOAc buffer, 37 °C, 30 minutes 
Upon digestion, the mono internally labelled probe CT-1 resulted in a greater signal than 
the control probe CT-C, with an increase in signal also being observed for the CT-2 probe, 
however similar to findings with the IC probes, the introduction of 3 or more ferrocenes did 
not result in any significant increase in signal (Figure 2.10). 
 
Figure 2.10 CT probes (6 µM), pH 4.5 NaOAc buffer, S1 nuclease (10 U). 37 °C, 30 minutes 
The CT sequence gave lower signals than the IC sequence. The max current generated was 
2000 nA, however the IC sequence could give currents up to 2500 nA. Additionally, the 
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signal plateau was observed at a lower substitution value of two units, (cf. three for IC 
sequence). This was contrary to initial thoughts, as it was hypothesised that by increasing 
spacing between functionalised dT units would improve digestion properties, however this 
was not the case. 
Probes CT-1 to CT-5 were studied by mass spectrometry (MS) to study the digestion profile 
via UPLC-MS, however due to the already low concentration of the probes, no information 
fragments or intact probes could be identified. Due to the small scale and low yields of 
conjugating the MS-labelled species to uridine, it was deemed unviable to convert these into 
the corresponding phosphoramidites. 
2.5. Conclusion 
A range of ferrocenyl azides were coupled to 2’-deoxyuridine utilising the CuAAC reaction. 
One of these redox active nucleobases was chosen as a suitable test substrate in which to 
incorporate into oligonucleotides. The internal control and C. trachomatis sequences used 
by Atlas Genetics were chosen and up to five ferrocenes were successfully incorporated into 
the 23mer oligonucleotides as confirmed by HPLC-MS for all probes. The oligonucleotides 
showed a linear increase in background current for the substitution level. It was shown that 
it was possible to increase the signal for single strand S1 digestions, indicating compatibility 
with enzymes and the probes were shown to undergo digestion despite high level of 
substitution, however there was no benefit to including more than three ferrocenes on a 
single strand. The continued digestion of all probes was promising for further development 





3. Design, synthesis, and testing of di-ferrocenylated nucleosides 
3.1. Introduction 
Chapter 2 focussed on the synthesis of a library of mono-ferrocenyl azides, with initial 
studies investigating the suitability of internally labelled oligonucleotides in solution-based 
DNA detection. It was shown that upon digestion, the new labelling strategy allowed for 
increased signal in a simple single-stranded S1 digestion. 
It was next investigated whether the signal could be further improved in a digestion assay 
through increasing the number of ferrocenes, without increased substitution of thymidine 
units, as a signal plateau was observed and no increase in signal could be generated past 
three substituted nucleotides. 
There were two main goals for the work in this chapter, namely increasing the signal that 
could be generated in a digestion and generating a system which would enable improved 
multiplex detection. 
Atlas Genetics has found great success with di-ferrocene labels (Figure 3.1), finding that 
they give higher signals and tend to have smaller peak widths. As well as improved 
sensitivity, the smaller peak width allows increased multiplex capability, as this enables a 
greater number of ferrocenes with different oxidation potentials to be incorporated into a 
single voltammogram.155 However, only labels 70 and 71 have been successfully 
incorporated into diagnostic assays due to limited sensitivity of mono-labels and difficulties 
with the synthesis of other labels. 
One of the first labels used by Atlas Genetics in a diagnostic assay was di-275 (70), a di-
substituted amine which contained two ferrocene cores. This label, and derivatives thereof 
(Figure 3.1), gave a greater than twofold increase when used in diagnostic assays, indicating 
a synergistic effect of the multiple redox centres. The ferrocene label nomenclature used 
relates to both the structure and oxidation potential e.g. “di-275” (70) is a 





Figure 3.1 Atlas Genetics’ di-ferrocene labels 
To date, Atlas Genetics have not carried out any investigations into the crystal structures of 
the di-ferrocenes. It was hypothesised that the presence of the tertiary amine and shape of 
the di-ferrocenes could be responsible for the vastly improved electronic properties. There 
are scant literature examples of this bis(ferrocenylmethyl) amine structure, with Kaifer and 
co-workers dominating the examples with their work towards dendritic ferrocenes.112,156–
161 The bis(ferrocenylmethyl) amine crystal structures refined by Tice et al.160 (74), Alvarez 
et al.159 (75), and Kerr et al.161 (76) showed an interesting perpendicular arrangement 
between the ferrocene cores, while the  structure of tris(ferrocenylmethyl) amine (77) 
reported by Sun et al.157 also exhibited the interesting arrangement to some degree. 
 
Figure 3.2 bis and tris (ferrocenylmethyl) amines exhibiting perpendicular arrangement 
It was of interest to investigate the structure of the library of Atlas Genetics’ labels to 
determine whether they also adopt a similar spatial arrangement to those previously 
reported. As such, crystals of a selection of bis(metallocenylmethyl) amine structures were 
grown. Previous attempts to grow crystals have proven futile, with crystals being twinned 
or amorphous and therefore unsuitable for crystallography. Samples of 70 and 73 were 
synthesised (Scheme 3.1), while the chloride 71 and ruthenocene 72 derivatives were 
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donated by Atlas Genetics, however 71 is unsuitable for crystallography as it is an oil at 
room temperature. 
 
Scheme 3.1 Reductive amination of ferrocenecarboxaldehydes 
To grow crystals of suitable quality, the compounds were first subjected to standard 
recrystallisation from hot ethyl acetate to improve sample purity after silica gel 
chromatography. Single crystals were then grown through combined warming and layering 
methods, first dissolving in the minimum warm ethyl acetate, followed by gentle layering of 
petroleum ether (60–80 °C) on top. This was a suitable method and single crystals of each 
compound were grown. 
It was interesting to discover a perpendicular orientation between the two metallocene 
centres, which was observed for all three metallocenes studied. The most pronounced 
arrangement was that of the 1’-bromo derivative 73 (Figure 3.4), while the ruthenocene 
derivative did not exhibit such an obvious structure (Figure 3.5). It was hypothesised that 
the orientation between the two ferrocene units would allow for communication between 
the two, resulting in a synergistic effect and as such giving a greater than twofold increase 
in signal. The structures of these labels are similar to the structures previously reported in 
the literature, which could give further evidence towards the origin of the improved 
performance of these structures. 
 




Figure 3.4 ORTEP diagram of di-437 (73) 
 
Figure 3.5 ORTEP diagram of di-763 (72) 
Knowledge of the relationship between structure and enzymatic performance could allow 
for informed and intelligent design of probes, selecting probes whose signals are far 
superior. These crystal structures could form the basis of computational studies in which 
the relationship is further explored. 
3.2. Di-ferrocene synthesis and nucleobase conjugation 
Given the superior performance of di-ferrocenes in diagnostic assays, it was desirable to 
incorporate the di-ferrocene labels into the internal labelling strategy. As such, the synthesis 
of a library of di-ferrocenyl labels was attempted, first synthesising the ferrocenyl alcohols, 
followed by conversion to the corresponding azide. 
Following the success of the route towards 3-azido-1-ferrocenylpropane 39, it was 
attempted generate the di-ferrocenyl azide 78 via a telescoped Appel reaction and 
nucleophilic substitution with sodium azide (Scheme 3.2). Pleasingly, this gave the desired 




Scheme 3.2 Azidation of di-275 
It was also attempted to convert alcohols 71 and 73 to the corresponding azides via the 
Appel reaction, however attempts to convert the labels to the bromide failed, returning only 
starting material. 
 
Scheme 3.3 Appel reaction of substituted di-ferrocenes 
It was thought that by installing the azide functionality before the reductive amination could 
overcome this issue, improving synthesis by first forming the azide from 6-aminohexan-1-
ol (81). The amine was first Boc protected using standard conditions, and formation of the 
bromide was achieved via an Appel reaction to give the desired product 82. 
 
Scheme 3.4 Protection and Appel reaction of 6-aminohexan-1-ol 
After finding success for the conversion of primary bromides to azides with sodium azide in 
acetone, 82 was subjected to the same conditions, however the reaction did not proceed, 
and no formation of product was observed. As the azide nucleophile failed to displace the 
bromide, further optimisation was performed to convert the alcohol to an azide. It was 
found that by forming the mesylate intermediate from 81, followed by addition of azide in 
situ allowed formation of the desired intermediate protected compound 83 in quantitative 




Scheme 3.5 Azidation of 6-aminohexan-1-ol 
This was then deprotected using trifluoroacetic acid, followed by a basic aqueous work up 
to yield the desired aminoazide 84 (Scheme 3.6). 
 
Scheme 3.6 TFA deprotection of Boc-aminoazide 
The aminoazide 84 was then substituted into the reductive amination, and this allowed the 
reaction to proceed cleanly, giving the desired product in 68% yield (Scheme 3.7). 
 
Scheme 3.7 Reductive amination with aminoazide  
By performing the reactions in this order, this led to a 17% increase in yield from 
ferrocenecarboxaldehyde. Additionally, this would allow for reduced complexity when 
synthesising substituted di-ferrocenes due to the fewer linear steps. 
To test the route towards redox active nucleobases, the ferrocene 78 was conjugated to 2’-
deoxyuridine via the CuAAC conditions developed in Chapter 2 (Scheme 3.8), which was 





Scheme 3.8 CuAAC reaction between 5-ethynyl-2’-deoxyuridine and di-ferrocenylazide. 
Due to the size of the additional ferrocene unit and the lengthy 6-carbon linker, it was 
hypothesised that a shorter linker should be synthesised to reduce the structural flexibility 
in the system as this could interfere with duplex formation or inhibit enzymatic digestion of 
the probes. To this extent, 3-aminopropan-1-ol 86 was converted to the azide via the same 
method as the hexanol derivative. The reaction was telescoped from the alcohol through to 
the HCl salt of the azide 27, obtaining the desired product 87 in a 63% yield (Scheme 3.9). 
The salt is incredibly hygroscopic and difficult to work with unless fully dry, which could 
not be achieved via high vacuum oil pump alone, however a vacuum desiccator with P2O5 
was found to efficiently dry the compound to a constant mass after one week. 
 
Scheme 3.9 Conversion of alcohol to azide 
This shorter linker 87 was employed in the reductive amination of 
ferrocenecarboxaldehyde (Scheme 3.10). Pleasingly, the formation of the freebase in situ 
did not hinder the reaction, generating the desired product 88 in 72%¸ similar to the yield 






Scheme 3.10 Reductive amination with shorter aminoazide 
It was then sought to conjugate the ferrocenyl azide 88 deoxyuridine, which was achieved 
through treatment of the azide and alkyne with the copper (II) sulfate and sodium ascorbate 
catalyst system, in the same manner as the mono-ferrocene derivatives, yielding the desired 
product 89 in a 58% yield (Scheme 3.11).  
 
Scheme 3.11 Click between shorter di-ferrocenylazide and 5-ethynyl-2’-deoxyuridine. 
After the successful synthesis of an unsubstituted di-ferrocenyl deoxyuridine, attention was 
turned to synthesise substituted ferrocene derivatives. As the mono-ferrocene library 
focussed on the synthesis of mass spectrometry labels, it was of interest to generate a 
system with multiplex capability to allow for the detection of multiple targets in a single 
assay utilising the internal labelling strategy. As such, electron-rich and electron-poor 
derivatives were adapted from Atlas Genetics’ patents. Having already synthesised the 
unsubstituted di-275 derivative, it was required to synthesise electron-poor and electron-
rich ferrocenecarboxaldehydes to enable the formation of substituted di-ferrocenes via the 
reductive amination reaction. 
The halogen series offers an opportunity to increase electron-withdrawing capability with 
relatively simple synthetic ease. As the synthetic route towards substituted ferrocenes 
requires access to 1’-bromoferrocenecarboxaldehyde 45 (synthesis in Chapter 2), this gives 
access to an electron-poor substituent with no additional synthesis required. 
82 
 
To keep in line with AG’s library, the chloride derivative was also synthesised. The synthesis 
of chloroferrocene 90 was achieved via the use of Schlosser’s base to achieve mono-lithiated 
ferrocene (Scheme 3.12).162 Lithioferrocene was then quenched with hexachloroethane, and 
subjected to oxidative purification, cf. 1,1’-dibromoferrocene,150 to remove any unreacted 
ferrocene. The product was recrystallised to yield the chloroferrocene in 60% yield. 
 
Scheme 3.12 Chlorination of ferrocene 
This was then converted to the corresponding carboxaldehyde via the modified Vilsmeier-
Haack reaction as a melt to install the desired aldehyde functionality (Scheme 3.13). The 
reaction proceeded with 4:1 regioselectivity, with the 1,1’- substituted carboxaldehyde 
being the major product. As the unsubstituted cyclopentadienyl ring is more electron rich, 
the regioselectivity generated is in favour of the top ring, confirmed by the splitting pattern 
upon 1H NMR analysis. 
 
Scheme 3.13 Formylation of chloroferrocene 
An electron-rich ferrocenylaldehyde was also required, and to achieve this, 1’,2’,3’,4’,5’-
pentamethylferrocenecarboxaldehyde 95 was synthesised. The ferrocene core was 





Scheme 3.14 Synthesis of 1’,2’,3’,4’,5’-pentamethylferrocenecarboxaldehyde 
Although the yield of the reaction is not particularly high (34%), and has complex timings, 
the reaction is simple to purify. Unsubstituted ferrocenes are very apolar, and as such any 
mixed sandwich would be difficult to purify as it is inevitable that both decamethylferrocene 
and ferrocene would also form in the reaction. By pre-installing the aldehyde moiety on the 
cyclopentadienyl ring, any mixed sandwich that forms will have significantly different Rf 
values, therefore allowing the material to be isolated cleanly via silica gel chromatography 
without the need for sublimation techniques. 
The introduction of a mass spectrometry substituent was also investigated. Earlier studies 
with the tributylstannane derivative proved unsuccessful due to high levels of 
protodestannylation observed during synthesis of the azide, and regardless of the low 
yields, the stannane did not survive the conditions of the CuAAC reaction, instead yielding 
the protodestannylated ferrocene derivative (Chapter 2). It was thought that by moving 
from tributyl to trimethyl derivative, the stannane may be more stable and therefore survive 
the CuAAC reaction to yield a stannylated deoxyuridine. To this extent, 1’-bromoferrocene-
1,3-dioxolane 46 was converted to the trimethylstannane derivative 96, using trimethyltin 
chloride as a source of electrophilic tin. 
 
Scheme 3.15 Lithium halogen exchange and quench with tin electrophile 
This was then converted into the corresponding aldehyde 97 through treatment of the 
acetal with an excess of p-toluenesulfonic acid in dichloromethane and water. The reaction 
proceeds cleanly and is high yielding with no trace of the protio species, however as is 
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common with substituted ferrocenecarboxaldehydes, the resulting aldehyde 97 was 
unstable and as such must be used immediately or stored at –20 °C over argon. 
 
Scheme 3.16 Acetal deprotection of stannylated ferrocene 
The reductive amination was then performed on the library of ferrocenylcarboxaldehydes 
that had been synthesised. The reaction was tolerant of all substituents, yielding the di-
ferrocenyl azides in 18–74% yields (Scheme 3.17), and gave minimal levels of the undesired 
alcohol by-product. The stannyl derivative was well tolerated in the reaction, giving the 
desired product 100 in 60% yield, however both the chloride 101 and pentamethyl 102 
derivatives performed poorly. This was clear during purification as both derivatives cause 
staining of silica, indicative of ferrocene decomposition. The chloride derivative left 
significant levels of brown residue on the silica, indicative of oxidation from Fe(II) to Fe(III), 




Scheme 3.17 Reductive aminations on ferrocenecarboxaldehydes 
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The CuAAC reactions were performed on 5-ethynyl-2’-deoxyuridine with the di-ferrocene 
library (Scheme 3.18). The unsubstituted, bromide, chloride, and pentamethyl derivatives 
were well tolerated in the reaction, all giving yields above 50%, however the stannylated 
derivative 106 was not isolated, instead showing complete protodestannylation during the 
reaction. 
 
Scheme 3.18 Click reactions of substituted ferrocenes and deoxyuridine 
Previously, Atlas Genetics have used the unsubstituted and chloro di-ferrocenes as a duplex 
detection method, however they have struggled to find a third label of suitable sensitivity. 
The pentamethyl derivative has never been fully evaluated by Atlas Genetics due to poor 
initial screening results, so it was of interest to investigate whether this could be improved 
through internal labelling. 
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To assess the multiplex capability, compounds 89, 103, and 107 were dissolved in pH 9.0 
Tris buffer, and subjected to voltammetric analysis. The three labels in a single, equimolar 
solution gave three easily distinguishable peaks, with only a slight overlap in the baseline 
(Figure 3.6). 
 
Figure 3.6 DPV of Multiplex labels 89, 103, 107, 5 µM, PCR buffer 
It was then sought to synthesise the phosphoramidites of each label. In each case, the 
reaction proceeds cleanly, with early indications of success visible by the precipitation of 





Scheme 3.19 Phosphoramidite formation of di-ferrocenyldeoxyuridines 
The reaction can be tracked via TLC without the need for visualisation methods, with the 
reaction showing the formation of a single new spot after 10 minutes. As was the case with 
the mono-ferrocenes, the Rf of the phosphoramidite is significantly higher than the free 3’-
OH, allowing for visual isolation of desired product during chromatography. 
A pragmatic approach was employed for the isolation of desired product, opting for purity 
rather than yield. Due to the compounds’ susceptibility to oxidation when solvated, TLCs 
are not used to identify desired column fragments, instead utilising the compounds’ colour 
to isolate desired fractions. As such, to minimise risk of including starting material in the 
isolated product, some of the desired product remains on the column. 
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3.3. S1 digestions of di-ferrocene oligonucleotides 
The mono-ferrocene probes gave promising results, however it was clear that there was a 
limit in the current that could be generated due to the increased substitution of the probes. 
It was therefore investigated whether an increase in effective ferrocene concentration could 
be achieved via the introduction of the di-ferrocenes, rather than increase the level of 
substitution on the oligonucleotide probes. In theory, this would allow for a twofold 
increase in signal for the same level of oligonucleotide substitution. 
The C. trachomatis sequence was chosen to allow future incorporation in a double stranded 
DNA digestion assay with clinical targets. Atlas Genetics have had great success with the 
label whose core 108 is based on, and as such this nucleoside was chosen for incorporation 
into the CT sequence (Table 3.1). All labels were shown to have been fully incorporated into 
the probe sequences confirmed by HPLC-MS provided by the oligonucleotide suppliers. 
Probe Sequence 
CT-dC 5’-Z- CTG TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
CT-6 5’-[p]-CUd275G TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
 CT-7 5’-[p]-CUd275G TCC GCU275 GGT TCT TCC TTA CT-[p]-3’ 
CT-8 5’-[p]-CUd275G TCC GCU275 GGT TCT TCC TTA CUd275-[p]-3’ 
 
 
CT-9 5’-[p]-CUd275G Ud275CC GCUd275 GGT TCT TCC TTA CUd275-[p]-3’ 
CT-10 5’-[p]-CUd275G Ud275CC GCUd275 GGT TCT TCC Ud275TA CUd275-[p]-3’ 
Table 3.1 Chlamydia trachomatis probe di-ferrocene sequences. [p] = phosphorylated.  
 
Figure 3.7 Key for Table 3.1 
The digestions were carried out at the reduced concentration of 3 µM (previously 6 µM for 
mono-ferrocenes), to account for the increased effective concentration of ferrocene 
compared to the mono labels.  The probes were digested using the same protocol as the 
mono-ferrocene labels discussed in Chapter 2. Upon treatment with S1 nuclease, the control 
5’-ferrocenylated probe CT-dC was shown to undergo full digestion in 30 minutes, and the 
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digested product resulted in a shift in Eox of roughly 50 mV when compared to the intact 
oligonucleotide (Figure 3.8).  
 
Figure 3.8 DPV of intact oligonucleotide CT-dC against digested probe. pH 4.5 NaOAc buffer, S1 nuclease (10 
U), 37 °C, 30 mins 
The internally labelled probes were also subjected to digestion under the same conditions, 
and it was shown all probes undergo full digestion in 30 minutes. The shift in oxidation 
potential between the intact and digested probe was similar at roughly 60 mV (Figure 3.9). 
 
Figure 3.9 DPV of intact oligonucleotide CT-6 against digested probe. pH 4.5 NaOAc buffer, S1 nuclease (10 U), 
37 °C, 30 mins 
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The shift in oxidation potential observed was much smaller than that of the mono-
ferrocenes. This is likely due to the proximity of the labels to the nucleoside. In the mono-
ferrocene derivatives, the linker between the triazole and the ferrocene moiety was much 
smaller, whereas with the di-ferrocenyl labels, they have two additional atoms between the 
ferrocene and the triazole. In theory, this makes it more difficult to determine whether the 
probes have undergone full digestion. In the case of the mono-ferrocenylated probes, the 
Eox of the two species have distinct oxidation potentials, and it is clear when there is a second 
peak. As the digested and undigested Eox of the di-ferrocene probes are close together, the 
presence of a shoulder would potentially not be as clear as in previous digestion studies, as 
it would be masked by the large peak height of the digested product. 
 
Figure 3.10 Di-ferrocene CT probe background, pH 3.4 NaOAc buffer, 30 mins, 37 °C 
As was observed in Chapter 2 for both IC and CT sequences, moving from 5’- to internal 
labelling resulted in a slight reduction in background signal for CT-6 vs.  CT-dC, and a linear 
increase in background oxidation of the probes CT-6 through CT-10 (Figure 3.10). 
The probes proved significantly more sensitive than their mono-ferrocene equivalents. For 
the mono-ferrocene oligonucleotide probes, neither IC nor CT sequences were able to 
generate currents above 3000 nA at 6 µM. With the di-ferrocene CT probes, it was possible 
to increase this signal up to 10000 nA at only 3 µM, a huge increase in current compared to 




Figure 3.11 di275-CT probes, S1 nuclease, 37 °C, 30 minutes, Autolab detection 
The digestion appears to follow a similar trend to the mono-ferrocene probes (Chapter 2), 
with a maximum current being generated with the incorporation of two labels. As most of 
the data points overlap for 2, 3, 4, and 5 substitutions, it can be said that no clear benefit 
arises from having more than two labels. With the mono-ferrocene label in Chapter 2, a 
signal increase was observed up to the point of three substitutions, however with the di-
ferrocene this maximum was observed at two. The only difference in the probes is the label 
used, as such it is likely that there is some degree of enzyme inhibition caused by the bulky 
di-ferrocene. 
3.3.1. Comparison of probe sensitivity 
To quantify any improvements between traditional 5’-labelling and internally labelled 
probes, the sensitivity and limit of detection (LOD) were calculated in the range of 0.5 µM 
to 6.0 µM (Table 3.2). 
Probe Sensitivity (nAµM-1) Limit of Detection (µM) 
CT-mC 76 0.128 
CT-1 149 0.074 
CT-dC 808 0.005 
CT-6 1452 0.003 
Table 3.2 Sensitivity and LOD calculations for selected probes 
Internal labelling resulted in a twofold increase in sensitivity for both the mono-ferrocenes 
and the di-ferrocenes. The di-ferrocene labels are known to perform better in diagnostic 
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assays, however have never been evaluated for their sensitivity. These studies indicate the 
di-ferrocene labels gave a tenfold improvement in signal compared to the mono-ferrocene 
equivalent.  
3.3.2. Mass spectrometry analysis 
It is believed the increase in signal from the control to the digestion can be attributed to the 
release of mononucleotides which are able to diffuse to the electrode surface. The intact 
23mer is unable to diffuse to the electrode surface, but the small nucleotide has increased 
availability at the electrode, therefore leading to higher electrochemical signals. 
To confirm this hypothesis, the digestion mixtures were subjected to HRMS, searching for 
monomers, dimers, and trimers of the digest products. Probes CT-dC and CT-6 were 
subjected to digestion, identifying the [M-H]- peak in both for the expected mononucleotide 
released. CT-dC is conjugated to the 5’-end where cytidine is the terminal nucleotide, 
therefore releasing the 3’-hydroxyl nucleotide into solution (112), while for CT-6 the 
presence of the phosphorylated ferrocenyl-uridine CuAAC adduct (113) was also confirmed 
(Appendix 6). No di- or tri-nucleotide species were detected in either solution. 
 
Figure 3.12 Structures of mononucleotides released by S1 nuclease 
The control digestions were also analysed, displaying the intact oligonucleotide for both 
probes. The monomers were not detected in either of the control solutions.  
3.4. Conclusion 
The internal labelling strategy was expanded to di-ferrocene structures to study the 
potential improved signal through increased ferrocene concentration. A range of di-
ferrocenyluridine phosphoramidites were synthesised, allowing for multiplex capability. 
One of these labels was incorporated into a clinically relevant 23mer showing improved 
signal over the mono-ferrocene probes developed in Chapter 2. 
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4. Internal Labelling in Diagnostic Assays 
4.1. Introduction 
Sexually transmitted infections (STIs) are a major health concern globally. It is estimated 
that in the US $16 billion is spent annually on STI related diseases, with direct costs in 
treating infections totalling to $740 million.163 In 2012, the estimated worldwide prevalence 
of C. trachomatis was 4.2% in women and 2.7% in men,164 with other common STIs (e.g. N. 
gonorrhoea, trichomoniasis, syphilis) typically having 0.5–1% prevalence,165 while there are 
roughly 1 million new curable STI infections every day.166 Patients with STIs have increased 
susceptibility to HIV, due to associated inflammation or ulcers.167 
Like much of the world, diagnosis rates of STIs in England has risen over the last decade, 
(20% increase in new STI diagnoses)168 however this cannot be wholly attributed to 
increased transmission rates. Increased awareness towards testing amongst all age groups 
has resulted in an increase of access to sexual health services, with total visits to specialist 
health services increasing by 386,000 (15.2%) between 2012 and 2016.169 
Efficient testing protocols are essential to enable timely and effective treatment. As 
discussed in Chapter 1, a range of testing protocols have been developed, such that the 
diagnosis of most pathogens can be achieved in only a few days. Regardless of the method 
in which the pathogen is detected (culture, immunoassay, NAAT, etc.), tests are typically 
performed in central laboratory settings, and as such have a significant time delay from the 
initial appointment to results and the administration of antibiotics (Scheme 4.1). Rapid 
point-of-care tests (POCTs) allow for decentralised diagnosis and can therefore offer 
significantly reduced waiting times for patients. 
The speed of diagnosis can have significant impact on the patient’s view of treatment, with 
some reports suggesting 99% of patients are willing to wait 2 hours for C. trachomatis 
results,170 and 98.8% would wait 1 hour for N. gonorrhoeae results.171 There is some 
discrepancy, however, with other reports indicating only 50% of patients would be willing 
to wait 40 minutes for CT diagnosis.172 Despite the differences in statistics, it is clear there 




Scheme 4.1 Typical diagnosis pathway (adapted from Atlas Genetics marketing material) 
Nucleic acid detection methods offer improvements over culture methods not only because 
of their speed, but the increased information that can be obtained could offer quicker 
treatment for critical, time-sensitive conditions such as sepsis or bacterial meningitis. The 
knowledge of specific serotypes can improve treatment protocols, allowing personalised 
medicine. For example, N. gonorrhoeae (NG)¸ amongst other bacteria, exhibits many 
different strains globally, each with varying antibiotic resistance. Infections caused by 
Staphylococcus bacteria are one of the most common and most can be treated with common 
antibiotics, however S. aureus has developed resistance to many antibiotics and is 
notoriously difficult to treat.173 Diagnosis of the bacteria’s serotype, and determination of 
which antibiotic to use, is usually conducted via culture followed by in vitro susceptibility 
testing, however rapid NAAT tests would eliminate the requirement for susceptibility 
testing, given the site of mutagenesis is known.16 
4.1.1 Point-of-Care diagnostics 
POCTs allow users with limited skills to execute highly complex analysis with minimal 
training. Typically, the healthcare worker which has the face-to-face interaction would not 
carry out any analysis as they do not have the required equipment, training, or time. 
Through the development of user-friendly devices which require little to no skilled input, 
centralised testing can be made more accessible with reduced waiting times. 
A number of rapid POC tests are now commercially available, however few have been widely 
implemented in their target market and routine testing can still take up to 9 days to 
complete.174 Early evaluations of implemented POC tests in England show a potential £11.7 
million saving per year to the NHS,175 as well as preventing up to 17,000 new infections and 
nearly 100,000 overtreatments compared to standard care.175 Several commercial POCTs 
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based on nucleic acid amplification exist for pathogenic bacteria,15 while a range of non-
NAATs exist for both CT,176 and NG177 with varying accuracy. 
The challenges facing POC devices varies between the developed and the developing world. 
Limited-resource settings use benchmark ASSURED criteria to identify the most 
appropriate testing equipment.178 This requires devices to be Affordable, Sensitive, Specific, 
User-friendly, Rapid and robust, Equipment-free and Deliverable to the end-users.12 Of 
course, sacrifices must be made for different criteria, but ultimately the devices must be 
reliable and available to users where other resources are limited. Devices are often limited 
due to their power needs or portability, particularly in rural areas, whereas developed 
countries have fewer constraints in the requirements of equipment, such that benchtop, 
rather than handheld, devices are usually sufficiently small and portable.  
Although cost reductions can be achieved through implementation of rapid POCTs, 
implications of false-negatives and false-positives remain a challenge. False-positives result 
in increased administration of unnecessary antibiotics, potentially contributing to the 
ongoing antibiotic crisis.173 False-negatives result in increased susceptibility to other 
infections and complications caused by the bacteria, as well as further transmission of 
infections to other patients. False-negatives, in the long term, can be costly due to 
complications requiring additional treatment. 
Sensitivity and specificity of POC tests is typically lower than gold standard assays,179 
however the improvement on the speed of patient treatment can outweigh the need for high 
sensitivity and specificity and result in an increase in the number of patients that receive 
treatment.180 
4.1.2 Atlas Genetics’ Diagnostic Assay 
Commercial POC NAATs mainly use fluorescent detection methods,174 however no device 
has been widely implemented in healthcare settings. Atlas Genetics’ (AG) proprietary 
technology combines chemistry, biology, and engineering into a single device to enable 
efficient patient diagnosis in a reduced time frame. AG have a range of patents covering their 
technology, ranging from the microfluidic system to the chemical labelling of the 
oligonucleotides.116,117,155,181–184 
The diagnostic assay is based on PCR amplification and solution-based electrochemical 
detection (Scheme 4.2), combining the sensitivity and specificity of PCR with the 




Scheme 4.2 Atlas Genetics’ diagnostic assay method 
The test requires minimal user intervention. The healthcare worker takes a clinical sample 
then loads the sample directly onto the disposable cartridge. This is then loaded into the 
desktop machine, the io®, where the patient’s details are input (Figure 4.1). From this point, 
the test is autonomous, with results displayed on screen showing either “positive” or 
“negative” for the desired target. 
 
Figure 4.1 Atlas Genetics io and cartridge 
The detection method allows for detection of essentially any DNA, given the target sequence 
is known. This lends itself well to applications for not only STIs, but also hospital acquired 
infections and genetic biomarkers. A range of tests are under development, with the CT 
assay achieving CE Marking in 2015, while the combined CT/NG assay is set to achieve CE 
Marking in 2019 and FDA approval in 2020. The CT assay offers sensitivity of 98.1% and 
specificity of 98.0%,185 while pre-clinical trials for the combined CT/NG assay showed a 
sensitivity of 91.9% and a specificity of 98.3% for CT, and sensitivity of 94.1% and 
specificity of 99.8% for NG. 
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The development of a library of labels has enabled a 6-plex detection system, exploiting the 
adjustable oxidation potential of ferrocene, however only two of these labels have been 
employed for use in a diagnostic assay due to limited sensitivity of the majority of the 
library. As such, the CT/NG assay utilises multiple detection chambers to allow for 
simultaneous detection of several targets, detecting for the internal control and a single 
target DNA sequence in each chamber. 
Improved digestion performance of probes could enable the use of multiple labels in a single 
chamber which have been previously unsuitable, therefore improving the multiplex 
capability of the system. If the improvements observed in Chapter 2 and Chapter 3 were 
also displayed in a full DNA detection assay, the detection of many more targets could be 
realised in a single test. In addition to improved multiplex capability, increased probe 
sensitivity could allow for fewer PCR cycles to be conducted, thus decreasing the time 




4.2 Double stranded digestions of internally labelled probes 
There is clear need for POC diagnostics in both the developed and developing world, with 
rapid diagnostics offering increased public health and reduced cost to healthcare providers. 
Nucleic acid amplification tests are superior to other methods (e.g. antigen detection) due 
to their sensitivity. Combining NAAT technology with solution-based DNA detection offers 
an opportunity to create sensitive, reliable, and cheap tests which could be widely 
implemented. 
It was of interest to investigate whether the introduction of internal labels into NAAT based 
tests could offer improved detection sensitivity, thus improving the performance of the 
diagnostic assays. The proof-of-concept single stranded assays discussed in Chapter 1 and 
Chapter 2 displayed promising results, suggesting that the internal labelling strategy could 
result in improved performance in double-stranded assays. 
After successful single stranded digestions, the probes were substituted into double 
stranded assays for future incorporation into DNA detections. There are a number of stages 
where the modified probes could fail in the assay. Firstly, the probes must hybridise with 
the complimentary DNA, as T7 exonuclease (T7 or T7 exo) will only digest dsDNA.186 
Secondly, the probes must not inhibit T7’s activity and allow the release of smaller units 
into solution. 
For reduced complexity, initial studies were conducted on synthetic target (ST) DNA, which 
are complementary oligonucleotides which have been made on a DNA synthesiser, rather 
than enzymatically (e.g. via PCR). This allows the probes to be studied with increased 
complexity compared to the ssDNA assays, but does not introduce such complex matrices 
associated with using PCR to prepare the complimentary DNA strands.  
Assays are conducted by combining a “detection mix” containing the appropriate probe and 
T7 exonuclease in T7 buffer with the target DNA. These are then heated to 37 °C for 3 
minutes using either thermal cyclers and an Autolab potentiostat for detection, or digesting 
the probes directly on the io machine. The digestion protocol was not optimised for internal 
probes, instead directly adopting the digestion protocol developed by AG for use in their 
assays, to see how these probes perform in comparison to the AG in-house standard. 
4.2.1 Internal Control double stranded assays 
The modified derivatives of AG’s internal control probes were first studied, using a “no 
template control” (NTC) to study the background in the new buffer, and to assess the 
reactivity between the internally labelled ssDNA probe and T7 exo (Figure 4.2). As the 
synthetic target negatives are completely DNA free and T7 is inactive on ssDNA (to any 
99 
 
reasonable degree), the negatives look to determine the inherent current that can be 
generated from probes in the T7 buffer. 
Probe Sequence 
IC-C 5’Y-GCA CGA TCC CTT TCC TAA AGA CG-3’ 
IC-1 5’-[p]-GCA CGA Um144CC CTT TCC TAA AGA CG-[p]-3’ 
IC-2 5’-[p]-GCA CGA Um144CC CUm144T TCC TAA AGA CG-[p]-3’ 
IC-3 5’-[p]-GCA CGA Um144CC CUm144Um144 TCC TAA AGA CG-[p]-3’ 
IC-4 5’-[p]-GCA CGA Um144CC CUm144Um144 Um144CC TAA AGA CG-[p]-3’ 
IC-5 5’-[p]-GCA CGA Um144CC CUm144Um144 Um144CC Um144AA AGA CG-[p]-3’ 
Table 4.1 Internal Control oligonucleotide sequences 
In initial testing, a probe concentration of 6 µM was utilised. This was too low to give a 
detectable signal, and as such the probes were studied at the increased concentration of 12 
µM. The background current in the T7 buffer was significantly lower than that of the S1 
buffer, despite doubling the concentration of the probes. The background of IC-C, IC-1 and 
IC-2 were either too low to detect, or under 5 nA even at 12 µM. (cf. in the range of 102 nA 
for S1 nuclease). Concurrent with S1 buffer, the signal of IC-3, IC-4, and IC-5 increased in a 
linear fashion such that IC-5 had the greatest background signal. The background signal is 
believed to be supressed slightly by the addition of bovine serum albumin (BSA) and Triton 
added to the detection mix. 
 
Figure 4.2 Internal Control probes, double stranded digestions. Detection mix: Probe (12 µM), detection 




The digestion of the probes in T7 buffer was then studied. The probes were treated with 
synthetic target (12 µM) and heated in PCR tubes at 37 °C for 3 minutes followed by 
electrochemical analysis at room temperature. Crucially, and most importantly, the probes 
gave a positive result in the presence of both T7 exo and complementary DNA, showing that 
the probes undergo hybridisation and are susceptible to enzymatic digestion. 
It was, however, disappointing to observe no significant difference in signal between any of 
the probes, or if anything slightly worse performance when comparing IC-C and IC-1. This 
was in contrast to the results observed for the S1 digestions, where increasing the level of 
substitution led to a concurrent increase in the current generated. As T7 and S1 have 
different directions of action, with T7 working in the 5’-3’ direction, this could account for 
the difference in signal observed between these two digestion protocols. Additionally, the 
different buffer solutions could account for the reduction. 
Synthetic target digestions give a crude indication of whether the dsDNA assay will be 
successful, as it is a simplified version of the full diagnostic assay. As such, to investigate the 
properties of the new probes in a full assay mimic, DNA was amplified via PCR to increase 
the complexity of the system, instead of using purified synthetic target DNA. To this extent, 
10 pg IC DNA was amplified via the rapid PCR protocol developed by AG. The probes were 
then studied under identical conditions to the ST assays, but replacing the synthetic target 
mix for PCR amplicon.  
Again, the background was first studied, and there was some degree of signal suppression 
observed compared to the ST assays. The additional complexity of the PCR solution 
(primers, polymerases etc.) is possibly limiting the availability of the ferrocene at the 
electrode surface, acting as blocking agents. The trend of the background oxidations, 




Figure 4.3 Internal Control probes, double stranded digestions. Detection mix: Probe (12 µM), detection 
buffer, T7 exo (16 U). DNA mix: NTC PCR mix (20 µL) or IC PCR (10 pg) mix (20 µL). 37 °C, 3 minutes in tube, 
Autolab detection. 
The IC probes were then treated with IC amplicon produced via PCR, which were then 
incubated in PCR tubes at 37 °C for 3 minutes followed by detection via DPV at room 
temperature (Figure 4.3). While all probes still gave positive results in the presence of 
cDNA, the results were somewhat disappointing compared to the synthetic target 
digestions, resulting in a lower signal than the control IC-C for all probes. 
These digestions showed that these probes were unable to give any increase in signal 
compared to traditional 5’ labelling. In efforts to increase the poor signal observed during 
the T7 digestions, the probes were next analysed using AG’s custom-build potentiostat, 
which is coupled to a Peltier in order to conduct digestions directly on the electrode sub-
circuit, and also allows the detections to be conducted at elevated temperatures. 
As such, the digestions were repeated, instead conducting both the digestion and detection 
on the sub-circuit surface. The samples are held at 37 °C for 3 minutes to allow for T7 
digestion, followed by DPV analysis while holding at 37 °C. 
The main downfall of the custom-build potentiostat is that both the hardware and software 
are inferior to that of the Autolab, and as such the DPVs generated are not of such good 
quality. The increased scan rate results in signals which have significantly more noise. 
Additionally, the code which was written for the peak analysis is very sensitive to peak 
width and the potential around which it is centred, meaning the algorithms written for AG 
are not optimised for use with the internally labelled oligonucleotides developed in this 
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thesis. This results in a slightly lower signal than would be expected by visual inspection, as 
part of the peak is included in in the calculation for the baseline. The move to the io also 
resulted in apparent elimination in background current, as this can often no longer be 
distinguished from the noise of the instrument by the algorithm used to calculate peaks. 
Upon digestion, there was an increase in signal observed for all probes due to the elevated 
detection temperature (Figure 4.4). Probe IC-2 containing two substitutions offered a slight 
increase in signal over the 5’-labellec control IC-C, however the digestion of the other probes 
containing multiple substitutions could not improve the signal generated.  
 
Figure 4.4 Internal Control probes, double stranded digestions. Probe (12 µM), detection buffer, T7 (16 U), IC 
PCR (10 pg) mix (20 µL). 37 °C, 3 minutes, io detection. 
The IC probes were the first internally labelled probes to be subjected to dsDNA digestions. 
While it was disappointing that the new probes did not yield an increase in signal compared 
to the control probe, it was promising to observe digestion for all probes under all 
conditions tested. The experiments in this chapter showed that crucially, the internal labels 
did not inhibit duplex formation or T7 exonuclease action. 
4.2.2 Chlamydia trachomatis double stranded assays 
As previously discussed in Chapter 2, the sequence selection of C. trachomatis was chosen 
to ensure as much space between labelled nucleosides as possible. Although S1 digestions 
of the mono-ferrocenyl CT probes showed a reduction in current compared to the IC 
sequence, an increase in signal of the assay was still a possibility due to the different mode 
of action between enzymes T7 vs.  S1. 
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4.2.2.1 Mono-ferrocene C. trachomatis probes 
To this extent, the mono-labelled CT probes were first subjected to T7 digestion with 
synthetic target DNA. The backgrounds of the probes were studied at the increased 
concentration of 12 µM in T7 buffer, and were of a similar level in current to the IC 
background signal. The CT probes CT-1 to CT-5 displayed increasing current in a linear 
fashion such that CT-5 gave the highest background signal (Figure 4.5). 
 
Figure 4.5 mono-CT probes, double stranded digestions. Detection mix: Probe (12 µM), detection buffer, T7 
exo (16 U). DNA mix: NTC ST mix (20 µL) or CT ST (12 µM) mix (20 µL). 37 °C, 3 minutes in tube, Autolab 
detection 
Probe Sequence 
CT-mC 5’Y - CTG TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
CT-1 5’-[p]-CUm144G TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
 CT-2 5’-[p]-CUm144G TCC GCUm144 GGT TCT TCC TTA CT-[p]-3’ 
CT-3 5’-[p]-CUm144G TCC GCUm144 GGT TCT TCC TTA CUm-[p]-3’ 
 CT-4 5’-[p]-CUm144G Um144CC GCUm144 GGT TCT TCC TTA CUm-[p]-3’ 
CT-5 5’-[p]-CUm144G Um144CC GCUm144 GGT TCT TCC Um144TA CUm144-[p]-3’ 
Table 4.2 mono-Ferrocene C. trachomatis oligonucleotide sequences 
The probes were then treated with T7 exonuclease in the presence of CT synthetic target, 
digesting in PCR tubes at 37 °C for 3 minutes. Pleasingly, the digestion of all internally 
labelled probes gave increased signal compared to the 5’- labelled control probe, CT-mC, 
increasing in current in a manner similar to the S1 digestions. CT-1 gave increased signal, 
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followed by further increases in signal for all probes, however there was a plateau with 
probes CT-4 and CT-5, showing no significant increase compared to CT-3. 
These results were promising, showing that with synthetic target DNA, the signal of the 
system can be increased upon digestion due to an increased number of labels. This data set 
also gave some evidence towards the hypothesis that the labelled nucleosides should be 
spread out to give optimum signal, as the IC sequence has three adjacent labelled 
nucleotides, which is thought to inhibit the assay. 
After these promising results, the CT probes were subjected to digestion with PCR 
amplicons of C. trachomatis serovar F (100 IFUs). As observed with the IC probes, there was 
a slight suppression in background current when using PCR mix, rather than synthetic 
target (Figure 4.6). Again, this could be attributed to a possibly blocking effect of the 
additional components on the availability of the probe at the electrode surface. 
 
Figure 4.6 mono-CT probes, double stranded digestions. Detection mix: Probe (12 µM), detection buffer, T7 
exo (16 U). DNA mix: NTC PCR mix (20 µL) or CT PCR (100 IFUs) mix (20 µL). 37 °C, 3 minutes in tube, Autolab 
detection. 
The amplicon solution was then treated with detection mixture and digested in PCR tubes 
at 37 °C for 3 minutes (Figure 4.6). Compared to IC, the CT probes gave higher current upon 
digestion, although this was still significantly lower than signals that would be generated in 
a standard assay. Digestions for the control showed higher signals than CT-1 and CT-2, with 
CT-3 giving similar signals to the control. It was clear, however that there was a significant 
reduction in signal for CT-4 and CT-5 which was not observed in the synthetic target studies. 
In contrast to synthetic target digestions the internal probes gave no significant increase in 
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signal in comparison to the control probe, but still exhibited activity towards T7 
exonuclease upon introduction of cDNA. 
Further CT dsDNA digestions were carried out on the io sub-circuits to mimic the 
commercial assay digestion protocol, with digestion and detection occurring directly on the 
electrodes. In a similar manner to the IC, when detections were carried out on the io, it 
resulted in reduced background current and an increase in signal of around 100 nA due to 
the increased detection temperature. Again, the internal probes showed a slight reduction 
for CT-1 and CT-2, however the digestion of probes CT-4 and CT-5 gave significantly 
improved results, generating similar signals to the control probe (Figure 4.7). 
 
Figure 4.7 mono-CT probes, double stranded digestions. Probe (12 µM), detection buffer, T7 (16 U), CT PCR 
(100 IFUs) mix (20 µL). 37 °C, 3 minutes, io detection. 
The increase in signal observed from the move from Autolab detection to io detection was 
larger than expected, but was displayed across both IC and mono-CT probes. The 
discrepancy in currents generated upon digestion between the Autolab and io is attributed 
to the increased temperature, however additional benefit could be due to the proximity of 
probes to the electrode prior to detection. The very low levels of potential across the 
electrode could allow for pre-equilibration during digestion, therefore leading to higher 
concentration at the electrode surface. 
The mono-CT probes showed promising results across all dsDNA digestions, showing 
improved performance over the IC probes. This gave some evidence towards the optimal 
labelling pattern. IC has labelled uridine units adjacent to each other, which is believed to 
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cause some level of disruption in base-pairing ability and T7 activity. The labelling pattern 
of the mono-CT probes, however, is much more spread out, with no labels being adjacent to 
each other. This was believed to improve the performance of the probes upon treatment 
with T7 exonuclease. 
4.2.2.2 Di-ferrocene C. trachomatis probes 
The mono-ferrocene probes showed improved digestion performance over the IC sequence 
which was attributed to the spacing of the labelled nucleotides, however the concentration 
of probe required was still relatively high compared to AG typical probe concentration in an 
assay (12 µM vs.  6 µM in a typical assay). Due to the di-ferrocene probes’ increased 
sensitivity over the mono-ferrocenes in S1 digestions discussed in Chapter 2 and Chapter 3, 
it was investigated whether the di-ferrocene probes could offer increased signal in dsDNA 
assays. Due to the increased sensitivity exhibited by these probes in an S1 digestion 
compared to the mono-labels, the concentration of the probe was reduced to 6 µM, to mirror 
the typical probe concentration in an AG diagnostic assay.  
To mimic the diagnostic assay, the di-ferrocene CT probes were treated with PCR amplicon 
to investigate whether the di-ferrocene CT internally labelled probes could be used to 
increase the signal in dsDNA assays compared to the control probe.  
To this extent, the background of the probes was studied in NTC PCR mix, and concurrent 
with previous studies the probes gave an increase in background current for each 
sequential dT substitution (Figure 4.8). The background currents generated were a similar 
level to the mono-ferrocene CT equivalents despite the reduced concentration of the di-Fc 
CT probes. 
Probe Sequence 
CT-dC 5’-Z- CTG TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
CT-6 5’-[p]-CUd275G TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
 CT-7 5’-[p]-CUd275G TCC GCU275 GGT TCT TCC TTA CT-[p]-3’ 
CT-8 5’-[p]-CUd275G TCC GCU275 GGT TCT TCC TTA CUd275-[p]-3’ 
 
 
CT-9 5’-[p]-CUd275G Ud275CC GCUd275 GGT TCT TCC TTA CUd275-[p]-3’ 
CT-10 5’-[p]-CUd275G Ud275CC GCUd275 GGT TCT TCC Ud275TA CUd275-[p]-3’ 





Figure 4.8 di-CT probes double stranded digestions. Detection mix: Probe (6 µM), detection buffer, T7 exo (16 
U). DNA mix: NTC PCR mix (20 µL) or CT PCR (100 IFUs) mix (20 µL). 37 °C, 3 minutes in tube, Autolab 
detection. 
CT PCR amplicon mixture was then treated with detection mixture and heated to 37 °C for 
3 minutes and analysed via DPV on the Autolab (Figure 4.8). The probes displayed increased 
signal vs. their mono-ferrocene equivalents, allowing detection to be carried out at the 
standard probe concentration of 6 µM while still offering an increase in signal. Probe CT-6, 
containing a single Ud275 substitution, offered a slight increase in signal compared to the 
control probe, CT-dC, however further substitution of the probe resulted in significant 
reduction in signal. The probes containing four and five substitutions (CT-9 and CT-10) 
failed to digest in the given conditions, displaying neither a shift in Eox or increase in current.  
The probes were then incorporated into io digestion and detection to mimic the digestion 
protocol used in an AG diagnostic assay (Figure 4.9). An increase in signal was again 
observed from moving from the Autolab to the io potentiostat despite the same 
concentration of probe used. This increased the current of the probes containing two and 
three substitutions such that CT-dC, CT-6 and CT-7 showed a similar spread of results, with 
a slight reduction in signal for CT-8, however the probes containing four and five Ud275 units 
remained inactive to T7 exonuclease. Due to their inactivity, CT-9 and CT-10 were omitted 
from any further studies due to inactivity. The complete inactivity suggests these probes are 




Figure 4.9 di-CT probes, double stranded digestions. Detection mix: Probe (6 µM), detection buffer, T7 exo (16 
U). DNA mix: NTC PCR mix (20 µL) or CT PCR (100 IFUs) mix (20 µL). 37 °C, 3 minutes, io detection. 
In a clinical assay, all the reagents would be pre-loaded into a disposable cartridge. To mimic 
this, the detection mixture containing the probe was applied to Atlas io sub-circuits and 
dried onto the surface prior to detection. To achieve this, a detection mix spot of 4 µL was 
applied to the centre of the sub-circuit and dried at 45 °C, 10% relative humidity for 10 
minutes. The sub-circuit was then sealed with adhesive and the screen-printed electrodes 
(Figure 4.10). 
 
Figure 4.10 Atlas Genetics sub-circuit and screen-printed electrodes 
These “dried-down” cartridges are reconstituted prior to use by applying the PCR amplicon 
mixture into the opening and mixing between the rest position and first stop of the pipette 
three times (Figure 4.11). This replicates the microfluidic movement of solutions through 
the cartridge in a full assay. The sub-circuits are then placed in the heated detection rig and 
subjected to the same digestion protocol as before, such that the probes are heated at 37 °C 





Figure 4.11 Loading of sample to dried-down sub-circuits 
The move from wet to dry detection mixture resulted in a large increase in signal of around 
200 nA generated for the probes analysed (Figure 4.12). The control, CT-6, and CT-7 gave 
nearly identical digestion signals, while CT-8 resulted in slightly reduced signal, as observed 
with the previous io detection (cf. Figure 4.9). Although there was an improved signal using 
the dry detection mix, there was no benefit to using the internally labelled system compared 
to the traditional 5’-labelling. 
 
 Figure 4.12 di-CT probes, double stranded dried detection. Detection mix (dry down, sub-circuit): Probe (6 
µM), detection buffer, T7 exo (16 U). DNA mix: NTC PCR mix (20 µL) or CT PCR (100 IFUs) mix (20 µL). 37 °C, 3 
minutes, io detection. 
Due to the similarity of double stranded digestion results observed across all probes, it was 
thought that the mechanism of T7 exonuclease digestion may result in incomplete digestion 
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of the probe strand, therefore limiting the signal that could be generated despite the 
increased ferrocene substitution. 
It is hypothesised that while the first label is being released, the next labels further down 
the sequence are not being digested, instead remaining as long oligonucleotides. Upon 
cleavage at the 5’ end, and therefore shortening of the probe, the duplex will be destabilised 
due to a reduction Tm, and as such the probe will be displaced and T7 will no longer be active 
on the single strand.  
The probes all showed promising results that it is indeed possible to digest the internally 
labelled probes, however these could not be used to increase signal in a full AG style assay 




4.2.3 Labelling patterns and mechanistic insight into T7 exonuclease digestion 
The exact mechanism of T7 exonuclease is currently unclear, and as such it is unclear what 
digestion products are being released after digestion (i.e. mono, di, tri-nucleotides). If this 
could be determined, it would allow more informed decisions to be made on probe 
sequences and allow for intelligent design of probes. 
The first CT sequences were designed with the hypothesis that ensuring the labels were as 
spread out as possible would enable digestion. It was decided to investigate the effect of 
grouping the substitutions closer together and determining whether the probe would still 
digest. The original probes labelled base positions 2 and 9, and 2, 9 and 23, so two new 
probes were designed to condense the spacing between the labels, and labelling bp 
positions 2 and 4, and 2, 4 and 9. This could give insight into optimal label sequencing. 
Probe Sequence 
CT-7 5’-[p]-CUd275G TCC GCU275 GGT TCT TCC TTA CT-[p]-3’ 
CT-8 5’-[p]-CUd275G TCC GCU275 GGT TCT TCC TTA CUd275-[p]-3’ 
 
 
CT-11 5’-[p]-CUd275G Ud275CC GCT GGT TCT TCC TTA CT-[p]-3’ 
 
CT-12 5’-[p]-CUd275G Ud275CC GCUd275 GGT TCT TCC TTA CT-[p]-3’ 
 Table 4.4 Chlamydia trachomatis probe sequences 
These probes were digested via S1 digestion to investigate the theory that the closer the 
labels are together, the larger the digested products and therefore lower the signal. Both 
new probes CT-11 and CT-12 were successfully digested by S1 nuclease while displaying 
reduced current compared to the labels which were more spread out (cf. CT-7 and CT-8) 
(Figure 4.13). This supports the hypothesis that the probes are required to be more spread 





Figure 4.13 di-CT probes, S1 digestions. Probe (3 µM), pH 4.5 NaOAc buffer. Negative control or S1 (10 U). 37 
°C, 30 minutes in tube, Autolab detection. 
These probes were then subjected to double stranded digestion with PCR amplicon under 
standard conditions, however neither CT-11 nor CT-12 showed any increase in current for 
amplicon vs. NTC, suggesting the probes were unable to form a duplex due to their inactivity. 
An additional di-ferrocene CT probe containing a single Ud275 substitution, CT-13, was 
designed such that the Ud275 unit was at the 3’ terminus on the 23rd base to investigate the 
effect of terminal labelling. It was hypothesised that by introducing the label at the terminus, 
T7 exonuclease would not fully digest this probe and no signal would be generated, as the 
duplex would be insufficiently stable due to its shortened length. 
Probe Sequence 
CT-13 5’-[p]-CUG UCC GCU GGT TCT TCC TTA CUd275-[p]-3’ 




Treatment of CT-13 with S1 nuclease resulted in a reduction in current compared to CT-6 
(Figure 4.14). The background oxidation was, as expected, of a similar level to that of CT-6, 
however upon digestion the probe did not result in a significant increase in current 
generated, being a factor of ten times lower than the CT-6 digest. Due to the proximity of the 
labelled nucleotide to the 3’-end, this is possibilty inhibiting the 3’-5’- action of S1 nuclease. 
 
Figure 4.14 di-CT, probes S1 digestions. Probe (3 µM), pH 4.5 NaOAc buffer. Negative control or S1 (10 U). 37 
°C, 30 minutes in tube, Autolab detection. 
The probe was then treated with CT PCR amplicon however it was shown to be completely 
inactive with no change in Eox or current observed. This is supports the hypothesis the 
formation of a shorter sequence will reduce duplex stability, therefore denaturing at a lower 
temperature and being unable to be digested as far down as the label. 
These studies have shown that for successful duplex formation and digestion, the probes 
must have more than one unsubstituted base in between them. If the labelled base is too 
close to the terminus, the probe will not undergo complete digestion as the T7 does not fully 




4.3 Multiplex detections with internally labelled oligonucleotides  
Double stranded digestions of the internally labelled probes with T7 exonuclease did not 
result in an improvement over traditional oligonucleotide labelling strategies. It was sought 
to determine whether this strategy could be used to increase the sensitivity of existing AG 
labels through improved digestion properties. In AG’s multiplex system, they have 
previously utilised two di-ferrocene labels for duplex detection. Other labels designed have 
lacked sensitivity therefore generating weak signals upon digestion and as such have not 
been successfully implemented into a triplex detection. For further development, it is 
desirable to create a library of labels with similar sensitivity to enable accurate diagnosis. 
The di-ferrocene deoxyuridine units previously synthesised allow for three labels to be 
detected in a single voltammogram. It was sought to create a multiplex detection system 
with the internally labelled ferrocenyl probes, and to this extent probes were designed to 
detect for IC, CT, and NG targets simultaneously. AG use two sequences for the detection of 
N. gonorrhoeae, however one was deemed to be less suitable for testing due to the location 
of the thymidine residues.187 
Probe Sequence 
IC-098 5’-[p]- CGG Ud098GT AGT TAT CTT GAC TCC TCC CGA GC -[p]-3’ 
NG-437 5’-[p]- GCA CGA Ud437CC CTT TCC TAA AGA CG -[p]-3’ 
 
CT-6 5’-[p]-CUd275G TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
 
Table 4.6 Multiplex probes for internal control, C. trachomatis, and N. gonorrhoeae 
 
Figure 4.15 Key for Table 4.6 
These probes were first subjected to S1 digestion individually to test for enzymatic activity. 
The background oxidation of IC-098 was studied in S1 buffer, and unfortunately there was 
an additional peak centred around -100 mV.  Upon treatment with S1 nuclease, the impurity 
peak did not change oxidation potential or increase in current, while the peak centred 
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around 180 mV shifted roughly 80 mV and increased the current generated, indicating 
successful digestion had occurred despite contamination with impurities. Due to the Cp* 
derivative’s issues with purification, this was not entirely surprising. Additionally, the mass 
return of these probes was significantly lower than other substituted oligonucleotides, 
further indicating probe instability. 
 
Figure 4.16 IC-098 probe S1 digestion. Probe (3 µM), pH 4.5 NaOAc buffer. Negative control or S1 (10 U). 37 
°C, 30 minutes in tube, Autolab detection. 
The N. gonorrhoeae probe was also subjected to the S1 digestion protocol, displaying full 
digestion in 30 minutes (Figure 4.17). Despite similar background currents, both the NG and 
IC probes were shown to produce significantly reduced signal upon digestion compared to 




Figure 4.17 NG-437 probe S1 digestion. Probe (3 µM), pH 4.5 NaOAc buffer. Negative control or S1 (10 U). 37 
°C, 30 minutes in tube, Autolab detection. 
  
Figure 4.18 IC/CT/NG probes, S1 individual digestions. Probe (3 µM), pH 4.5 NaOAc buffer. Negative control 




The probes were then detected in the same solution to test for multiplex capability. The 
probes were able to fully multiplex together, clearly showing the three different labels, 
despite the impurity from the IC-098 probe (Figure 4.19). 
  
Figure 4.19 IC/CT/NG probes combined S1 digestion. IC-098 (3 µM) CT-6 (3 µM), NG-437 (3 µM), pH 4.5 
NaOAc buffer. Negative control or S1 (10 U). 37 °C, 30 minutes in tube, Autolab detection.  
From visual inspection, it is difficult to immediately see the IC and NG probes, however upon 
peak search and analysis through individual value plot (Figure 4.20), both a shift in 
oxidation potential and an increase in signal are observed for each probe. Crucially, 
combining all three probes into a single mixture did not inhibit the digestion of any of the 
probes, with all three able to undergo digestion with S1 nuclease. The signal of each probe 
is relatively unaffected by combining all three probes into a single solution, with only a slight 




Figure 4.20 IC/CT/NG probes combined S1 digestion. IC-098 (3 µM), CT-6 (3 µM), NG-437 (3 µM), pH 4.5 
NaOAc buffer. Negative control or S1 (10 U). 37 °C, 30 minutes in tube, Autolab detection. 
The probes were then assessed for suitability in a double-stranded assay. The probes were 
first digested with amplified DNA in separate assays to individually assess their reactivity 
towards T7 exonuclease. 
Unfortunately, the IC-098 probe did not digest showing no change in either Eox or current 
after treatment with T7 and IC amplicons. This could be due to the proximity of the label to 
the start of the sequence, however the IC-1 probe was able to undergo digestion, which has 
the same labelling pattern, differing in the ferrocene label used. Alternatively, the size of the 




Figure 4.21 IC/CT/NG probes, double stranded individual digestions. Detection mix: Probe (6 µM), detection 
buffer, T7 exo (16 U). DNA mix: NTC PCR mix (20 µL), or IC PCR (10 pg) mix (20 µL), or CT PCR (100 IFUs), or 
NG PCR (100 nmoles). 37 °C, 3 minutes in tube, Autolab detection. 
Due to the inactivity of IC-098 in target assays, it was eliminated from the multiplex assay. 
To this extent, a simultaneous CT/NG PCR was conducted and detected using a CT/NG 
combined detection mix. Pleasingly, this showed both probes underwent digestion in the 
target assay, with minimal detectable backgrounds. The peaks can clearly be distinguished 
from NTCs (Figure 4.22). Analysis of the results clearly shows both probes have been 
successfully digested by T7 exonuclease in the presence of amplified DNA, displaying both 




Figure 4.22 Voltammogram of CT/NG multiplex digestion. Detection mix: CT-6 (6 µM), NG-437 (6 µM), 
detection buffer, T7 exo (16 U). DNA mix: NTC PCR mix (20 µL), or combined CT (100 IFUs)/NG (100 nmoles) 
PCR. 37 °C, 3 minutes in tube, Autolab detection. 
Despite their similar performance in individual assays, the NG probe resulted in slightly 
reduced signal compared to the CT probe (Figure 4.23). The CT and NG probes both showed 
large increase in signal compared to the NTCs. 
 
Figure 4.23 CT/NG multiplex digestion individual value plot. Detection mix: CT-6 (6 µM), NG-437 (6 µM), 
detection buffer, T7 exo (16 U). DNA mix: NTC PCR mix (20 µL), or combined CT (100 IFUs)/NG (100 nmoles) 
PCR. 37 °C, 3 minutes in tube, Autolab detection. 
121 
 
These results show the internally labelled probes are suitable for use in a duplex detection 
assay. Disappointingly, one of the labels chosen did not digest under the conditions studied, 
however combined with other results this can be attributed to the properties of the 
ferrocene label itself being incompatible, rather than due to the internal labelling strategy. 
Further studies of ferrocene derivatives incorporating electron-donating substituents may 




4.4 Lambda-exonuclease digestions 
The digestion of dsDNA with T7 exonuclease is very quick, being complete in only 3 minutes. 
It is believed its mode of action involves “jumps” on and off the duplex, digesting small di-, 
tri- and tetranucleosides at a time. Once T7 has digested the target strand to a certain 
degree, the duplex will no longer be stable due to its reduced Tm, and will denature at the 
detection temperature of 37 °C. This hypothesis is supported with the results shown by CT-
13, which has a labelled uridine residue at the 3’-end, on the 23rd base pair. The mechanism 
of lambda exonuclease (λ or λ-exo) is a threading action from 5’ to 3’, whereby the enzyme 
threads DNA through the active site, releasing mononucleotides and ssDNA.188 It is 350 
times more active on dsDNA than ssDNA and the substrate requires 5’-phosphorylated 
DNA189  
The traditional 5’-labelled probes are unsuitable substrates for λ-exo due to the bulky 5’-
ferrocene label and lack of 5’-phosphate. After design of the new internal labelling, it was 
thought the new probes may be suitable substrates for λ-exo. 
Probe Sequence 
CT-13 5’-[p]-CTG TCC GCT GGT TCT TCC TTA CUd275-[p]-3’ 
 
CT-6 5’-[p]-CUd275G TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
 CT-dC 5’-Z- CTG TCC GCT GGT TCT TCC TTA CT-[p]-3’ 
Table 4.7 Lambda exonuclease probes 
Initial studies conducted by AG on CT-6 and CT-dC indicated that while λ-exo successfully 
digested PCR amplicons, as demonstrated by gel electrophoresis, neither the 5’- or 
internally labelled probes digested to a significant level in 60 minutes.190 As both of these 
probes were shown to digest after treatment with cDNA and T7 exonuclease, it was believed 
the mid-strand ferrocene in CT-6 was blocking the action of λ-exo. This was later discovered, 
however, to be due to the length of the 3’-overhang generated in PCR, as overhangs greater 
than 100 base pairs in length inhibit the digestion reaction 30-fold.191 
After synthesis of probe CT-13, the experiments were repeated with synthetic target rather 
than amplicon, showing that previous results indicating CT-6 was inactive were masking 
the true reactivity of the probe. The runs were repeated, showing that CT-6 and ST cDNA do 
indeed digest in the presence of λ-exo, while probes CT-dC and CT-13 are completely 




Figure 4.24 CT probes, λ-exonuclease susceptibility testing. Probe (6 µM), lambda buffer, λ-exonuclease (5 U), 
synthetic target mix (12 µM), 
λ-exo has slower reactivity than T7 exo, which is seen in the growth of signal over a 60-
minute period. The signal generated, however, is far superior to that of the T7 assay, with 
12-minute digestion with λ-exo offering similar signal to the 3-minute digestion of T7 exo. 
The enzyme did, however, generate higher signals, which can be attributed to the known 
release of mono-nucleotides and an intact single-stranded DNA. The mono-nucleotides 
released are likely to have superior signal compared to the dimers and trimers that are 
thought to be released with T7 exonuclease. 
The extension of the redox active nucleotides into probes which are selective for particular 
enzymes could allow for improved diagnostic assays, or use of labels which were previously 
unsuitable with T7 exonuclease. A two-enzyme system could allow for logic gate style 
functionality if suitable buffer systems can be created. 
4.5 Conclusion 
This chapter has discussed the application of internally labelled oligonucleotides in double-
stranded DNA assays. The internally labelled probes were shown to undergo digestion in 
the same fashion to 5’-labelled control probes without any increase in signal, as was 
observed for the S1 digestions. Integration of the probes onto the diagnostic platform 
proved successful, however no significant performance increase compared to the 5’-
labelled controls was observed. 
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The internal multiplex labels were incorporated into suitable probe sequences and used to 
detect a CT/NG combined PCR in a single assay. 
Along with the synthesis of a number of sequence permutations, the use of multiplex system 
offered some insight into the necessary ordering of labelled oligonucleotides to allow for 
digestion. These results indicate labels must be at least three base pairs away from each 
other to allow for optimal digestion. It is here that the mass spectrometry labels would be 
particularly useful, to identify intact fragments to determine how much of the 
oligonucleotide is being successfully digested. However, studies conducted with 
oligonucleotide digests did not offer information as due to high dilution and high salt 
concentration. Further development of these labels, in combination with de-salting columns 
to improve resolution, could provide valuable information on sequence selection. 
Due to the additional synthesis required for the internally labelled probes, studies 
conducted in this thesis suggest that they are not worth pursuing for use with T7 to offer an 
improved digestion protocol. 
The new internally labelled probes allowed for use of λ-exonuclease, which has been 
previously unsuitable for use with the 5’-labelled probes. The digested probe gave higher 
signal than its T7 equivalent assay in a similar timeframe in an un-optimised system. 
Further development of this assay could allow for the incorporation of labels that have been 
unsuitable (e.g. IC-098 if the impurity issue can be overcome) and improve the multiplex 
properties of the system. Additionally, λ-exonuclease is a cheaper than T7-exonuclease, 





The probes described in this thesis were subjected to digestion with various nucleases to 
assess any potential improvements in electrochemical current that could be achieved. Initial 
results of ssDNA digestions with S1 nuclease indicated that improved digestion could be 
achieved through additional ferrocene substitution. From the data collected, it has been 
shown that there is no real benefit to introducing more than three substituted sites due to 
the increased material required for oligonucleotide synthesis, as these did not display 
improved digestion, which would not outweigh the additional cost of custom 
oligonucleotide. 
The incorporation of di-ferrocenes synthesised via reductive amination offered 
dramatically improved sensitivity over mono-ferrocene probes, however concurrent with 
other S1 nuclease studies, there was no benefit to including more than three modified 
nucleotides in the sequence. 
The move to dsDNA digestions showed promising results with, showing that some increase 
in electrochemical signal was possible. The probes were shown to undergo digestion in the 
presence of T7 exonuclease and complementary DNA which had been synthesised by both 
solid phase and enzymatic methods. The use of synthetic showed promise, indicating 
increased current was indeed possible, however the move to cDNA generated via PCR 
showed no difference between any of the probes synthesised. Given the additional chemical 
synthesis required for the modified oligonucleotides, it would not be a commercially viable 
route unless significant improvements could be achieved.  
The probes were subjected to digestion with lambda exonuclease, which showed promising 
results, showing that 5’-labelled probes were not suitable for use with this nuclease, 
however the introduction of internal labels allowed a vastly improved digestion. The system 
has not yet been optimised, and as such further work would focus on finding the optimal 
buffer solution and additives, as well as aiming to reduce the digestion times required. 
Further work arising from this thesis would include variation on labelling position of 
pyrimidine. Current 5-position labelling is located in the major groove section, however to 
compare any stabilising or destabilising effects of substitution, synthesis of the equivalent 
6-substituted nucleoside would allow for analysis of the effects of the chemical modification. 
UV-melt analysis would allow for determination of Tm, indicative of duplex stability, which 
would further inform optimal labelling position on both the nucleobase itself, and the labels’ 




5.1. General considerations 
5.1.1. Equipment 
1H, 13C, and 31P nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 
Avance 300 MHz spectrometer or an Agilent Technologies 500 MHz spectrometer at 298 K 
unless otherwise stated. Chemical shifts are reported in parts per million downfield from 
Si(CH3)4 and are referenced to residual solvent peaks,192 and the multiplicity (s = singlet, d 
= doublet, dd = doublet of doublets, dt = doublet of triplets, t = triplet, td = triplet of doublets, 
tt= triplet of triplets, q = quartet, p = pentet, h = hextet, m = multiplet, app. = apparent), 
coupling constant(s) (in hertz), and integration are reported. Electrospray ionisation high 
resolution time-of-flight mass spectrometry (HRMS) were recorded on a Bruker micrOTOF 
spectrometer. Infrared (IR) spectra were recorded on a PerkinElmer 1600 Fourier 
transform IR spectrometer with selected absorbencies quoted as wavenumber (ν (cm-1)). 
PCR tubes were heated using an MJ Research PTC-200 Thermal Cycler. Electrochemical 
analysis was performed on a Metrohm Autolab PGSTAT30 potentiostat controlled by a 
personal computer running General Purpose Electrochemical System (GPES) software. 
Samples of 24 µL were applied to electrodes and were analysed using differential pulse 
voltammetry (modulation = 0.04 s, interval = 0.1 s, step potential = 3mV, modulation 
amplitude = 50 mV), the voltammograms were baseline corrected using the software’s 
“baseline correction” function, and peak current was measured through the software’s 
“peak search” function. io® electrochemical analysis was performed on an Atlas Genetics io 
with external Peltier-potentiostat using differential pulse voltammetry (modulation = 0.04 
s, interval = 0.06 s, step potential = 3 mV, modulation amplitude = 50 mV), and the 
voltammograms were baseline corrected and peak current was calculated in the 
corresponding range using AG’s peak search algorithm. 
5.1.2. Reagents 
Silica gel chromatography was performed using 60 Å, 200-400 mesh silica gel purchased 
from Sigma-Aldrich. Analytical thin-layer chromatography (TLC) was performed using 
aluminium-backed plates coated with Alugram® SIL G/UV254 purchased from Fischer and 
visualised by UV light (254 nm), and/or KMnO4 staining. Screen printed electrodes (carbon 
working and counter, Ag/Ag+ reference) were donated by Atlas Genetics (Trowbridge, UK). 
Reactions were performed using oven-dried glassware. All reactions used solvents and 
reagents as obtained from Sigma Aldrich without further purification, unless otherwise 
stated. Petrol refers to petroleum ether (40-60 °C). All temperatures quoted are external. 5-
iodo-2’-deoxyuridine was purchased from Carbosynth (Cambridge, UK). Di-tert-butyl 
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dicarbonate was purchased from Fluorochem (Hadfield, UK). 6-
(bis(ferrocenylmethyl)amino)hexan-1-ol, 6-(bis((chloroferrocenyl)methyl)amino) hexan-
1-ol, and 6-(bis(ruthenocenenylmethyl)amino)hexan-1-ol were donated by Atlas Genetics 
(Trowbridge, UK). Oligonucleotides were synthesised by ATDbio (Southampton, UK) and 
used as supplied 100 µM aqueous solutions. S1 nuclease (100 U/µL) was purchased from 
ThermoFisher Scientific and diluted prior to use (1 U/µL in molecular biology grade H2O). 
S1 5X reaction buffer was used as supplied by ThermoFisher Scientific. dUTPs were 
purchased from Bioline (London, UK). T7 exonuclease was purchased from ThermoFisher. 
Taq-B and UNG were purchased from Enzymatics (MA, USA). Lambda exonuclease emzyme 
and buffer were purchased from New England BioLabs (MA, USA).  
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5.2. Biological Procedures 
5.2.1. Primer sequences 
Oligonucleotide Sequence 
IC Forward 5’ –  TCG CTG TCG GGA AGT TTG GTT GAA – 3’ 
IC Reverse 5’ –  AGG CCT GAA CTG GGA ATC CTT TG – 3’ 
CT Forward 5’ –  GTT TGG ACA CTA GTC AGC ATC AAG CTA GG – 3’ 
CT Reverse Mod 5’ – A*G*A* T*TC CAG AGG CAA TGC CAA AGA AA – 3’ 
NG2 Forward 5’ – ACG CAA ACG GAG GTC TTA CGG ATT TAG – 3’  
NG2 Reverse 5’ – CGT TGG CGC AAT TTC CAT ATA GTC CTG – 3’ 
IC Synthetic Target 
5’ – GTG AAA ATC GGT AAC GTC TTT AGG AAA GGG ATC GTG 
CTC TCC GGT TCA ACC AAA C – 3’ 
CT Synthetic Target 
5’ – GCC AAA GAA AAA AGT AAG GAA GAA CCA GCG GAC AGG 
ACG GCG ATG CTT CCT TTT A – 3’ 
Table 5.1 Primer and target sequences. * indicates phosphorthioate (P(S)O3) linkages 
5.2.2. Buffer solutions 
Elution Buffer 
EDTA (500 mM) in pH 8.9 Trizma HCl (496 mM) buffer. 
50x PCR Buffer 
KCl 2.47 M, Trehalose (1.01 M) in pH 9.0 Trizma HCl (496mM) buffer. 
Detection surfactant solution 
Amino-butyric-acid (356 mM), Trehalose (0.971 M) and Triton X-305 (0.25% v/v) in water. 
T7 Diluent 
Dithiothreitol (3.48 mM), ethylenediaminetetraacetic acid (10mM) and BSA (2% w/v) in pH 
6.4 K3PO4 buffer (216 mM). 
S1 buffer used as supplied from ThermoFisher. 




5.2.3. Enzymatic assay protocols & mixtures 
5.2.3.1. S1 Digestions 
The appropriate probe was chosen and mixed according to Tables 5.2–5.5. A master 
solution was made, with the addition of S1 nuclease (if applicable) the final addition. The 
solutions were shaken by hand, and aliquoted in 30 µL portions into PCR tubes. The tubes 
were heated to 37 °C for 30 minutes and stored at 4 °C prior to detection for a maximum of 
15 minutes. 
Component Stock Conc. Final Conc. Required Volume 
Buffer - - 6 
Probe 100 µM 6 µM 0.9 
Water - - 13.1 
S1 Nuclease 1 U/µL 10 U/rxn 10 
Table 5.2 S1 Digestions (3 µM probe) 
Component Stock Conc. Final Conc. Required Volume 
Buffer - - 6 
Probe 100 µM 6 µM 0.9 
Water - - 23.1 
Table 5.3 S1 Nuclease negative controls (3 µM probe) 
Component Stock Conc. Final Conc. Required Volume 
Buffer - - 6 
Probe 100 µM 6 µM 1.8 
Water - - 12.2 
S1 Nuclease 1 U/µL 10 U/rxn 10 
Table 5.4 S1 Digestions (6 µM probe) 
Component Stock Conc. Final Conc. Required Volume 
Buffer - - 6 
Probe 100 µM 6 µM 1.8 
Water - - 22.2 




5.2.3.2. PCRs and synthetic target mixes 
The appropriate PCR mixture was made into a master mix according to Tables 5.6–5.9. For 
no template controls, target DNA was replaced with MBG water. 
The solutions were vortexed for 10 s, aliquoted into PCR tubes (64 µL), and thermally 
cycled. After thermal cycling, each tube was combined into a bijou tube and vortexed for 10 
s. The amplicons were stored at –20 °C for up to 3 months prior to detection. 
Protocol: 37 °C for 120 s, 94 °C for 180 s, then cycle x40 (94 °C (2 °C/s) for 5 s, 65 °C (2 °C/s) 
for 10 s) then store at 8 °C. 
Component Stock conc. Final conc. Required volume (µL) 
50x PCR buffer - - 1.28 
dUTP mix 50 mM 1 mM 1.28 
UNG 50 U/µL 0.05 UµL 0.06 
TaqB 25 U/µL 0.10 U/µL 0.26 
MgCl2 1.0 M 5 mM 0.32 
IC Forward 10 µM 0.04 µM 0.26 
IC Reverse 100 µM 0.3 µM 0.19 
Brij 58 5% w/w 0.02% 0.26 
MBG Water - - 1.18 
IC DNA 100 pg/µL 10 pg/rxn 1 
Elution buffer - - 53.91 
 
 
Table 5.6 Internal Control PCR Primer mixes 
Component Stock conc. Final conc. Required volume (µL) 
50x PCR buffer - - 1.28 
dUTP mix 50 mM 1 mM 1.28 
UNG 50 U/µL 0.05 UµL 0.06 
TaqB 25 U/µL 0.10 U/µL 0.26 
MgCl2 1.0 M 5 mM 0.32 
CT Forward 100 µM 0.40 µM 0.26 
CT Reverse Mod 100 µM 0.60 µM 0.38 
Brij 58 5% w/w (H2O) 0.02% 0.26 
MBG Water - - 1.18 
CT DNA 1000 IFU/µL 100 IFU/rxn 1 
Elution buffer - - 53.72 




Component Stock conc. Final conc. Required volume (µL) 
50x PCR buffer - - 1.28 
dUTP mix 50 mM 1 mM 1.28 
UNG 50 U/µL 0.05 UµL 0.06 
TaqB 25 U/µL 0.10 U/µL 0.26 
MgCl2 1.0 M 3.5 mM 0.22 
NG2 Forward 100 µM 0.45 µM 5.76 
NG2 Reverse 100 µM 0.45 µM 5.76 
Brij 58 5% w/w (H2O) 0.02% 0.26 
MBG Water - - 0.27 
NG DNA 100 nM 1.56 nM 1 
Elution Buffer - - 57.72 
Table 5.8 Nerissa gonorrhoeae PCR Primer mixes 
Component Stock conc. Final conc. Required volume (µL) 
50x PCR buffer - - 1.28 
dUTP mix 50 mM 1 mM 1.28 
UNG 50 U/µL 0.05 UµL 0.06 
TaqB 25 U/µL 0.10 U/µL 0.26 
MgCl2 1.0 M 5 mM 0.32 
CT Forward 100 µM 0.40 µM 0.25 
CT Reverse Mod 100 µM 0.60 µM 0.38 
NG2 Forward 100 µM 0.45 µM 0.29 
NG2 Reverse 100 µM 0.45 µM 0.29 
Brij 58 5% w/w 0.02% 0.26 
MBG Water - - 0.27 
CT DNA 100 IFU/µL 100 IFU/rxn 1 
NG DNA 100 nM 1.56 nM 1 
Elution Buffer - - 53.06 
Table 5.9 NG/CT multiplex PCR primer mix 
Component Stock Conc. Final Conc. Required volume (µL) 
Synthetic Target DNA 100 µM 12 µM 2.76 
MgCl 1.0 M 5 mM 0.1 
50x PCR buffer - - 0.4 
Elution buffer - - 16.74 




5.2.3.3. Double-stranded digestions 
The appropriate detection mix was made into a master mix and the appropriate procedure 
was followed. 
Digestion in tube 
The detection mix was aliquoted into PCR tubes and the appropriate DNA mix (amplicon or 
synthetic target) (20 µL) was added. The tubes were vortexed for 5 s, centrifuged for 5 s, 
and heated to 37 °C for 3 minutes in a thermocycler. The mixtures were stored at 4 °C for 
up to 15 minutes prior to detection. 
Digestion “on sub-circuits” 
The detection mix was aliquoted into PCR tubes and the appropriate DNA amplicon (20 µL) 
was added. The tubes were vortexed for 5 s, centrifuged for 5 s, and then applied to the 
electrode sub-circuit, inserted into the clamping rig, then heated to 37 °C for 3 minutes, 
followed by immediate detection at 37 °C. 
Digestion “dried-down” 
The detection mix was applied to bare sub-circuits and heated to 45 °C at 10% relative 
humidity for 10 minutes. Adhesive and electrodes were used to seal the sub-circuit, and 
were used the same day. To the sub-circuit was applied amplicon (24 µL), mixing by adding 
to the first stop and rest position three times. The sub-circuit was inserted into the clamping 
rig, heated to 37 °C for 3 minutes, followed by immediate detection at 37 °C. 
Component Stock Conc. Final Conc. Required volume (µL) 
Detection surfactant solution - - 0.29 
T7 diluent - - 0.45 
T7 exonuclease 50 U/µL 0.825 U/µL 0.33 
Probe 100 µM 6 µM 1.45 
Water - - 1.45 
Table 5.11 Single probe (6 µM) detection mix 
Component Stock Conc. Final Conc. Required volume (µL) 
Detection surfactant solution - - 0.29 
T7 diluent - - 0.45 
T7 exonuclease 50 U/µL 0.825 U/µL 0.33 
Probe 100 µM 12 µM 2.89 




Component Stock Conc. Final Conc. Required volume (µL) 
Detection surfactant solution - - 0.29 
T7 diluent - - 0.45 
T7 exonuclease 50 U/µL 0.825 U/µL 0.33 
CT Probe 100 µM 6 µM 1.45 
NG2 Probe 100 µM 6 µM 1.45 
Table 5.13 CT/NG Multiplex detection mix 
Component Stock Conc. Final Conc. Required volume (µL) 
1,4-dithiothreitol 34.8 mM 0.67 µM 0.513 
Bovine serum albumin 0.925% 0.02% 0.513 
Detection surfactant solution - - 0.28 
Lambda buffer - - 1.9 
 Lambda exonuclease 5 U/µL 5 U/rxn 1 
Probe 100 µM 6 µM 1.78 
Table 5.14 Lambda exonuclease digestion mix  
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5.3. Chemical procedures and characterisation 
5-(trimethylsilyl)ethynyl-2’-deoxyuridine 25141 
 
To an oven-dried round bottom flask was added 5-iodo-2’-deoxyuridine (2.48 g, 7 mmol) 
and dissolved in anhydrous MeCN (87 mL) and triethylamine (87 mL). Argon was bubbled 
through the solution for 10 minutes with stirring. To the colourless solution was added 
bis(triphenylphosphine)palladium(II) chloride (98 mg, 0.14 mmol) and copper (I) iodide 
(67 mg, 0.35 mmol) and stirred for 10 minutes under argon. The yellow solution was treated 
with trimethylsilyl acetylene (3.95 mL, 28 mmol) and heated to 50 °C for 4 hours. The 
reaction was cooled to rt and solvent was removed to give a thick gum, which was purified 
via flash chromatography, eluting with CHCl3/MeOH (19:1) to yield the title compound as 
an off-white foam (1.98 g, 86%). 
MP 160–162 °C (lit. 162–165 °C).142 1H NMR (500 MHz, CD3OD) δ 8.29 (s, 1H, ArH), 6.19 (t, 
J = 6.5 Hz, 1H, 1’-H), 4.36 (dt, J = 6.5, 3.6 Hz, 1H, 3’-H), 3.89 (q, J = 3.3 Hz, 1H, 4’-H), 3.78 (dd, 
J = 12.0, 3.3 Hz, 1H, 5’-H), 3.70 (dd, J = 12.0, 3.3 Hz, 1H, 5’-H), 2.27 (ddd, J = 13.6, 6.5, 3.6 Hz, 
1H, 2’-H), 2.23–2.14 (m, 1H, 2’-H), 0.16 (s, 9H, 3 x CH3). 13C NMR (126 MHz, CD3OD) δ 163.1 
(CO), 150.1 (ArC), 144.5 (ArC), 99.1 (ArC), 97.6 (C), 95.8 (C), 87.7 (4’-C). 85.6 (1’-C), 70.5 (3’-






To a stirred solution of 25 (670 mg, 2.0 mmol) in freshly distilled pyridine (8 mL) was added 
DMTrCl (746 mg, 2.2 mmol). The orange solution was allowed to stir at rt for 2 hrs. The 
reaction was cooled to 0 °C and quenched with MeOH (1 mL). The solution was concentrated 
in vacuo to an oil and dissolved in CH2Cl2 (20 mL) and washed with NaHCO3(sat.)(aq.) (3 x 20 
mL) and brine(sat.) (20 mL) and the organics were dried over MgSO4, and concentrated in 
vacuo. The crude solid was purified via silica gel chromatography (CH2Cl2/MeOH/TEA 
99:1:0.5) to yield a colourless foam (755 mg, 60%). 
MP 109–110 °C. 1H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H, ArH), 7.46–7.40 (m, 2H, ArH), 7.35–
7.31 (m, 4H, ArH), 7.28 (t, J = 7.8 Hz, 2H, ArH), 7.22–7.16 (m, 1H, ArH), 6.89–6.68 (m, 4H, 
ArH), 6.29 (dd, 8.0, 5.8 Hz, 1H, 1’-H), 4.41–4.43 (m, 1H, 3’-H), 4.07 (q, J = 3.4 Hz, 1H, 4’-H), 
3.77 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.38 (dd, J = 10.6, 3.4 Hz, 1H, 5’-H), 3.28 (dd, J = 10.6, 
3.4 Hz, 1H, 5’-H), 2.46 (ddd, J = 13.5, 5.8, 2.6 Hz, 1H, 2’-H), 2.17 (ddd, J = 13.5, 8.0, 5.8 Hz, 1H, 
2’-H), -0.01 (s, 9H, 3 x CH3). 13C NMR (126 MHz, CDCl3) δ 162.6 (CO), 158.6 (ArC), 150.1 (CO), 
144.5 (ArC), 142.7 (ArC), 135.7 (ArC), 130.0 (ArC), 128.1 (ArC), 128.0 (ArC), 127.0 (ArC), 
113.4 (ArC), 100.6 (ArC), 99.2 (ArC), 95.5 (C), 86.9 (4’-C), 86.5 (OCAr3), 85.7 (1’-C), 72.2 (3’-
C), 63.6 (5’-C), 55.3 (2 x OCH3), 41.5 (2’-C), -0.2 (CH3).  
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5-ethynyl-5'-O-(bis(4-methoxyphenyl)phenylmethyl)-2'-deoxyuridine 27193  
 
To a stirred slurry of 26 (5.18 g, 8.3 mmol) in THF (9 mL) was added TBAF (1.0 M in THF) 
(12.4 mL, 12.4 mmol) in one portion and allowed to stir at rt overnight. The solution was 
concentrated and purified via silica gel chromatography (EtOAc) to yield the title compound 
as a colourless foam (3.14 g, 58%). 
MP 123–125 °C. 1H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H, ArH), 7.44–7.38 (m, 2H, ArH), 7.32 
(dd, J = 8.9, 1.8 Hz, 4H, ArH), 7.29 (t, J = 7.7 Hz, 2H, ArH), 7.24–7.17 (m, 1H, ArH), 6.84 (dd, J 
= 8.9, 1.8 Hz, 4H, ArH), 6.28 (dd, J = 7.4, 5.8 Hz, 1H, 1’-H), 4.58–4.51 (m, 1H, 3’-H), 4.12–4.07 
(m, 1H, 4’-H), 3.78 (s, 6H, 2 x CH3), 3.41–3.36 (m, 2H, 5’-H), 2.89 (s, 1H, CH), 2.52 (ddd, J = 
13.7, 5.8, 2.5 Hz, 2H, 2’-H), 2.32–2.22 (m, 1H, 2’-H). 13C NMR (126 MHz, CDCl3) δ 161.3 (CO), 
158.6 (ArC), 149.0 (CO), 144.4 (ArC), 143.6 (ArC), 135.4 (ArC), 130.0 (ArC), 128.0 (ArC), 
127.9 (ArC), 127.0 (ArC), 113.3 (ArC), 99.2 (ArC), 87.1 (4’-C), 86.4 (OCAr3), 85.7 (1’-C), 82.0 






To a round-bottom flask fitted with magnetic stirrer bar was added 2’-deoxycytidine (6.80 
g, 30 mmol), iodic acid (2.70 g, 15.4 mmol), and iodine (4.50 g, 17.7 mmol), and the solids 
were dissolved in acetic acid (24 mL) CCl4 (6 mL) and H2O (9 mL) and the solution was 
heated to 40 °C for 90 minutes. The reaction was cooled to rt, diluted with H2O (50 mL) and 
filtered. The filtrate was concentrated in vacuo and co-evaporated with MeOH (3 x 20 mL). 
The solid was dissolved in water, adjusted to pH 10 and concentrated in vacuo. The solid 
was dissolved in the minimum amount of hot water and allowed to recrystallise at 4 °C 
overnight to yield the title compound as a white powder (3.25 g, 31%). 
MP 137–139 °C decomp. (lit. 133–135 (decomp.)).146 1H NMR (500 MHz, (CD3)2SO) δ 8.28 
(s, 1H, ArH), 6.07 (t, J = 6.4 Hz, 1H, 1’-H), 4.21 (dt, J = 6.4, 3.4 Hz, 1H, 3’-H), 3.78 (q, J = 3.4 Hz, 
1H, 4’-H), 3.62 (dd, J = 11.8, 3.4 Hz, 1H, 5’-H), 3.55 (dd, J = 11.8, 3.4 Hz, 1H, 5’-H), 2.13 (ddd, 
J = 13.1, 6.4, 3.4 Hz, 1H, 2’-H), 1.99 (dt, J = 13.1, 6.4 Hz, 1H, 2’-H). 13C NMR (126 MHz, 
(CD3)2SO) δ 164.1 (CO), 154.3 (ArC), 147.7 (ArC), 87.8 (4’-C), 85.7 (1’-C), 70.4 (3’-C), 61.3 





To a stirred solution of 29 (1.059 g, 3.0 mmol) in deoxygenated DMF (22 mL) was added 
bis(triphenylphosphine) palladium (II) chloride (105 mg, 0.15 mmol, 5 mol%) and copper 
(I) iodide (57 mg, 0.3 mmol, 10 mol%) and the yellow solution was allowed to stir under Ar 
for 10 minutes. The solution was treated with trimethylsilyl acetylene (2.1 mL, 15.0 mmol) 
and stirred for 10 minutes, then treated with triethylamine (6 mL) and allowed to stir at rt 
overnight. The solvents were removed in vacuo and purified via flash chromatography 
eluting with CH2Cl2/MeOH (9:1) to yield the title compound as an off-white foam (0.596 g, 
62%). 
MP 162–167 °C. 1H NMR (500 MHz, CD3OD) δ 8.37 (s, 1H, ArH), 6.20 (t, J = 6.5 Hz, 1H, 1’-H), 
4.39 (dt, J = 6.5, 3.6 Hz, 1H, 3’-H), 3.96 (q, J = 3.6 Hz, 1H, 4’-H), 3.83 (dd, J = 12.0, 3.6 Hz, 1H, 
5’-H), 3.75 (dd, J = 12.0, 3.6 Hz, 1H, 5’-H), 2.38 (ddd, J = 13.5, 6.5, 3.6 Hz, 1H, 2’-H), 2.15 (dt, J 
= 13.5, 6.5 Hz, 1H, 2’-H), 0.24 (s, 9H, 3 x CH3). 13C NMR (126 MHz, CD3OD) δ 164.6 (CO), 155.2 
(ArC), 145.0 (ArC), 100.5 (C), 95.1 (C), 87.7 (4’-C), 86.5 (1’-C), 70.3 (3’-C), 61.0 (5’-C), 40.9 






To a stirred solution of 2’-deoxyguanosine (2.85 g, 10 mmol) in 4:1 MeCN/H2O (140 mL) 
was added N-bromosuccinimide (2.65 g, 15 mmol) and the reaction was allowed to stir at 
rt for 45 minutes. The solution was evaporated to dryness, suspended in acetone and 
allowed to stir for 2 hours. The solution was cooled to -20 °C for 48 hours after which time 
the precipitate was collected to yield the title compound as an off-white powder (3.14 g, 
86%). 
MP 201–205 °C (lit. 209–213 °C)149 1H NMR (500 MHz, (CD3)2SO) δ 10.79 (s, 1H), 6.48 (s, 
2H, NH2), 6.16 (dd, J = 7.9, 6.7 Hz, 1H, 1’-H), 5.24 (d, J = 4.3 Hz, 1H), 4.85 (t, J = 5.9 Hz, 1H, 4’-
H), 4.40 (dq, J = 5.9, 3.0 Hz, 1H, 3’-H), 3.62 (dt, J = 10.9, 5.9 Hz, 1H, 5’-H), 3.50 (dt, J = 10.9, 
5.9 Hz, 1H, 5’-H), 3.16 (ddd, J = 13.2, 7.9, 6.7 Hz, 1H, 2’-H), 2.10 (ddd, J = 13.2, 6.7, 3.0 Hz, 1H, 
2’-H). 13C NMR (126 MHz, (CD3)2SO) δ 155.8 (ArC), 153.7 (ArC), 152.4 (ArC), 120.9 (ArC), 






To a stirred solution of 2’-deoxyadenosine (3.43 g, 22.3 mmol) in 1M acetic acid buffer (pH 
4.0) (450 mL) was added Br2 (1.3 mL, 44.6 mmol) and the solution was allowed to stir at rt 
for 4 hrs in the absence of light. The solution was quenched by the addition of NaHSO3(sat.)(aq.) 
(200 mL) and extracted with CHCl3 (3 x 200 mL). The combined organics were concentrated 
and the residual AcOH was azeotroped with toluene (2 x 100 mL) to yield the compound as 
a white power (3.84 g, 52%). 
MP 240–243 °C (lit. 242–245 °C (decomp.))196  1H NMR (300 MHz, (CD3)2SO) δ 8.10 (s, 1H, 
ArH), 6.30 (dd, J = 8.1, 6.4 Hz, 1H, 1’-H), 4.48 (dt, J = 5.9, 2.6 Hz, 1H, 3’-H), 3.90 (td, J = 4.4, 
2.6 Hz, 1H, 4’-H), 3.66 (dd, J = 12.0, 4.4 Hz, 1H, 5’-H), 3.49 (dd, J = 12.0, 4.4 Hz, 1H, 5’-H), 3.21 
(ddd, J = 13.2, 8.1, 5.9 Hz, 1H, 2’-H), 2.19 (ddd, J = 13.2, 6.4, 2.6 Hz, 1H, 2’-H). 13C NMR (75 
MHz, (CD3)2SO) δ 155.3 (ArC), 152.6 (ArC), 150.2 (ArC), 126.9 (ArC), 119.9 (ArC), 88.7 (4’-






To a suspension of sodium hydride (60% dispersion in mineral oil) (1.56 g, 39 mmol) in 
anhydrous THF (60 mL) at 0 °C was added triethyl phosphonoacetate (7.7 mL, 39 mmol) 
dropwise via syringe and the solution was allowed to stir at rt for 30 minutes. The slurry 
was cooled to 0 °C and treated with a solution of ferrocenecarboxaldehyde (6.42 g, 30 mmol) 
in anhydrous THF (60 mL) dropwise. Once addition was complete the solution was allowed 
to stir at rt for 60 minutes. The solution was then poured into NH4Cl(sat.) (60 mL) and the 
aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organics were washed 
with brine(sat.) (50 mL), dried over MgSO4, filtered, and concentrated in vacuo to give a red 
solid. 
The red solid was dissolved in methanol (120 mL) and cooled to 0 °C, and treated with 10% 
palladium on carbon (1.57 g, 5 mol%) and ammonium formate (7.50 g 120 mmol). Once 
addition was complete the suspension was warmed to rt. The suspension was then stirred 
for 4 hours, then filtered through celite, washing the solids with methanol until the washings 
ran clear. The orange solution was concentrated in vacuo, and partitioned between EtOAc 
(100 mL) and NaHCO3 (sat.) (50 mL). The aqueous layer was extracted with EtOAc (3 x 50 mL) 
and the combined organics were washed with brine (sat.) (50 mL), dried over MgSO4, filtered, 
and concentrated in vacuo to yield a yellow solid. 
To a stirred suspension of LiAlH4 (3.40 g, 90 mmol) in anhydrous Et2O (150 mL) at 0 °C was 
added a solution of the yellow solid in anhydrous Et2O (150 mL) dropwise via a pressure 
equalising funnel. Once addition was complete, the solution was warmed to rt and allowed 
to stir for 60 minutes. The solution was cooled to 0 °C and quenched sequentially with H2O 
(3.4 mL), 15% NaOH(aq.) (3.4 mL), and H2O (10.2 mL). The slurry was stirred at rt for 10 
minutes, then filtered through celite, washing with Et2O until the washings ran clear. The 
yellow solution was dried over MgSO4, filtered, and concentrated in vacuo, yielding a yellow 
oil which was purified via silica gel chromatography, eluting with petrol/EtOAc (8:2) to 
yield the title compound as a yellow oil (6.10 g, 83%). 
1H NMR (300 MHz, C6D6) δ 4.01 (s, 5H, CpH), 3.98–3.94 (m, 4H, CpH), 3.41 (t, J =6.4 Hz, 2H, 
CH2), 2.29 (dd, J = 8.6, 6.4 Hz, 2H, CH2), 1.64–1.59 (m, 2H, CH2). 13C NMR (126 MHz, C6D6) δ 





To a stirred solution of 38 (1.22 g, 5 mmol) and tetrabromomethane (1.82 g, 5.5 mmol) in 
anhydrous CH2Cl2 (12.5 mL) at 0 °C was added triphenylphosphine (1.44 g, 5.5 mmol) 
portionwise over a 10-minute period. The reaction was allowed to warm to rt and stirred 
for 30 minutes. The solution was concentrated in vacuo to give a thick oil, which was 
suspended in hexane (50 mL) and stirred vigorously for 30 minutes. The solution was 
filtered, and the slurry was suspended further with hexane (50 mL) and filtered. The 
combined organics were concentrated in vacuo and filtered through silica, washing with 
EtOAc until the washings ran clear. The organics were concentrated in vacuo to yield a 
brown oil. 
The oil was dissolved in acetone (15 mL) and H2O (5 mL) and treated with sodium azide 
(0.97 g, 15 mmol) and the solution was heated at 70 °C for 18 hours. The reaction was cooled 
to rt and diluted with EtOAc (25 mL) and water (10 mL). The aqueous layer was extracted 
with EtOAc (3 x 20 mL) and the combined organics were washed with brine(sat.) (20 mL), 
dried over MgSO4, filtered, and concentrated in vacuo. The yellow oil was purified via silica 
gel chromatography, eluting with petrol/EtOAc (1:1) to yield the title compound as a yellow 
oil (1.30 g, 93%). 
IR ν (cm-1) 3089, 2933, 2857, 2094. 1H NMR (300 MHz, C6D6) δ 3.97 (s, 5H, CpH), 3.92 (t, J = 
1.8 Hz, 2H, CpH), 3.85 (t, J = 1.8 Hz, 2H, CpH), 2.72 (t, J = 6.7 Hz, 2H, CH2), 2.09 (dd, J = 8.4, 
6.7 Hz, 2H, CH2), 1.47–1.33 (m, 2H, CH2). 13C NMR (75 MHz, C6D6) δ 88.1 (CpC), 69.3 (CpCH), 
68.7 (CpCH), 68.1 (CpCH), 51.2 (CH2), 30.8 (CH2), 27.1 (CH2). HRMS (ESI) calculated for 





To a stirred solution of 38 (1.22 g, 5 mmol) in anhydrous THF (50 mL) was added tosyl 
chloride (0.95 g, 5 mmol) and triethyl amine (0.80 mL, 5.5 mmol) and the reaction heated 
to 60 °C overnight. The reaction poured into NaHCO3 (50 mL) and the aqueous layer was 
extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (sat.) (50 
mL), dried over MgSO4 and concentrated in vacuo. The crude oil was purified via silica gel 
chromatography, eluting with neat petrol to yield the title compound as an undesired by-
product (84 mg, 30%). 
IR ν (cm-1) 3076, 2967, 2869. 1H NMR (250 MHz, C6D6) δ 3.97 (s, 10H, CpH), 3.92 (t, J = 1.8 
Hz, 4H, CpH), 3.86 (t, J = 1.8 Hz, 4H, CpH), 3.14 (t, J = 6.4 Hz, 4H, CpH), 2.29–2.18 (m, 4H, 
CpH), 1.71–1.56 (m, 4H, CpH). 13C NMR (63 MHz, C6D6) δ 87.5 (CpC), 68.9 (CpCH), 68.4 
(CpCH), 67.7 (CpCH), 44.5 (CH2), 34.2 (CH2), 26.9 (CH2). HRMS (ESI) calculated for 






To an oven-dried three-neck flask was added ferrocene (18.60 g, 0.1 mol) and N,N,N’,N’-
tetramethylethylene diamine (35 mL, 0.233 mol) and were suspended in anhydrous hexane 
(100 mL). The suspension was cooled to 0 °C and n-butyllithium (2.5 M in hexanes) (85 mL, 
0.212 mol) was added to a pressure equalising funnel, then added dropwise to the ferrocene 
solution. The suspension was warmed to rt and allowed to stir overnight. After this time, 
the orange precipitate was allowed to settle, and the hexane was removed via cannula 
filtration. The bright orange precipitate was suspended in anhydrous Et2O (300 mL) and 
cooled to -78 °C. To the orange suspension was added 1,1,2,2-tetrabromoethane (25 mL, 
0.215 mol) in Et2O (150 mL) dropwise over 4 hours, maintaining -78 °C throughout, after 
which time the solution was allowed to warm to rt overnight. The solution was allowed to 
settle to give a biphasic mixture, and the top orange layer was decanted. The solution was 
washed with H2O (100 mL) and the aqueous layer was extracted with Et2O (3 x 100 mL). 
The solution was concentrated, and the orange oil was dissolved in hexane (100 mL) and 
washed with 2M FeCl3(aq.) (2 x 200 mL) and the combined organics were washed with H2O 
(3 x 100 mL). The organics were dried over MgSO4, filtered, and concentrated. The orange 
oil was dissolved in the minimum amount of hot MeOH (~15 mL) and allowed to 
recrystallise at –20 °C overnight. The solids were filtered, washed with cold MeOH and dried 
under reduced pressure to yield the title compound as an orange solid (11.09 g, 32%). 
MP 53–54 °C. 1H NMR (500 MHz, C6D6) δ 4.16 (t, J = 1.9 Hz, 4H, CpH), 3.71 (t, J = 1.9 Hz, 4H, 






To an oven-dried Schlenk tube equipped with magnetic stirrer bar was added 44 (6.88 g, 20 
mmol). The flask was sealed, then evacuated and back-filled with argon four times, and left 
over an argon atmosphere. The solid was dissolved in anhydrous THF (70 mL) and cooled 
to –78 °C. To the orange solution was added n-butyllithium (2.5 M in hexanes) (8 mL, 20 
mmol) dropwise and after addition was complete, the solution was allowed to stir at –78 °C 
for 1 hour. The orange precipitate was then treated with dimethyl formamide (4.6 mL, 60 
mmol) and the solution was allowed to warm to rt and stirred overnight. The solution was 
quenched with 2M NaOH(aq.) (40 mL) and the aqueous layer was extracted with Et2O (3 x 
100 mL). The combined organics were washed with brine(sat.) (100 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The oil was purified via flash chromatography, eluting 
with petrol/EtOAc (9:1) to yield the title compound as a deep red solid (5.53g 94%). 
MP 52–53 °C. 1H NMR (500 MHz, C6D6) δ 9.79 (s, 1H, CHO), 4.49 (s, 2H, CpH), 4.10 (s, 2H, 
CpH), 4.05 (s, 2H, CpH), 3.61 (s, 2H, CpH). 13C NMR (126 MHz, C6D6) δ 191.8 (CHO), 81.7 






To a stirred solution of 45 (3.37 g, 10 mmol) and p-toluenesulfonic acid (170 mg, 1 mmol) 
in anhydrous benzene (60 mL) was added ethylene glycol (5.57 mL, 100 mmol). The flask 
was fitted with a Dean-Stark trap and condenser, and allowed to stir under reflux for 18 
hours. The solution was quenched with K2CO2 (3 g) and stirred for 10 minutes, filtered 
through celite and concentrated under reduced pressure. The crude dark solid was purified 
via silica gel chromatography, eluting with petrol/EtOAc (95:5) to yield an orange solid 
(2.99 g, 78%). 
MP 58–60 °C IR ν (cm-1) 3097, 2918, 2800. 1H NMR (500 MHz, C6D6) δ 5.69 (s, 1H, FcCHO2), 
4.35 (t, J = 2.0 Hz, 2H, CpH), 4.29 (t, J = 2.0 Hz, 2H, CpH), 4.00 (t, J = 2.0 Hz, 2H, CpH), 3.90 (t, 
J = 2.0 Hz, 2H, CpH), 3.64–3.55 (m, 2H, CH2), 3.51–3.41 (m, 2H, CH2). 13C NMR (126 MHz, 
C6D6) δ 102.4 (FcCHO2), 87.0 (CpC), 78.4 (CpC), 71.4 (CpCH), 71.4 (CpCH), 70.0 (CpCH), 68.4 
(CpCH), 65.2 (CH2). HRMS (ESI) calculated for C13H13BrFeO2 [M+H]+ : m/z 336.9521, found 
336.9526.   
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General procedure A for the electrophilic addition to bromoferrocene 
An oven dried Schlenk flask was charged with (1’-bromo)ferrocenyl-1,3-dioxolane 46 (1 
equiv.) under argon. The ferrocene was dissolved in anhydrous THF (0.2 M), cooled to -78 
°C, and treated with a solution of n-butyllithium (1 equiv.) dropwise. The resulting yellow 
precipitate was allowed to stir at -78 °C for 30 minutes, after which time it was treated with 
the desired electrophile (1 equiv.) at -78 °C and allowed to warm to rt overnight. The 
solution was poured into 2M NaOH(aq.) (10 mL/mmol) and extracted with Et2O (3 x 50 
mL/mmol). The combined organics were washed with brine(sat.), dried over MgSO4, filtered, 
and concentrated in vacuo. The crude oil was purified via silica gel chromatography to yield 
the desired compounds. 
(1’-trimethylselanyl)ferrocenyl-1,3-dioxolane 47 
 
General procedure A was followed using 46 (1.65 g, 5 mmol), n-butyllithium (2.5 M in 
hexanes) (2.0 mL), and dimethyl diselenide (475 µL, 5 mmol), eluting with petrol/EtOAc 
(9:1) to yield the title compound as a yellow oil (1.54 g, 88%). 
IR ν (cm-1) 3083, 2908, 2815. 1H NMR (500 MHz, C6D6) δ 5.76 (s, 1H, FcCHO2), 4.36–4.31 (m, 
4H, CpH), 4.11 (t, J = 1.9 Hz, 2H, CpH), 4.04 (t, J = 1.9 Hz, 2H (CpH), 3.66–3.56 (m, 2H, CH2), 
3.53–3.43 (m, 2H, CH2), 1.90 (s, 3H, 2 x CH3). 13C NMR (126 MHz, C6D6) δ 102.4 (FcCHO2), 
85.9 (CpC), 74.3 (CpCH), 70.1 (CpCH), 69.7 (CpCH), 68.8 (CpC), 68.4 (CpCH), 64.8 (CH2), 8.9 






General procedure A was followed using 46 (1.65 g, 5 mmol), n-butyllithium (2.5 M in 
hexanes) (2.0 mL), and tributyltin chloride (1.35 mL, 5 mmol), eluting with petrol/EtOAc 
(9:1) to yield the title compound as a yellow oil (2.32 g, 64%). 
IR ν (cm-1) 3094, 2921 2820. 1H NMR (500 MHz, C6D6) δ 5.79 (s, 1H, FcCHO2), 4.46–4.40 (m, 
2H, CpH), 4.40 (t, J = 1.9 Hz, 2H, CpH), 4.15–4.12 (m, 2H, CpH), 4.09 (t, J = 1.9 Hz, 2H, CpH), 
3.68–3.58 (m, 2H, CH2), 3.54–3.44 (m, 2H, CH2), 1.76–1.52 (m, 6H, 3 x CH2), 1.42–1.30 (m, 
1H, 3 x CH2), 1.19–1.02 (m, 6H, 3 x CH2), 0.95 (t, J = 7.3 Hz, 9H, 3 x CH3). 13C NMR (126 MHz, 
C6D6) δ 103.5 (FcCHO2), 85.6 (CpC), 75.8 (CpCH), 72.2 (CpCH), 69.7 (CpC), 68.8 (CpCH), 67.6 
(CpCH), 65.4 (CH2), 29.9 (CH2), 28.0 (CH2), 14.2 (CH2), 10.7 (CH2). HRMS (ESI) calculated for 
C25H40FeO2SnNa [M+Na]+ : m/z 571.1292, found 571.1301. 
(1’-trimethylstannyl)ferrocenyl-1,3-dioxolane 96 
  
General procedure A was followed using 46 (1.65 g, 5 mmol), n-butyllithium (2.5 M in 
hexanes) (2.0 mL), and trimethyltin chloride (995 µL, 5 mmol), eluting with petrol/EtOAc 
(9:1) to yield the title compound as a yellow oil (1.51 g, 72%). 
IR ν (cm-1) 3086, 2899, 2807. 1H NMR (500 MHz, C6D6) δ 5.75 (s, 1H, FcCHO2), 4.42–4.37 (m, 
2H, CpH), 4.35–4.33 (m, 2H, CpH), 4.12–4.05 (m, 2H, CpH), 4.01 (d, J = 1.8 Hz, 2H, CpH), 3.67–
3.56 (m, 2H, CH2), 3.53–3.41 (m, 2H, CH2), 0.26 (s, 9H, 3 x CH3). 13C NMR (126 MHz, C6D6) δ 
103.2 (FcCHO2), 85.5 (CpC), 75.3 (CpCH), 72.0 (CpCH), 69.6 (CpC), 68.5 (CpCH), 67.4 (CpCH), 







To a stirred slurry of LiAlH4 (277 mg, 7.5 mmol) in anhydrous THF (5 mL) at 0 °C was added 
a solution of 45 (1.47 g, 5.0 mmol) in anhydrous THF (5 mL) dropwise, and once addition 
was complete the suspension was allowed to stir at rt for 1 hour. The yellow slurry was 
cooled to 0 °C and quenched sequentially with water (277 µL), 15% NaOH(aq.) (277 µL), then 
water (831 µL) and stirred at rt for 15 minutes. The suspension was filtered through celite, 
dried over MgSO4, filtered, and concentrated in vacuo. The crude oil was purified via flash 
chromatography, eluting with petrol/EtOAc (8:2) to yield the title compound as a yellow oil 
(1.28 g, 86%). 
IR ν (cm-1) 3310, 3101, 2897. 1H NMR (500 MHz, C6D6) δ 4.23 (s, 2H, CH2), 4.17 (t, J = 1.9 Hz, 
2H, CpH), 4.05 (t, J = 1.9 Hz, 2H, CpH), 3.94 (t, J = 1.9 Hz, 2H, CpH), 3.70 (t, J = 1.9 Hz, 2H, 
CpH). 13C NMR (126 MHz, C6D6) δ 90.4 (CpC), 78.3 (CpCH), 70.8 (CpCH), 70.4 (CpCH), 68.6 
(CpC), 67.7 (CpCH), 60.1 (CH2OH). HRMS (ESI) calculated for C11H12BrFeO [M+H]+: m/z 






To a stirred solution of 49 (710 mg, 2.4 mmol) in ethylene glycol (24 mL) was added 
ytterbium (III) triflate (74 mg, 0.12 mmol), and the solution was heated to 120 °C for 20 
minutes. The reaction was cooled, diluted with H2O (200 mL), and extracted with EtOAc (3 
x 100 mL). The combined organics were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude orange oil was purified via flash chromatography, eluting with 
petrol/EtOAc (8:2) to yield the title compound as an orange oil (703 mg, 69%). 
IR ν (cm-1) 3287, 3057, 2953, 2889. 1H NMR (500 MHz, C6D6) δ 4.30 (s, 2H, FcCH2), 4.25 (s, 
2H, Cp), 4.18 (s, 2H, Cp), 4.07 (s, 2H, Cp), 3.83 (s, 2H, Cp), 3.71–3.59 (m, 2H, CH2), 3.47–3.35 
(m, 2H, CH2), 2.76 (s, 1H, OH). 13C NMR (126 MHz, C6D6) δ 85.5 (CpC), 78.5 (CpC), 72.0 
(CpCH), 71.8 (CH2), 71.2 (CpCH), 71.0 (CpCH), 68.8 (CH2), 67.9 (CpCH), 61.9 (CH2). HRMS 




General procedure B 
 
To a stirred solution of acetal (1 equiv.) in dichloromethane (3.3 mL/mmol) and water (1.6 
mL/mmol) under argon was added p-toluenesulfonic acid (1.1 equiv.) and the mixture was 
allowed to stir at rt for 2 hours. The solution was quenched with NaHCO3(sat.)(aq.) (10 
mL/mmol) and the aqueous layers were extracted with EtOAc (3 x 25 mL/mmol). The 
combined organics were washed with brine, dried over MgSO4, filtered, and concentrated in 
vacuo. 
To a stirred slurry of LiAlH4 (1.5 equiv.) in anhydrous THF (1 mL/mmol) at 0 °C was added 
a solution of the crude oil in anhydrous THF (1 mL/mmol) dropwise, and once addition was 
complete the suspension was allowed to stir at rt for 1 hour. The reaction was cooled to 0 
°C and quenched sequentially with H2O (1 µL per mg LiAlH4), 15% NaOH (aq.) (1 µL per mg 
LiAlH4), and H2O (3 µL per mg LiAlH4). The suspension was filtered through celite, dried 
over MgSO4, filtered, and concentrated in vacuo. The crude oil was dissolved in ethylene 
glycol (0.1 M), treated with ytterbium (III) triflate (5 mol%), and heated to 120 °C for 20 
minutes. The reaction was cooled and poured into H2O (100 mL/mmol) and extracted with 
EtOAc (3 x 50 mL/mmol). The combined organics were washed with brine(sat.), dried over 
MgSO4, filtered, and concentrated in vacuo. The crude oil was purified via flash 






General procedure B was followed using 47 (1.40 g, 4 mmol), p-toluenesulfonic acid (756 
mg, 4.4 mmol) in CH2Cl2 (15 mL) and water (7 mL), then LiAlH4 (222 mg, 6 mmol) in THF (6 
mL), and finally ytterbium (III) triflate (124mg, 0.2 mmol) in ethylene glycol (40 mL), 
eluting with petrol/EtOAc (8:2) to yield the title compound as a yellow oil (708 mg, 50%). 
IR ν (cm-1) 3219, 3048, 2931, 2876. 1H NMR (500 MHz, C6D6) δ 4.21 (t, J = 1.8 Hz, 2H, CpH), 
4.19 (s, 2H, FcCH2), 4.12 (t, J = 1.9 Hz, 2H, CpH), 4.01 (t, J = 1.8 Hz, 2H, CpH), 3.93 (t, J = 1.9 
Hz, 2H, CpH), 3.60 (dd, J = 9.5, 6.0 Hz, 2H, CH2), 3.37–3.33 (m, 2H, CH2), 2.67 (t, J = 6.0 Hz, 1H, 
OH), 1.88 (s, 3H, SeCH3). 13C NMR (126 MHz, C6D6) δ 85.2 (CpC), 74.8 (CpCH), 71.9 (CH2), 
70.8 (CpC), 70.1 (CpCH), 69.9 (CpCH), 69.1 (CH2), 68.8 (CpC), 61.9 (CH2), 9.62 (SeCH3). HRMS 
(ESI) calculated for C14H18FeO2SeNa [M+Na]+: m/z 376.9714, found 376.9728. 
2-((1’-tributylstannyl)ferrocenyl)methyloxyethan-1-ol 54 
 
General procedure B was followed using 48 (2.178 g, 3 mmol), p-toluenesulfonic acid (567 
mg, 3.3 mmol) in CH2Cl2 (10 mL) and water (5 mL), then LiAlH4 (166 mg, 4.5 mmol) in THF 
(6 mL), and finally ytterbium (III) triflate (93 mg, 0.15 mmol) in ethylene glycol (30 mL), 
eluting with petrol/EtOAc (8:2) to yield the title compound as a yellow oil (474 mg, 29%). 
IR ν (cm-1) 3310, 3058, 2947, 2913, 2847. 1H NMR (500 MHz, C6D6) δ 4.22 (s, 2H, FcCH2), 
4.21 (t, J = 1.6 Hz, 2H, CpH), 4.16 (t, J = 1.8 Hz, 2H, CpH), 4.06 (t, J = 1.8 Hz, 2H, CpH), 3.99 (t, 
J = 1.6 Hz, 2H, CpH), 3.56 (q, J = 5.6 Hz, 2H, CH2), 3.38–3.34 (m, 2H, CH2), 2.35 (t, J = 5.6 Hz, 
1H, OH), 1.71–1.57 (m, 6H, 3 x CH2), 1.40 (h, J = 7.4 Hz, 6H, 3 x CH2), 1.12–1.04 (m, 6H, 3 x 
CH2), 0.95 (t, J = 7.4 Hz, 9H, 3 x CH3). 13C NMR (126 MHz, C6D6) δ 83.7 (CpC), 75.2 (CpCH), 
71.6 (CH2), 71.5 (CpCH), 69.7 (CpCH), 69.1 (CpC), 68.8 (CpCH), 61.9 (CH2), 29.7 (CH2), 27.8 
(CH2), 14.0 (CH2), 10.6 (CH3). HRMS (ESI) calculated for C25H42FeO2SnNa [M+Na]+: m/z 






55 was isolated as a by-product of the formation of 54 due to protodestannylation to yield 
the title compound as a yellow oil (117 mg, 15%). 
IR ν (cm-1) 3289, 3063, 2894. 1H NMR (500 MHz, C6D6) δ 4.14 (s, 2H, FcCH2), 4.11 (t, J = 1.8 
Hz, 2H, CpH), 3.97 (s, 5H, CpH), 3.97 (t, J = 1.8 Hz, 2H, CpH), 3.59 (t, J = 4.8 Hz, 2H, CH2), 3.37–
3.33 (m, 2H, CH2), 2.77 (s, 1H, OH). 13C NMR (126 MHz, C6D6) δ 83.9 (CpC), 71.6 (CH2), 69.7 
(CpCH), 69.5 (CH2), 68.8 (CpCH), 68.7 (CpCH), 61.9 (CH2). HRMS (ESI) calculated for 




General procedure C for the azidation of ferrocenyl alcohols 
 
To a stirred solution of ferrocenyl alcohols (1 equiv.) in toluene (4 mL/mmol) at 0 °C was 
added methanesulfonyl chloride (1 equiv.) in one portion and allowed to stir for 5 minutes. 
Triethylamine (1 equiv.) was added dropwise and allowed to stir for 5 minutes. To this 
solution was added water (2 mL/mmol), tetrabutylammonium bromide (0.1 equiv.) and 
sodium azide (8.5 equiv.). The flask was fitted with a reflux condenser and allowed to stir at 
80 °C overnight. The reaction was cooled and the aqueous layer was extracted with EtOAc 
(3 x 25 mL/mmol). The combined organics were washed with brine(sat.) (25 mL/mmol), 
dried over MgSO4, filtered, and concentrated in vacuo. The crude oil was purified via flash 
chromatography to yield the desired compound. 
((2-azido ethoxy)methyl)ferrocene 56 
  
General procedure C was followed using 55 (117 mg, 0.45 mmol) eluting with petrol/EtOAc 
(9:1) to yield the title compound as an orange oil (80 mg, 62%). 
IR ν (cm-1) 3093, 2925, 2854, 2091. 1H NMR (500 MHz, C6D6) δ 4.08 (s, 2H, CpH), 4.06 (s, 
2H, FcCH2), 3.98 (s, 5H, CpH), 3.96 (s, 2H, CpH), 3.17 (t, J = 5.0 Hz, 2H, CH2), 2.78 (t, J = 5.0 
Hz, 2H, CH2). 13C NMR (126 MHz, C6D6) δ 83.8 (CpC), 69.5 (CH2), 69.4 (CpCH), 68.8 (CpCH), 
68.7 (CH2), 68.7 (CpCH), 50.8 (CH2). HRMS (ESI) calculated for C13H15FeN3ONa [M+Na]+: m/z 






General procedure C was followed using 49 (560 mg, 1.6 mmol), eluting with petrol/EtOAc 
(9:1) to yield the title compound as an orange oil (230 mg, 39%). 
IR ν (cm-1) 3098, 2858, 2096. 1H NMR (500 MHz, C6D6) δ 4.29–3.85 (m, 8H, CH2, 3 x CpH), 
3.85–3.62 (m, 2H, CpH), 3.22–2.99 (m, 2H, CH2), 2.87–2.62 (m, 2H, CH2). 13C NMR (126 MHz, 
C6D6) δ 86.2 (CpC), 78.5 (CpC), 71.9 (CpCH), 71.0 (CpCH), 71.0 (CpCH), 70.0 (CH2), 68.8 
(CH2), 68.0 (CpCH), 50.8 (CH2). HRMS (ESI) calculated for C13H14BrFeN3ONa [M+Na]+: m/z 
385.9562, found 385.9567. 
1’-methylseleno-1-((2-azidoethoxy)methyl)ferrocene 58 
 
General procedure C was followed using 53 (353 mg, 1.0 mmol), eluting with petrol/EtOAc 
(9:1) to yield the title compound as an orange oil (289 mg, 76%). 
IR ν (cm-1) 3088, 2926, 2855, 2090. 1H NMR (500 MHz, C6D6) δ 4.19 (t, J = 1.8 Hz, 2H, CpH), 
4.13 (s, 2H, FcCH2), 4.10 (t, J = 1.9 Hz, 2H, CpH), 4.00 (t, J = 1.9 Hz, 2H, CpH), 3.94 (t, J = 1.8 
Hz, 2H, CpH), 3.18 (t, J = 5.0 Hz, 2H, CH2), 2.80 (t, J = 5.0 Hz, 2H, CH2), 1.88 (s, 3H, CH3). 13C 
NMR (126 MHz, C6D6) δ 84.7 (CpC), 74.6 (CpCH), 70.7 (CpCH), 70.1 (CpCH), 70.0 (CpC), 69.0 
(CH2), 68.9 (CpC), 68.8 (CH2), 50.8 (CH2), 9.5 (CH3). HRMS (ESI) calculated for 






General procedure C was followed using 54 (474 mg, 0.86 mmol), eluting with petrol/EtOAc 
(9:1) to yield the title compound as an orange oil (280 mg, 55%). 
IR ν (cm-1) 3091, 2955, 2924, 2853, 2100. 1H NMR (500 MHz, C6D6) δ 4.23 (t, J = 1.6 Hz, 2H, 
CpH), 4.19–4.14 (m, 4H, CpH, CH2), 4.06 (t, J = 1.9 Hz, 2H, CpH), 4.01 (t, J = 1.9 Hz, 2H, CpH), 
3.24–3.20 (m, 2H, CH2), 2.81–2.76 (m, 2H, CH2), 1.71–1.60 (m, 6H, 3 x CH2), 1.45–1.36 (m, 
6H, 3 x CH2), 1.13–1.06 (m, 6H, 3 x CH2), 0.96 (t, J = 7.3 Hz, 9H, 3 x CH3). 13C NMR (126 MHz, 
C6D6) δ 83.2 (CpC), 74.8 (CpCH), 71.2 (CpCH), 69.5–68.9 (m, CpCH), 69.0 (CH2), 68.4–68.2 
(m, CpCH), 68.3 (CH2), 50.3 (CH2), 29.2 (3 x CH2), 27.4 (3 x CH2), 13.5 (3 x CH2), 10.2 (3 x 





To a stirred solution of 39 (266 mg, 1 mmol) and trimethylsilyl acetylene (0.14 mL, 1 mmol) 
in tBuOH (2.5 mL) and water (2.5 mL) was added CuSO4·5H2O (25 mg, 0.1 mmol) and 
sodium ascorbate (20 mg, 0.1 mmol) and the solution was allowed to stir for 4 hours at rt. 
The solution was dissolved in EtOAc (10 mL), and the aqueous layer was extracted with 
EtOAc (2 x 10 mL). The combined organics were dried over MgSO4, filtered, and 
concentrated in vacuo. The oil was purified via flash chromatography, eluting with n-
hexane/EtOAc (4:1) to yield the title compound as a brown solid (227 mg, 62%). 
IR ν (cm-1) 3124, 3093, 2958, 2940, 2898. 1H NMR (300 MHz, C6D6) δ 7.03 (s, 1H, CH), 4.05–
4.02 (m, 7H, CpH), 4.00–3.94 (m, 4H, CpH, CH2), 2.18 (d, J = 7.1 Hz, 2H, CH2), 1.82 (p, J = 7.1 
Hz, 2H, CH2), 0.46 (s, 9H, CH3). 13C NMR (75 MHz, C6D6) δ 145.8 (ArC), 87.4 (CpC), 68.9 
(CpCH), 68.4 (CpCH), 67.7 (CpCH), 48.7 (CH2), 32.0 (CH2), 26.5 (CH2), –0.78 (CH3). HRMS 





To a stirred solution of 39 (1.07 mg, 4 mmol) and propargyl alcohol (0.23 mL, 4 mmol) in 
tBuOH (5 mL) and H2O (5 mL) was added CuSO4·5H2O (100 mg, 0.4 mmol) and sodium 
ascorbate (80 mg, 0.4 mmol) and allowed to stir for 18 hours at rt. The solution was 
dissolved in EtOAc (10 mL) and the aqueous layer was extracted with EtOAc (2 x 10 mL). 
The combined organics were dried over MgSO4, filtered, and concentrated in vacuo. The oil 
was purified via flash chromatography, eluting with n-hexane/EtOAc (4:1) to yield the title 
compound as a brown solid (1.23 g, 95%). 
IR ν (cm-1) 3233, 3123, 2981, 2931, 2851. 1H NMR (500 MHz, CDCl3) δ 7.52 (s, 1H, ArH), 4.82 
(s, 2H, CH2), 4.35 (t, J = 1.7 Hz, 2H, CpH), 4.18–4.03 (m, 9H, CpH, CH2), 2.61 (s, 1H, OH), 2.39 
(t, J = 7.5 Hz, 2H, CH2), 2.16–2.07 (m, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 147.3 (ArC), 
121.2 (ArC), 86.6 (CpC), 68.3 (CpCH), 67.8 (CpCH), 67.2 (CpCH), 56.4 (OCH2), 49.5 (CH2), 
31.4 (CH2), 26.2 (CH2). HRMS (ESI) calculated for C16H19FeN3ONa [M+Na]+: m/z 348.0775, 





To a stirred solution of 28 (1.14 g, 3.5 mmol) in MeOH (12 mL) was added K2CO3 (1.93 g, 14 
mmol) and the solution was allowed to stir at room temperature for 30 minutes. The 
solution was filtered and concentrated and the colourless gum was dissolved in EtOAc (7 
mL) and H2O (7 mL) with 39 (0.94 g, 3.5 mmol). The yellow solution was treated with 
CuSO4·5H2O (87 mg, 0.35 mmol) and sodium ascorbate (138 mg, 0.7 mmol) and the solution 
was heated to 70 °C for 3 hours. The solvent was removed and the yellow residue was 
filtered through silica eluting with CDCl3/MeOH (9:1). The filtrate was dried with MgSO4 
and concentrated to give a yellow gum. The gum was recrystallised from hot MeOH to yield 
a yellow powder (867 mg, 48%). 
IR ν (cm-1) 3270, 3161, 3037, 2935, 2835, 1686. 1H NMR (500 MHz, CD3OD) δ 8.59 (s, 1H, 
ArH), 8.21 (s, 1H, ArH), 6.28 (dd, J = 7.5, 5.9 Hz, 1H, 1’-H), 4.44 (dt, J = 6.5, 3.2 Hz, 1H, 3’-H), 
4.32 (t, J = 7.0 Hz, 2H, CH2), 4.05–4.01 (m, 7H, CpH), 3.96 (q, J = 3.0 Hz, 1H, 4’-H), 3.90 (dd, J 
= 12.3, 3.0 Hz, 1H, 5’-H), 3.76–3.71 (m, 3H, CpH, 5’-H), 2.39–2.30 (m, 3H, CH2, 2’-H), 2.17 
(ddd, J = 13.7, 7.5, 5.9 Hz, 1H, 2’-H), 2.08 (p, J = 7.0 Hz, 2H, CH2). 13C NMR (126 MHz, CD3OD) 
δ 170.8 (CO), 135.4 (ArC), 121.6 (ArC), 104.5 (ArC), 87.8 (4’-C), 86.9 (CpC), 85.8 (1’-C), 70.7 
(CpCH), 69.6 (CpCH), 67.6 (3’-C), 67.1 (CpCH), 66.5 (5’-C), 60.4 (CH2), 40.1(2’-C), 30.4 (CH2), 





General procedure D for the copper catalysed azide-alkyne cycloaddition of uridines 
and ferrocenes 
To a stirred solution of 5-ethynyl-2’-deoxyuridine 27 (1 equiv.) and the corresponding azide 
(1 equiv.) in EtOAc (5 mL/mmol) and H2O (1 mL/mmol) was added CuSO4·5H2O (10 mol%) 
and sodium ascorbate (20 mol%) and the yellow solution was allowed to stir at rt for 24 
hrs. The solution was diluted with CH2Cl2 (20 mL/mmol) and H2O (10 mL/mmol), and the 
aqueous layer was extracted with CH2Cl2 (3 x 20 mL/mmol). The combined organics were 
washed with brine(sat.) (10 mL/mmol), dried over MgSO4, filtered, and concentrated in vacuo. 
The crude solids were purified via silica gel chromatography (petrol/EtOAc/Et3N 







General procedure C was followed using 27 (4.48 g, 8.3 mmol), 39 (2.69 g, 8.3 mmol), 
CuSO4·5H2O (207 mg, 10 mol%), sodium ascorbate (328 mg, 20 mol%) and EtOAc/H2O (5:1) 
(50 mL) to yield the title compound as a yellow foam (5.47 g, 81%). 
MP 103–107 °C. IR ν (cm-1) 3159, 2981, 1684. 1H NMR (300 MHz, (CD3)2SO) δ 11.77 (s, 1H, 
NH), 8.37 (s, 1H, ArH), 8.34 (s, 1H, ArH), 7.37 (d, J = 7.2 Hz, 2H, ArH), 7.30–7.20 (m, 6H, ArH), 
7.15 (t, J = 7.2 Hz, 1H, ArH), 6.89–6.79 (m, 4H, ArH), 6.19 (t, J = 6.5 Hz, 1H, 1’-H), 4.41 (t, J = 
6.8 Hz, 2H, CH2), 4.19 (dd, J = 9.6, 4.2 Hz, 1H, 3’-H), 4.09 (s, 2H, CpH), 4.07 (s, 5H, CpH), 4.05 
(s, 2H, CpH), 3.95 (q, J = 4.2 Hz, 1H, 4’-H), 3.70 (s, 3H, OCH3), 3.70 (s, 3, OCH3), 3.42–3.29 (m, 
2H, 5’-H), 2.39–2.19 (m, 4H, 2’-H, CH2), 1.74 (p, J = 6.9 Hz, 2H, CH2). 13C NMR (126 MHz, 
CD3CN) δ 162.1 (CO), 159.5 (ArC), 159.5 (ArC), 150.6 (ArC), 146.0 (ArC), 140.0 (ArC), 136.9 
(ArC), 136.8 (ArC), 136.6 (ArC), 131.0 (ArC), 131.0 (ArC), 129.0 (ArC), 128.8 (ArC), 127.7 
(ArC), 123.0 (ArC), 114.0 (ArC), 114.0 (ArC), 87.3 (4’-C), 87.1 (OCAr3), 86.6 (1’-C), 72.1 (3’-
C), 69.5 (CpH), 68.9 (CpH), 68.2 (CpH), 64.6 (5’-C), 55.9 (OCH3), 50.6 (CH2), 41.2 (2’-C), 32.1 









General procedure C was followed using 27 (138 mg, 0.25 mmol), 56 (72 mg, 0.25 mmol), 
CuSO4·5H2O (6 mg, 10 mol%), sodium ascorbate (10 mg, 20 mol%), EtOAc (1 mL), and H2O 
(0.2 mL) to yield the title compound as a yellow foam (92 mg, 44%). 
MP 101–105 °C. IR ν (cm-1) 3150, 2986, 2850, 1679. 1H NMR (500 MHz, CDCl3) δ 8.40 (s, 
1H, ArH), 8.23 (s, 1H, ArH), 7.45–7.37 (m, 2H, ArH), 7.35–7.28 (m, 4H, ArH), 7.24–7.16 (m, 
2H, ArH), 7.15–7.08 (m, 1H, ArH), 6.78 (d, J = 8.9 Hz, 4H, ArH), 6.36–6.28 (m, 1H, 1’-H), 4.43 
(t, J = 5.5 Hz, 2H, CH2), 4.37 (dt, J = 7.4, 3.9 Hz, 1H, 3’-H), 4.25 (s, 2H, FcCH2), 4.15 (t, J = 1.9 
Hz, 2H, CpH), 4.09 (t, J = 1.9 Hz, 2H, CpH), 4.05 (s, 5H, CpH), 4.05–4.01 (m, 1H, 4’-H), 3.76 (t, 
J = 5.5, 2H, CH2), 3.75 (s, 6H, 2 x OCH3), 3.42 (dd, J = 10.3, 4.9 Hz, 1H, 5’-H), 3.37 (dd, J = 10.3, 
4.9, 1H, 5’-H), 2.49–2.38  (m, 1H, 2’-H), 2.30–2.21 (m, 1H, 2’-H). 13C NMR (126 MHz, CDCl3) 
δ 161.5 (CO), 158.5 (ArC), 150.1 (ArC), 144.7 (ArC), 138.7 (ArC), 135.7 (ArC), 135.4 (ArC), 
130.1 (ArC), 128.0 (ArC), 127.9 (ArC), 126.8 (ArC), 123.0 (ArC), 113.3 (ArC), 86.8 (CAr3), 
85.8 (4’-C), 85.5 (1’-C), 82.5 (CpC), 71.7 (3’-C), 69.5 (FcCH2), 69.4 (CpCH), 68.6 (CpCH), 68.5 
(CpCH), 67.9 (CH2), 63.7 (5’-C), 55.1 (OCH3), 50.1 (CH2), 41.5 (2’-C). HRMS (ESI) calculated 







General procedure C was followed using 27 (277 mg, 0.5 mmol), 39 (182 mg, 0.5 mmol), 
CuSO4·5H2O (12 mg, 10 mol%), sodium ascorbate (20 mg, 20 mol%), EtOAc (2 mL) and H2O 
(0.5 mL) to yield the title compound as a yellow foam (221 mg, 48%). 
MP 114–116 °C. IR ν (cm-1) 3153, 2982, 1681. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H, ArH), 
8.28 (s, 1H, ArH), 7.42 (d, J = 7.1 Hz, 2H, ArH), 7.32 (d, J = 8.7 Hz, 4H), 7.22 (t, J = 7.6 Hz, 2H, 
ArH), 7.13 (t, J = 7.3 Hz, 1H, ArH), 6.80 (d, J = 8.9 Hz, 4H, ArH), 6.33 (t, J = 6.7 Hz, 1H, 1’-H), 
4.46 (t, J = 5.4 Hz, 2H, CH2), 4.45–4.39 (m, 1H, 3’-H), 4.30 (t, J = 1.9 Hz, 2H, CpH), 4.29 (s, 2H, 
FcCH2), 4.18 (t, J = 1.9 Hz, 2H, CpH), 4.17–4.15 (m, 2H, CpH), 4.12–4.05 (m, 1H, 4’-H), 4.00 (t, 
J = 1.9 Hz, 2H, CpH), 3.79 (t, J = 5.4 Hz, 2H, CH2), 3.73 (s, 6H, 2 x OCH3), 3.46 (dd, J = 10.3, 4.8 
Hz, 1H, 5’-H), 3.39 (dd, J = 10.3, 4.8 Hz, 1H, 5’-H), 2.47 (ddd, J = 13.8, 6.7, 3.5 Hz, 1H, 2’-H), 
2.28 (dt, J = 13.8, 6.7 Hz, 1H, 2’-H). 13C NMR (126 MHz, CDCl3) δ 161.5 (CO), 158.5 (ArC), 
158.4 (ArC), 149.9 (ArC), 144.7 (ArC), 138.8 (ArC), 136.1 (ArC), 135.8 (ArC), 135.8 (ArC), 
130.1 (ArC), 130.1 (ArC), 128.1 (ArC), 127.9 (ArC), 126.8 (ArC), 123.3 (ArC), 113.3 (ArC), 
113.2 (ArC), 86.7 (CAr3), 86.1 (4’-C), 85.8 (1’-C), 84.1 (CpC), 77.9 (CpC), 72.2 (3’-C), 71.7 
(CpCH), 71.2 (CpCH), 70.7 (CpCH), 68.8 (FcCH2), 67.9 (CH2), 67.7 (CpCH), 63.9 (5’-C), 55.2 
(OCH3), 50.3 (CH2), 40.2 (2’-C). HRMS (ESI) calculated for C45H44BrFeN5O8Na [M+Na]+: m/z 






General procedure C was followed using 27 (277 mg, 0.5 mmol), 58 (189 mg, 0.5 mmol), 
CuSO4·5H2O (12 mg, 10 mol%), sodium ascorbate (20 mg, 20 mol%), EtOAc (2 mL) and H2O 
(0.5 mL) to yield the title compound as a yellow foam (133 mg, 28%). 
MP 108–109 °C. IR ν (cm-1) 3160, 2983, 2868, 1684. 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 
1H, ArH), 8.26 (s, 1H, ArH), 7.43–7.39 (m, 2H, ArH), 7.33–7.29 (m, 4H, ArH), 7.21 (d, J = 7.7 
Hz, 2H, ArH), 7.16–7.11 (m, 1H, ArH), 6.80 (d, J = 8.9 Hz, 4H, ArH), 6.32 (t, J = 6.7 Hz, 1H, 1’-
H), 4.46 (t, J = 5.4 Hz, 2H, CH2), 4.42 (dt, J = 7.0, 3.8 Hz, 1H, 3’-H), 4.29 (s, 2H, CH2), 4.22 (t, J 
= 1.8 Hz, 1H, CpH), 4.16 (t, J = 1.8 Hz, 2H, CpH), 4.13 (t, J = 1.8 Hz, 2H, CpH), 4.10 (t, J = 1.8 
Hz, 2H, CpH), 4.09–4.05 (m, 1H, 4’-H), 3.78 (t, J = 5.4 Hz, 2H, CH2), 3.73 (s, 6H, 2 x OCH3), 3.46 
(dd, J = 10.2, 4.8 Hz, 1H, 5’-H), 3.38 (dd, J = 10.2, 5.1 Hz, 1H, 5’-H), 2.47 (ddd, J = 13.9, 6.7, 3.8 
Hz, 1H, 2’-H), 2.28 (dt, J = 13.9, 6.7 Hz, 1H, 2’-H), 2.08 (s, 3H, SeCH3). 13C NMR (126 MHz, 
CDCl3) δ 161.3 (CO), 158.4 (ArC), 158.4 (ArC), 149.8 (ArC), 144.8 (ArC), 138.7 (ArC), 136.5 
(ArC), 135.7 (ArC), 135.7 (ArC), 130.0 (ArC), 130.0 (ArC), 128.1 (ArC), 127.9 (ArC), 126.7 
(ArC), 123.0 (ArC), 113.2 (ArC), 113.2 (ArC), 86.7 (CAr3), 85.7 (4’-C), 85.7 (1’-C), 83.3 (CpC), 
74.2 (CpC), 73.3 (CpC), 72.1 (3’-C), 70.6 (CpCH), 70.0 (CpCH), 69.7 (CpCH), 69.1 (FcCH2), 67.8 
(CH2), 63.4 (5’-C), 55.1 (OCH3), 50.2 (CH2), 40.2 (2’-C), 9.8 (SeCH3). HRMS (ESI) calculated 






General procedure C was followed using 27 (277 mg, 0.5 mmol), 78 (270 mg, 0.5 mmol), 
CuSO4·5H2O (12 mg, 10 mol%), sodium ascorbate (20 mg, 20 mol%) EtOAc (2 mL) and H2O 
(0.5 mL) to yield the title compound as a yellow solid (212 g, 39%). 
MP 93–94 °C. IR ν (cm-1) 3078, 2930, 2858, 1687. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H, 
ArH), 8.16 (s, 1H, ArH), 7.42 (d, J = 7.0 Hz, 2H, ArH), 7.32 (d, J = 7.7 Hz, 4H, ArH), 7.23 (t, J = 
7.6 Hz, 2H, ArH), 7.14 (t, J = 7.2 Hz, 1H, ArH), 6.80 (d, J = 8.9 Hz, 4H, ArH), 6.33 (t, J = 6.1 Hz, 
1H, 1’-H), 4.39 (dt, J = 7.0, 3.7 Hz, 1H, 3’-H), 4.26 (t, J = 7.2 Hz, 2H, CH2), 4.16 (t, J = 1.8 Hz, 4H, 
CpH), 4.10 (t, J = 1.8 Hz, 4H, CpH), 4.08 (s, 10H, CpH), 4.05 (q, J = 4.8 Hz, 1H, 4’-H), 3.47 (dd, 
J = 10.2, 4.8 Hz, 1H, 5’-H), 3.74 (s, 4H, FcCH2), 3.38 (dd, J = 10.2, 4.8 Hz, 1H, 5’-H), 3.48–3.34 
(m, 6H, 2 x OCH3), 2.60 (q, J = 7.2 Hz, 2H, CH2), 2.44 (ddd, J = 13.7, 6.1, 3.7 Hz, 1H, 2’-H), 2.30–
2.22 (m, 3H, CH2, 2’-H), 1.84 (p, J = 7.1 Hz, 2H, CH2), 1.46–1.36 (m, 3H), 1.31–1.19 (m, 6H, 
CH2), 1.05 (t, J = 7.2 Hz, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 161.7 (CO), 158.5 (ArC), 158.5 
(ArC), 149.9 (ArC), 144.7 (ArC), 138.9 (ArC), 136.1 (ArC), 135.8 (ArC), 135.8 (ArC), 130.1 
(ArC), 130.1 (ArC), 128.2 (ArC), 127.9 (ArC), 126.8 (ArC), 122.1 (ArC), 113.3 (ArC), 113.2 
(ArC), 86.7 (OCAr3), 86.0 (4’-C), 85.8 (1’-C), 83.4 (CpC), 72.1 (3’-C), 70.3 (CpCH), 68.6 (CpCH), 
67.9 (CpCH), 63.9 (5’-C), 55.3 (OCH3), 52.6 (FcCH2), 51.6 (CH2), 50.3 (CH2), 40.4 (2’-C), 30.3 
(CH2), 26.8 (CH2), 26.8 (CH2), 26.4 (CH2). HRMS (ESI) calculated for C60H64Fe2N6O7Na 






General procedure C was followed using 27 (277 mg, 0.5 mmol), 88 (247 mg, 0.5 mmol), 
CuSO4·5H2O (12 mg, 10 mol%), sodium ascorbate (20 mg, 20 mol%) in EtOAc (2.5 mL) and 
H2O (2.5 mL) to yield the title compound as a yellow solid (611 mg, 65%). 
MP 95–97 °C. IR ν (cm-1) 3083, 2936, 2832, 1686, 1681. 1H NMR (500 MHz, CDCl3) δ 8.42 
(s, 1H, ArH), 8.08 (s, 1H, ArH), 7.42–7.39 (m, 2H, ArH), 7.32 (dd, J = 9.0, 1.3 Hz, 4H, ArH), 
7.24–7.20 (m, 2H, ArH), 7.16–7.12 (m, 1H, ArH), 6.82–6.77 (m, 4H, ArH), 6.32 (t, J = 6.7 Hz, 
1H, 1’-H), 4.41 (dt, J = 6.7, 3.5 Hz, 1H, 3’-H), 4.22 (t, J = 6.6, Hz, 2H, CH2), 4.17–4.11 (m, 4H, 
CpH), 4.09 (t, J = 1.9 Hz, 4H, CpH), 4.07 (s, 10H, CpH), 4.07–4.04 (m, 1H, 4’-H), 3.73 (s, 3H, 
OCH3), 3.73 (s, 3H, OCH3), 3.45 (dd, J = 10.3, 5.0 Hz, 1H, 5’-H), 3.43 (s, 4H, FcCH2), 3.38 (dd, J 
= 10.3, 5.0 Hz, 1H, 5’-H), 2.45 (ddd, J = 13.7, 6.7, 3.5 Hz, 1H, 2’-H), 2.32 (t, J = 6.6 Hz, 2H, CH2), 
2.27 (dt, J = 13.7, 6.7 Hz, 1H, 2’-H), 1.96 (p, J = 6.6 Hz, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 
161.4 (CO), 158.5 (ArC), 158.4 (ArC), 149.8 (ArC), 144.6 (ArC), 138.6 (ArC), 135.9 (ArC), 
135.8 (ArC), 135.7 (ArC), 130.1 (ArC), 130.0 (ArC), 128.1 (ArC), 127.8 (ArC), 126.8 (ArC), 
122.6 (ArC), 113.2 (ArC), 113.2 (ArC), 86.7 (OCAr3), 85.9 (4’-C), 85.7 (1’-C), 83.2 (CpC), 72.2 
(3’-C), 70.1 (CpCH), 68.5 (CpCH), 68.0 (CpCH), 63.8 (5’-C), 55.2 (OCH3), 52.9 (FcCH2), 48.3 
(CH2), 48.3 (CH2), 40.3 (2’-C), 28.1 (CH2). HRMS (ESI) calculated for C57H58Fe2N6NaO7 








General procedure C was followed using 27 (2.22 g, 4.0 mmol), 98 (2.50 g, 4.0 mmol), 
CuSO4·5H2O (100 mg, 10 mol%), sodium ascorbate (247 mg, 20 mol%) in EtOAc (20 mL) 
and H2O (4 mL) to yield the title compound as a yellow solid (3.05 g, 74%). 
MP 98–101 °C. IR ν (cm-1) 2948, 2828, 1677. 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H, ArH), 
8.09 (s, 1H, ArH), 7.46–7.37 (m, 2H, ArH), 7.32 (d, J = 8.1 Hz, 4H, ArH), 7.23 (t, J = 7.7 Hz, 2H, 
ArH), 7.17–7.11 (m, 1H, ArH), 6.80 (d, J = 8.9 Hz, 4H, ArH), 6.33 (t, J = 6.7 Hz, 1H, 1’-H), 4.42 
(dt, J = 7.0, 3.7 Hz, 1H, 3’-H), 4.30 (t, J = 1.9 Hz, 4H, CpH), 4.28–4.22 (m, 2H, CH2), 4.19–4.13 
(m, 8H, CpH), 4.09–4.06 (m, 1H, 4’-H), 4.02 (t, J = 1.9 Hz, 4H, CpH), 3.74 (s 3H, OCH3), 3.73 (s 
3H, OCH3), 3.48–3.43 (m, 5H, FcCH2, 5’-H), 3.39 (dd, J = 10.3, 5.1 Hz, 1H, 5’-H), 2.51–2.42 (m, 
1H, 2’-H), 2.35 (t, J = 6.8 Hz, 2H, CH2), 2.28 (dt, J = 13.7, 6.7 Hz, 1H, 2’-H), 1.98 (p, J = 6.8 Hz, 
2H, CH2). 13C NMR (126 MHz, CDCl3) δ 161.4 (CO), 158.5 (ArC), 149.9 (ArC), 144.7 (ArC), 
138.6 (ArC), 136.0 (CO), 135.8 (ArC), 135.7 (ArC), 130.1 (ArC), 128.1 (ArC), 127.9 (ArC), 
126.8 (ArC), 122.7 (ArC), 113.3 (ArC), 86.7 (OCAr3), 85.9 (4’-C), 85.7 (1’-C), 84.8 (CpC), 78.1 
(CpC), 72.6 (CpCH), 72.3 (3’-C), 70.7 (CpCH), 70.6 (CpCH), 67.7 (CpCH), 63.8 (5’-C), 55.2 
(OCH3), 52.1 (FcCH2), 48.6 (CH2), 48.3 (CH2), 40.3 (2’-C), 28.1 (CH2). HRMS (ESI) calculated 






General procedure C was followed using compound 27 (831 mg, 1.5 mmol), 101 (834 mg, 
1.5 mmol), CuSO4·5H2O (38 mg, 10 mol%), sodium ascorbate (60 mg, 20 mol%) in EtOAc 
(7.5 mL) and H2O (1.5 mL) to yield the title compound as a yellow solid (896 mg, 53%). 
MP 97–100 °C. IR ν (cm-1) 2956, 2834, 1690. 1H NMR (500 MHz, CDCl3) δ 8.40 (s, 1H, ArH), 
8.04 (s, 1H, ArH), 7.44–7.38 (m, 2H, ArH), 7.32 (d, J = 8.6 Hz, 4H, ArH), 7.26–7.22 (m, 2H, 
ArH), 7.18–7.12 (m, 1H, ArH), 6.81 (d, J = 8.6 Hz, 4H, ArH), 6.31 (t, J = 6.6 Hz, 1H, 1’-H), 4.41 
(dt, J = 7.4, 4.1 Hz, 1H, 3’-H), 4.28 (t, J = 1.9 Hz, 4H, CpH), 4.25 (t, J = 7.2 Hz, 2H, CH2) 4.20–
4.13 (m, 6H, CpH), 4.08–4.00 (m, 1H, 4’-H), 3.98 (t, J = 1.9 Hz, 2H, CpH), 3.76 (s, 6H, 2 x CH3), 
3.51–3.46 (m, 1H, 5’-H), 3.43 (s, 4H, FcCH2), 3.42–3.36 (m, 1H, 5’-H), 2.45 (ddd, J = 13.8, 6.6, 
4.1 Hz, 1H, 2’-H), 2.37–2.26 (m, 3H, CH2, 2’-H), 1.97 (p, J = 6.8 Hz, 2H, CH2). 13C NMR (126 
MHz, CDCl3) δ 161.2 (CO), 158.6 (ArC), 149.7 (ArC), 144.7 (ArC), 138.6 (ArC), 135.9 (CO), 
135.8 (ArC), 130.2 (ArC), 128.2 (ArC), 128.0 (ArC), 126.9 (ArC), 122.7 (ArC), 113.3 (ArC), 
86.9 (OCAr3), 85.7 (4’-C), 85.7 (1’-C), 84.9 (CpC), 77.9 (CpC), 72.5 (3’-C), 72.3 (CpCH), 70.3 
(CpCH), 68.5 (CpCH), 66.7 (CpCH), 63.9 (5’-C), 55.3 (OCH3), 52.3 (FcCH2), 48.7 (CH2), 48.4 
(CH2), 40.3 (2’-C), 28.3 (CH2). HRMS (ESI) calculated for C57H57Cl2Fe2N6O7 [M+H]+: m/z 








General procedure C was followed using 27 (249 mg, 0.47 mmol), 99 (325 mg, 0.47 mmol), 
CuSO4·5H2O (12 mg, 10 mol%), sodium ascorbate (20 mg, 20 mol%) EtOAc (1.5 mL) and 
H2O (0.5 mL) to yield the title compound as a yellow foam (308 mg, 50%). 
MP 93–95 °C. IR ν (cm-1) 2949, 2832, 1697. 1H NMR (500 MHz, CDCl3) δ 8.41 (s, 1H, ArH), 
8.07 (s, 1H, ArH), 7.41 (d, J = 8.2 Hz, 2H, ArH), 7.32 (d, J = 8.9 Hz, 4H, ArH), 7.22 (t, J = 7.7 Hz, 
2H, ArH), 7.16–7.11 (m, 1H, ArH), 6.80 (d, J = 8.9 Hz, 4H, ArH), 6.32 (t, J = 6.6 Hz, 1H, 1’-H), 
4.41 (dt, J = 7.1, 3.5 Hz, 1H, 3’-H), 4.25–4.20 (m, 6H, CH2, CpH), 4.16–4.10 (m, 8H, CpH), 4.10 
(t, J = 1.8 Hz, 4H, CpH), 4.09–4.02 (m, 1H, 4’-H), 3.74 (s, 6H, 2 x OCH3), 3.46 (dd, J = 10.2, 5.1 
Hz, 1H, 5’-H), 3.43 (s, 4H, FcCH2), 3.38 (dd, J = 10.2, 5.1 Hz, 1H, 5’-H), 2.46 (ddd, J = 13.7, 6.6, 
3.5 Hz, 1H, 2’-H), 2.33 (t, J = 6.6 Hz, 2H, CH2), 2.29–2.24 (m, 1H, 2’-H), 2.09 (s, 6H, SeCH3), 
1.96 (p, J = 6.6 Hz, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 161.3 (CO), 158.3 (ArC), 149.6 
(ArC), 144.8 (ArC), 138.3 (ArC), 135.9 (CO), 135.7 (ArC), 130.1 (ArC), 128.1 (ArC), 127.8 
(ArC), 126.7 (ArC), 122.5 (ArC), 113.2 (ArC), 86.7 (OCAr3), 86.6 (4’-C), 85.7 (1’-C), 84.1 
(CpCH), 74.2 (CpC), 73.1 (CpCH), 71.5 (CpCH), 71.5 (3’-C), 69.9 (CpCH), 69.4 (CpC), 63.8 (5’-
C), 55.2 (OCH3), 52.3 (FcCH2), 48.3 (CH2), 48.2 (CH2), 40.2 (2’-C), 28.1 (CH2), 9.9 (SeCH3). 







General procedure C was followed using 27 (720 mg, 1.3 mmol), 102 (826 mg, 1.3 mmol) 
CuSO4·5H2O (32 mg, 0.13 mmol), sodium ascorbate (26 mg, 0.13 mmol) and EtOAc/H2O 
(4:1) (5 mL) to yield the title compound as a yellow solid (1.28 g, 82%). 
MP 85–88 °C. IR ν (cm-1) 2985, 2856, 1687. 1H NMR (500 MHz, CDCl3) δ 8.37 (s, 1H, ArH), 
8.01 (s, 1H, ArH), 7.44–7.37 (m, 2H, ArH), 7.32 (d, J = 8.3 Hz, 4H, ArH), 7.23 (t, J = 7.6 Hz, 2H, 
ArH), 7.15 (t, J = 7.3 Hz, 1H, ArH), 6.81 (d, J = 8.8 Hz, 4H, ArH), 6.32 (t, J = 6.6 Hz, 1H, 1’-H), 
4.39 (dt, J = 7.4, 4.0 Hz, 1H, 3’-H), 4.19 (t, J = 7.0 Hz, 2H, CH2), 4.04–3.98 (m, 1H, 4’-H), 3.75 
(s, 6H, OCH3), 3.64 (t, J = 1.8 Hz, 4H, CpH), 3.55 (s, 4H, CpH), 3.48 (dd, J = 10.2, 4.7 Hz, 1H, 5’-
H), 3.37 (dd, J = 10.2, 5.5 Hz, 1H, 5’-H), 3.24 (s, 4H, FcCH2), 2.44 (ddd, J = 13.7, 6.6, 4.0 Hz, 1H, 
2’-H), 2.35–2.21 (m, 3H, 2’-H, CH2), 1.90 (p, J = 7.0 Hz, 2H, CH2), 1.85 (s, 30H, 10 x FcCH3). 13C 
NMR (126 MHz, CDCl3) δ 161.1 (CO), 158.6 (ArC), 158.6 (ArC), 149.7 (ArC), 144.7 (ArC), 
138.6 (ArC), 135.8 (ArC), 135.8 (ArC), 130.2 (ArC), 130.2 (ArC), 128.2 (ArC), 128.0 (ArC), 
126.9 (ArC), 122.7 (ArC), 113.4 (ArC), 113.4 (ArC), 86.9 (OCAr3), 85.6 (4’-C), 85.5 (1’-C), 82.0 
(CpC), 80.2 (CpC), 72.6 (CpCH), 72.5 (3’-C), 72.4 (CpCH), 63.9 (5’-C), 55.3 (OCH3), 55.3 
(OCH3), 52.2 (FcCH2), 48.6 (CH2), 48.5 (CH2), 40.3 (2’-C), 28.5 (CH2), 11.4 (10 x FcCH3). HRMS 





General procedure D for phosphoramidite formation 
To a stirred solution of alcohol (2.8 mmol) in anhydrous, deoxygenated THF (25 mL) under 
nitrogen was added DIPEA (1.95 mL, 11.2 mmol) and the solution was stirred for 10 
minutes. 2-cyano-N,N-diisopropylchlorophosphoramidite (1 g, 4.2 mmol) was added 
dropwise via syringe and allowed to stir at rt. After 5 minutes, a precipitate formed, and the 
reaction was treated with H2O (0.10 mL) and allowed to stir at rt for 30 minutes. The 
solution was treated with H2O (0.20 mL) to give a homogenous solution, which was then 
treated with EtOAc/TEA (25 mL, 1:1) and poured into NaHCO3(sat.)(aq.) (10 mL) and the 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organics were dried 
over MgSO4, concentrated and purified via flash chromatography (petrol/EtOAc/TEA 







General procedure D was followed using 63 (2.26 g, 2.8 mmol) to yield the title compound 
as a mixture of diastereomers, as a yellow solid (2.45 g, 86%). 
MP 103–105 °C. IR ν (cm-1) 2966, 1684, 1507. 1H NMR (500 MHz, CD3CN) δ 8.45 (s, 1H, 
ArH), 8.17 (s, 1H, ArH), 7.47–7.40 (m, 2H, ArH), 7.36–7.30 (m, 4H, ArH), 7.26–7.21 (m, 2H, 
ArH), 7.19–7.14 (m, 1H, ArH), 6.85–6.80 (m, 4H, ArH), 6.26–6.18 (m, 1H, 1’-H), 4.53–4.45 
(m, 1H, 3’-H), 4.34 (td, J = 7.0, 2.5 Hz, 2H, CH2), 4.17 (q, J = 3.5 Hz, 1H, 4’-H), 4.07–4.06 (m, 
2H, CpH), 4.04 (s, 5H, CpH), 4.03 (t, J = 1.9 Hz, 2H, CpH), 3.83–3.75 (m, 1H, CH2), 3.74–3.72 
(m, 6H, 2 x OCH3), 3.69–3.61 (m, 1H, CH2), 3.61–3.52 (m, 2H, NCH(CH3)2), 3.41–3.35 (m, 1H, 
5’-H), 3.35–3.28 (m, 1H, 5’-H), 2.67–2.60 (m, 1H, CH2), 2.56–2.45 (m, 2H, CH2, 2’-H), 2.41–
2.34 (m, 1H, 2’-H), 2.35–2.27 (m, 2H, CH2), 2.12–2.05 (m, 2H, CH2), 1.19–1.02 (m, 12H, 4 x 
CH3). 13C NMR (126 MHz, CD3CN) δ 162.1 (CO), 159.6 (ArC), 150.6 (ArC), 145.9 (ArC), 139.9 
(ArC), 136.7 (ArC), 136.7 (ArC), 136.5 (ArC), 131.0 (ArC), 129.0 (ArC), 128.8 (ArC), 127.7 
(ArC), 123.0 (ArC), 119.3 (CN), 114.1 (ArC), 88.6 (OCAr3), 86.7 (5’-C), 86.4 (d, J = 4.3 Hz, 4’-
C), 74.5 (d, J = 17.6 Hz, 3’-C), 69.3 (CpCH), 68.9 (CpCH), 68.1 (CpCH), 64.3 (5’-C), 59.5 (d, J = 
19.1 Hz, CH2), 55.8 (OCH3), 55.8 (OCH3), 50.5 (CH2), 44.0 (d, J = 12.4 Hz, NCH(CH3)2), 40.3 (d, 
J = 4.5 Hz, 2’-C), 32.0 (CH2), 26.8 (CH2), 24.9–24.7 (m, 4 x CH3), 20.9 (d, J = 7.1 Hz, CH2). 31P 
NMR (202 MHz, CD3CN) δ 148.09. HRMS (ESI) calculated for C54H62FeN7NaO8P [M+Na]+: 




2-cyanoethyl (3-(ferrocenyl)propyl) N,N-diisopropylphosphoramidite 69110 
 
General procedure D was followed using 38 (0.682 g, 2.8 mmol) to yield the title compound 
as a mixture of diastereomers, as a yellow oil (1.168 g, 93%). 
1H NMR (500 MHz, C6D6) δ 4.03 (s, 5H, CpH), 4.01 (s, 2H, CpH), 3.96 (s, 2H, CpH), 3.74– 3.67 
(m, 1H, POCH2), 3.66–3.60 (m, 1H, POCH2), 3.60–3.52 (m, 2H, NCH), 3.43–3.36 (m, 1H, 
POCH2), 3.35–3.26 (m, 1H, POCH2), 2.39 (t, J = 7.7 Hz, 2H, CH2), 1.84–1.71 (m, 4H, CH2, 
CH2CN), 1.15 (t, J = 6.7 Hz, 12H, 4 x CH3). 13C NMR (126 MHz, C6D6) δ 117.6 (CN), 88.7 (CpC), 
68.9 (CpCH), 68.4 (d, J = 1.8 Hz, CpCH), 67.6 (CpCH), 63.5 (d, J = 16.3 Hz, POCH2), 58.6 (d, J = 
18.7 Hz, POCH2), 43.4 (d, J = 12.4 Hz, PNCH), 33.1 (d, J = 7.0 Hz, CH2), 26.3 (CH2), 24.7 (d, J = 









General procedure D was followed using 89 (1.40 g, 1.3 mmol) to yield the title compound 
as a mixture of diastereomers, as a yellow foam (1.295 g, 80%). 
MP 120–121 °C. IR ν (cm-1) 3083, 2965, 2837, 2256, 1698, 1507. 1H NMR (500 MHz, CD3CN) 
δ 9.36 (s, 1H, NH), 8.42 (s, 1H, ArH), 8.06 (s, 1H, ArH), 7.48–7.43 (m, 2H, ArH), 7.39–7.32 (m, 
4H, ArH), 7.30–7.23 (m, 2H, ArH), 7.22–7.17 (m, 1H, ArH), 6.88–6.83 (m, 4H, ArH), 6.25 (q, J 
= 6.7 Hz, 1H, 1’-H), 4.51 (dddt, J = 13.4, 9.9, 6.8, 3.4 Hz, 1H, 3’-H), 4.28 (td, J = 7.0, 2.5 Hz, 2H, 
CH2), 4.20–4.17 (m, 1H, 4’-H), 4.16 (s, 2H, CpH), 4.09 (s, 10H, CpH), 4.08 (s, 4H, CpH), 3.85 – 
3.78 (m, 1H, CNCH2), 3.76 (s, 6H, 2 x OCH3), 3.67 (dtd, J = 8.0, 6.0, 1.9 Hz, 1H, CNCH2), 3.64–
3.54 (m, 2H, PNCH), 3.42–3.37 (m, 5H, FcCH2, 5’-H), 3.38–3.28 (m, 1H, 5’-H), 2.68–2.52 (m, 
2H, POCH2), 2.49 (ddd, J = 13.7, 6.7, 3.4 Hz, 1H, 2’-H), 2.43–2.33 (m, 1H, 2’-H), 2.28 (t, J = 6.7 
Hz, 2H, CH2), 1.21–1.05 (m, 12H, 4 x CH3). 13C NMR (126 MHz, CD3CN) δ 161.9 (CO), 159.6 
(ArC), 150.5 (ArC), 145.9 (ArC), 139.7 (ArC), 136.7 (ArC), 136.3 (ArC), 131.0 (ArC), 129.0 
(ArC), 128.8 (ArC), 127.7 (ArC), 123.4 (ArC), 119.4 (CN), 114.1 (ArC), 87.4 (OCAr3), 86.6 (1’-
C), 86.3 (d, J = 4.4 Hz, 4’-C), 84.9 (CpC), 74.0 (d, J = 17.1 Hz, 3’-C), 70.9 (CpCH), 69.4 (CpCH), 
68.6 (CpCH), 64.3 (5’-C), 59.6 (d, J = 2.8 Hz, POCH2), 55.9 (OCH3), 55.9 (OCH3), 53.4 (FcCH2), 
49.6 (CH2), 48.8 (CH2), 44.0 (d, J = 12.4 Hz, NCH(CH3)2), 40.3 (d, J = 3.7 Hz, 2’-C), 28.7 (CH2), 
25.2–24.6 (m, NCH(CH3)2), 21.0 (d, J = 7.3 Hz, CH2CN). 31P NMR (202 MHz, CD3CN) δ 148.11. 








General procedure D was followed using 104 (896 mg, 0.8 mmol) to yield the title 
compound as a mixture of diastereomers, as a yellow powder (480 mg, 45%). 
MP 125–128 °C. IR ν (cm-1) 2963, 2233, 1684. 1H NMR (500 MHz, CD3CN) δ 8.37 (s, 1H, 
ArH), 8.04 (s, 1H, ArH), 7.46–7.39 (m, 2H, ArH), 7.36–7.28 (m, 4H, ArH), 7.27–7.20 (m, 2H, 
ArH), 7.20–7.12 (m, 1H, ArH), 6.85–6.78 (m, 4H, ArH), 6.25–6.17 (m, 1H, 1’-H), 4.54–4.42 
(m, 1H, 3’-H), 4.37 (m, 2H, CH2) 4.30 (t, J = 1.9 Hz, 4H, CpH), 4.27 (td, J = 6.9, 3.6 Hz, 1H, 4’-
H), 4.18 (t, J = 1.9 Hz, 4H, CpH), 4.14 (t, J = 1.9 Hz, 4H, CpH), 4.02 (t, J = 1.9 Hz, 4H, CpH), 3.83–
3.75 (m, 1H, CH2), 3.73 (s, 6H, 3 x OCH3), 3.71–3.60 (m, 1H, CH2), 3.63–3.49 (m, 2H, 
NCH(CH3)2), 3.38 (s, 4H, FcCH2), 3.33 (dd, J = 10.6, 3.6 Hz, 1H, 5’-H), 3.29 (dd, J = 10.6, 5.2 Hz, 
1H, 5’-H), 2.63 (td, J = 6.0, 1.9 Hz, 1H, CH2), 2.51 (p, J = 6.0 Hz, 1H, CH2), 2.45 (ddd, J = 13.8, 
6.1, 3.5 Hz, 1H, 2’-H), 2.34 (dtd, J = 13.8, 6.1, 3.5 Hz, 1H, 2’-H), 2.27 (t, J = 6.0 Hz, 2H, CH2), 
2.02–1.99 (m, 2H, CH2), 1.16–1.02 (m, 12H, 4 x CH3). 13C NMR (126 MHz, CD3CN) δ 161.0 
(CO), 158.6 (ArC), 149.6 (ArC), 145.0 (ArC), 138.7 (ArC), 135.8 (ArC), 135.7 (ArC), 130.1 
(ArC), 130.0 (ArC), 128.0 (ArC), 127.8 (ArC), 122.5 (ArC), 118.4 (CN), 113.1 (ArC), 86.4 
(OCAr3), 85.5 (4’-C), 85.3 (1’-C), 85.1 (CpC), 73.0 (d, J = 17.1 Hz, 3’-C), 72.2 (CpCH), 70.8 
(CpC), 70.0 (CpCH), 68.2 (CpCH), 66.8 (CpCH), 63.4 (5’-C), 58.53 (d, J = 19.2 Hz, POCH2), 54.9 
(OCH3), 54.9 (OCH3), 51.6 (FcCH2), 48.7 (CH2), 47.8 (CH2), 43.05 (d, J = 12.3 Hz, NCH(CH3)2), 
39.3 (2’-C), 27.7 (CH2), 24.04–23.74 (m, NCH(CH3)2) 20.35–19.87 (m, CH2CN). 31P NMR (202 









General procedure D was followed using 103 (2.41 g, 2.0 mmol) to yield the title compound 
as a mixture of diastereomers, as a yellow powder (1.63 g, 58%). 
MP 119–121 °C. IR ν (cm-1) 3078, 2954, 2839, 2253, 1701. 1H NMR (500 MHz, CD3CN) δ 
8.44 (s, 1H, ArH), 8.08 (s, 1H, ArH), 7.50–7.43 (m, 2H, ArH), 7.39–7.32 (m, 4H, ArH), 7.29–
7.24 (m, 2H, ArH), 7.22–7.15 (m, 1H, ArH), 6.88–6.80 (m, 4H, ArH), 6.29–6.20 (m, 1H, 1’-H), 
4.57–4.45 (m, 1H, 3’-H), 4.33 (t, J = 1.8 Hz, 4H, CpH), 4.34–4.27 (m, 2H, CH2), 4.25–4.20 (m, 
1H, 4’-H), 4.18 (t, J = 1.8 Hz, 4H, CpH), 4.16 (t, J = 1.8 Hz, 4H, CpH), 4.08–4.06 (m, 4H, CpH), 
3.84–3.78 (m, 2H, CH2), 3.78–3.70 (m, 6H, 2 x OCH3), 3.67 (dtd, J = 8.0, 6.1, 1.8 Hz, 2H, CH2), 
3.64–3.52 (m, 2H, NCH(CH3)2), 3.44–3.39 (m, 5H, 2 x FcCH2, 5’-H), 3.34 (dd, J = 10.7, 5.0 Hz, 
1H, 5’-H), 2.54 (td, J = 5.8, 0.8 Hz, 2H, CH2), 2.49 (ddd, J = 13.7, 6.2, 3.5 Hz, 1H, 2’-H), 2.43–
2.33 (m, 1H, 2’-H), 2.30 (t, J = 6.7 Hz, 2H, CH2), 2.00–1.98 (m, 2H, CH2), 1.20–1.05 (m, 12H, 4 
x CH3). 13C NMR (126 MHz, CD3CN) δ 161.9 (CO), 159.4 (ArC), 150.6 (ArC), 145.9 (ArC), 139.6 
(ArC), 136.7 (ArC), 136.4 (ArC), 131.0 (ArC), 129.0 (ArC), 128.8 (ArC), 127.7 (ArC), 123.4 
(ArC), 119.3 (CN), 114.1 (ArC), 87.4 (OCAr3), 86.5 (1’-C), 86.3 (4’-C), 78.9 (CpC), 74.3 (d, J = 
16.9 Hz, 3’-C), 73.5 (CpCH), 71.5 (CpCH), 71.3 (CpCH), 69.4 (CpC), 68.8 (CpCH), 64.1 (5’-C), 
59.5 (d, J = 18.9 Hz, POCH2), 55.9 (2 x OCH3), 52.5 (FcCH2), 49.7 (CH2), 48.8 (CH2), 44.0 (d, J 
= 12.4 Hz, NCH(CH3)2), 42.0 (2’-C), 28.7 (CH2), 24.9–24.8 (m, NCH(CH3)2), 20.9 (d, J = 9.5 Hz, 
CH2CN). 31P NMR (202 MHz, CD3CN) δ 148.14, 148.12. HRMS (ESI) C66H74Br2Fe2N8O8P 








General procedure D was followed using 107 (1.191 g, 1.0 mmol) to yield the title 
compound as a mixture of diastereomers, as a yellow foam (0.988 g, 53%). 
MP 120–122 °C. IR ν (cm-1) 3091, 2950, 2247, 1695.  1H NMR (500 MHz, CD3CN) δ 8.39 (s, 
1H, ArH), 8.04 (s, ArH), 7.47–7.40 (m, 2H, ArH), 7.37–7.29 (m, 4H, ArH), 7.26–7.20 (m, 2H, 
ArH), 7.18–7.12 (m, 1H, ArH), 6.84–6.80 (m, 4H, ArH), 6.23 (dt, J = 7.3, 6.2 Hz, 1H, 1’-H), 4.49 
(dddt, J = 13.3, 9.9, 6.8, 3.4 Hz, 1H, 3’-H), 4.21 (td, J = 7.0, 2.6 Hz, 2H, CH2), 4.14 (q, 4.1 Hz, 1H, 
4’-H), 3.83–3.74 (m, 2H, CH2), 3.74–3.71 (m, 6H, 2 x OCH3), 3.68–3.63 (m, 2H, 2 x NCH), 3.62 
(d, J = 1.8 Hz, 4H, CpH), 3.55 (t, J = 1.8 Hz, 4H, CpH), 3.41–3.29 (m, 2H, 5’-H), 3.19 (s, 4H, 
FcCH2), 2.68–2.49 (m, 2H, CH2), 2.46 (ddd, J = 13.7, 6.2, 3.4 Hz, 1H, 2’-H), 2.35 (dtd, J = 13.7, 
6.2, 2.4 Hz, 1H, 2’-H), 2.19 (t, J = 6.8 Hz, 2H, CH2), 1.88 (p, J = 6.8 Hz, 2H, CH2), 1.81 (s, 30H, 
10 x FcCH3), 1.19–1.03 (m, 12H, 4 x CH3) 13C NMR (126 MHz, CD3CN) δ 162.0 (CO), 159.6 
(ArC), 150.6 (ArC), 146.0 (ArC), 139.6 (ArC), 139.6 (ArC), 136.7 (ArC), 136.7 (ArC), 136.7 
(ArC), 136.3 (ArC), 131.1 (ArC), 131.1 (ArC), 131.0 (ArC), 128.9 (ArC), 128.9 (ArC), 128.8 
(ArC), 127.7 (ArC), 123.4 (ArC), 119.43 (CN), 114.1 (ArC), 87.3 (OCAr3), 86.5 (1’-C), 86.3 (d, 
J = 4.3 Hz, 4’-C) 83.1 (CpC), 80.8 (CpC), 74.5 (d, J = 17.6 Hz, 3’-C), 73.43 (CpCH), 72.9 (CpC), 
64.4 (5’-C), 59.6 (d, J = 3.0 Hz, POCH2), 55.9 (OCH3), 55.9 (OCH3), 52.3 (FcCH2), 49.5 (CH2), 
48.9 (CH2), 44.0 (d, J = 12.4 Hz, NCH(CH3)2), 40.3 (d, J = 3.8 Hz, 2’-C), 28.8 (CH2), 25.0–24.7 
(m, NCH(CH3)2), 21.0 (d, J = 7.2 Hz, CH2CN), 11.4 (10 x CH3). 31P NMR (202 MHz, CD3CN) δ 





General procedure E for reductive amination of ferrocene carboxaldehydes 
To a stirred solution of the ferrocenecarboxaldehyde (1 equiv.) and 6-aminohexan-1-ol (0.6 
equiv.) in anhydrous THF (10 mL/mmol) under nitrogen was added sodium 
tris(acetoxy)borohydride (2.5 equiv.) portionwise over 5 minutes. Once addition was 
complete the red slurry was allowed to stir at rt overnight. The yellow solution was poured 
into NaHCO3(sat.)(aq.) (10 mL/mmol) and the aqueous layer was extracted with Et2O (3 x 50 
mL/mmol). The combined organics were dried over MgSO4, filtered, and dried in vacuo. The 
crude oil was purified via silica gel chromatography, eluting with petrol/EtOAc/Et3N 
(70:30:2) to yield the desired compounds.  
6-(bis(ferrocenylmethyl)amino)hexan-1-ol 71155  
 
Using general procedure E with ferrocenecarboxaldehyde (2.14 g, 10 mmol) and 6-
aminohexan-1-ol (585 mg, 5 mmol) gave the title compound as an orange solid (2.10 g, 
82%). 
MP 65–68 °C. 1H NMR (500 MHz, C6D6) δ 4.21 (t, J = 1.8 Hz, 4H, CpH), 4.01 (t, J = 1.8 Hz, 4H, 
CpH), 4.00 (s, 10H, CpH), 3.51 (s, 4H, FcCH2), 3.39 (t, J = 7.1 Hz, 2H, CH2), 2.44 (t, J = 7.1Hz, 
2H, CH2), 1.51 (p, J = 7.1 Hz, 2H, CH2), 1.39 (p, J = 6.5 Hz, 2H, CH2), 1.33–1.21 (m, 4H, 2 x CH2). 
13C NMR (126 MHz, C6D6) δ 84.7 (CpC), 70.4 (CpCH), 68.8 (CpCH), 68.0 (CpCH), 62.6 (CH2), 
53.2 (FcCH2), 52.2 (CH2), 33.1 (CH2), 27.6 (CH2), 27.3 (CH2), 25.9 (CH2). 
6-(bis((1’-bromo)ferrocenylmethyl)amino)hexan-1-ol 73155 
 
Using general procedure E with 46 (0.90 g, 3.1 mmol) to yield the title compound as an 
orange solid (0.65 g, 32%). 
MP 68–69 °C. 1H NMR (500 MHz, C6D6) δ 4.18 (s, 8H, CpH), 4.00 (s, 4H, CpH), 3.72 (t, J = 1.5 
Hz, 4H, CpH), 3.51 (s, 4H, FcCH2), 3.39 (t, J = 6.5 Hz, 2H, CH2), 2.41 (t, J = 7.1 Hz, 2H, CH2), 
1.58–1.49 (m, 2H, CH2), 1.44–1.37 (m, 2H, CH2), 1.31–1.24 (m, 4H, CH2), 1.18 (s, 1H, OH). 13C 
NMR (126 MHz, C6D6) δ 86.2 (CpC), 78.7 (CpC), 72.9 (CpCH), 71.0 (CpCH), 70.6 (CpCH), 68.8 





To a stirred solution of 6-(bis(ferrocenylmethyl)amino)hexan-1-ol (3.00 g, 5.9 mmol) and 
CBr4 (2.15 g, 6.5 mmol) in anhydrous CH2Cl2 (24 mL) at 0 °C was added triphenylphosphine 
(1.70 g, 6.5 mmol) portion wise, and after addition was complete the solution was allowed 
to warm to rt. The solution was stirred for 4 hours, then concentrated in vacuo to a dark oil. 
The oil was suspended in hexane (100 mL) and stirred vigorously for 30 minutes. The 
solution was filtered and the organics were concentrated and filtered through silica, 
washing with petrol/EtOAc (1:1) until the washings ran clear. The solution was 
concentrated to give an intermediate brown oil. The oil was dissolved in acetone (24 mL) 
and water (8 mL), and treated with NaN3 (1.03 g, 15. 9 mmol) then allowed to stir at 70 °C 
for 18 hours. The reaction was concentrated in vacuo and the oily residue was partitioned 
between EtOAc (30 mL) and water (10 mL), and the aqueous layer was extracted with EtOAc 
(3 x 20 mL). The combined organics were washed with brine(sat.) (20 mL), dried over MgSO4, 
filtered, and concentrated in vacuo, which was purified via flash chromatography, eluting 
with petrol/EtOAc/Et3N (80:20:5) to yield a yellow oil (1.80 g, 57%). 
IR ν (cm-1) 3094, 2929, 2857, 2802, 2091. 1H NMR (500 MHz, C6D6) δ 4.14 (t, J = 1.7 Hz, 4H, 
CpH), 3.97 (t, J = 1.7 Hz, 4H, CpH), 3.96 (s, 10H, CpH), 3.43 (s, 4H, FcCH2), 2.65 (t, J = 7.0 Hz, 
2H, CH2), 2.32 (t, J = 7.0 Hz, 2H, CH2), 1.35 (p, J = 7.0 Hz, 2H, CH2), 1.16 (p, J = 7.0 Hz, 2H, CH2), 
1.11–1.04 (m, 2H, CH2), 0.99 (m, 2H, CH2). 13C NMR (126 MHz, C6D6) δ 83.9 (CpC), 70.1 
(CpCH), 68.6 (CpCH), 67.7 (CpCH), 52.9 (CH2), 51.6 (FcCH2), 50.9 (CH2), 28.6 (CH2), 27.8 





tert-butyl (6-bromohexyl)carbamate 82198 
 
To a stirred solution of 6-aminohexan-1-ol (468 mg, 4 mmol) in anhydrous THF (3 mL) was 
added di-tert-butyl dicarbonate (872 mg, 4 mmol) in one portion and the clear solution was 
allowed to stir for 3 hours. After this time, the reaction was concentrated in vacuo to yield a 
colourless oil. 
The oil was dissolved in anhydrous CH2Cl2 (3 mL) and treated with tetrabromomethane 
(1.46 g, 4.4 mmol) and cooled to 0 °C. The solution was treated with triphenylphosphine 
(1.15 g, 4.4 mmol) portionwise over 10 minutes. The reaction was allowed to warm to rt 
and stirred for 30 minutes. The solution was concentrated in vacuo to give a thick oil, which 
was suspended in hexane (50 mL) and stirred vigorously for 30 minutes. The solution was 
filtered, and the slurry was suspended further with hexane (50 mL) and filtered. The 
solution was concentrated in vacuo, filtered through silica (petrol/EtOAc 1:1) and 
concentrated in vacuo to yield the desired compound as pale-yellow oil (817 mg, 73%). 
1H NMR (500 MHz, CDCl3) δ 4.62 (s, 1H, NH), 3.58 (t, J = 6.6 Hz, 2H, CH2), 3.07 (q, J = 6.6 Hz, 
2H, CH2), 1.52 (p, J = 6.6 Hz, 2H, CH2), 1.48–1.42 (m, 2H, CH2), 1.40 (s, 9H, CH3), 1.38–1.26 
(m, 4H, 2 x CH2). 13C NMR (126 MHz, CDCl3) δ 156.2 (CO), 79.1(C °4), 62.6 (CH2), 40.5 (CH2), 31.3 









To a stirred solution of 6-aminohexan-1-ol (468 mg, 4 mmol) in anhydrous THF (3 mL) was 
added di-tert-butyl dicarbonate (872 mg, 4 mmol) in one portion and the clear solution was 
allowed to stir for 3 hours. After this time, the reaction was concentrated in vacuo to yield a 
colourless oil. 
The oil was dissolved in toluene (20 mL) and treated with methanesulfonyl chloride (308 
µL, 4 mmol) and cooled to 0 °C. The reaction was treated with triethylamine (561 µL, 4 
mmol) dropwise, and after addition was complete, the solution was allowed to warm to rt 
over 20 minutes. The suspension was then treated with tetrabutylammonium bromide (128 
mg, 0.4 mmol), NaN3 (2.21 g, 34 mmol) and H2O (10 mL), and heated to 70 °C overnight. The 
reaction was cooled to rt and the aqueous layer was extracted with EtOAc (3 x 100 mL). The 
combined organics were washed with brine(sat.) (50 mL), dried over MgSO4, filtered, and 
concentrated in vacuo to yield a crude oil. 
The oil was dissolved in CH2Cl2 (10 mL) and treated with trifluoroacetic acid (918 µL, 12 
mmol) dropwise and allowed to stir at rt overnight. The reaction was concentrated in vacuo 
and partitioned between CH2Cl2 (50 mL) and NaHCO3(sat.)(aq.) (50 mL). The aqueous layer was 
extracted with CH2Cl2 (3 x 25 mL), and the combined organics were washed with brine(sat.) 
(20 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude oil was filtered 
through silica (petrol/EtOAc 1:1) and concentrated in vacuo to yield the desired compound 
as a colourless oil (510 mg, 90%). 
1H NMR (500 MHz, CDCl3) δ 5.31 (s, 2H, NH2), 3.19 (d, J = 6.9 Hz, 2H, CH2), 2.72 (t, J = 7.9 Hz, 
CH2), 1.58–1.44 (m, 4H, 2 x CH2), 1.34–1.20 (m, 4H, 2 x CH2). 13C NMR (126 MHz, CDCl3) δ 






3-azidopropan-1-amine hydrochloride 87200 
 
To a stirred solution of 3-aminopropan-1-ol (3.0 mL, 40 mmol) in CH2Cl2 (40 mL) at 0 °C 
was added Boc2O (9.59 g, 44 mmol), and the solution was allowed to stir at rt overnight. The 
solution was poured into NaHCO3(sat.)(aq.) (100 mL) and the aqueous layer was extracted with 
CH2Cl2 (3 x 100 mL). The combined organics were washed with brine(sat.) (50 mL), dried over 
MgSO4, filtered, and concentrated in vacuo. 
The crude oil was dissolved in toluene (100 mL), cooled to 0 °C, and treated with 
methanesulfonyl chloride (3.35 mL, 40 mmol), then triethylamine (5.6 mL, 40 mmol) 
dropwise, stirring vigorously. After addition was complete, the solution was allowed to 
warm to rt over 20 minutes, then suspension was treated with tetrabutylammonium 
bromide (1.28 g, 4 mmol), NaN3 (10.4 g, 160 mmol) and H2O (20 mL), and heated to 70 °C 
overnight. The reaction was cooled to rt and the aqueous layer was extracted with EtOAc (3 
x 100 mL). The combined organics were washed with brine(sat.) (50 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The crude oil was filtered through silica (petrol/EtOAc 
1:1) and concentrated. 
The crude oil was dissolved in 2M HCl in Et2O (40 mL, 80 mmol) and allowed to stir in a 
sealed flask for 24 h. The reaction was concentrated in vacuo and the gum was re-suspended 
in Et2O. The precipitate was filtered without further purification, yielding the title 
compound as a white solid (3.44 g, 63%). 
1H NMR (500 MHz, D2O) δ 3.57–3.49 (m, 2H, CH2), 3.18–3.08 (m, 2H, CH2), 2.02–1.93 (m, 2H, 




General procedure F for the synthesis of di-ferrocenyl azides 
To a stirred solution of the corresponding ferrocenecarboxaldehyde (1 equiv.) and 3-
azidopropan-1-amine hydrochloride, 87 (0.6 equiv.) in anhydrous THF (3 mL/mmol) at 0 
°C was added sodium tris(acetoxy)borohydride (3.5 equiv.) portionwise and the slurry was 
allowed to stir at rt overnight. The solution was quenched NaHCO3(sat.)(aq.) and extracted with 
Et2O (3 x 50 mL/mmol). The combined organics were washed with brine(sat.) (25 mL), dried 
over MgSO4, filtered, and concentrated in vacuo. The crude oils were purified via silica gel 
chromatography to yield the desired compounds. 
3-azido-N,N-bis(ferrocenylmethyl)propan-1-amine 88 
 
General procedure F was followed using ferrocenecarboxaldehyde (1.28 g, 6.0 mmol), 87 
(500 mg, 3.6 mmol), sodium tris(acetoxy)borohydride (4.45 g, 21 mmol), and THF (20 mL), 
eluting with petrol/EtOAc/Et3N (80:20:5) to yield the title compound as an orange oil (1.06 
g, 72%) 
IR ν (cm-1) 3092, 2948, 2809, 2093. 1H NMR (500 MHz, C6D6) δ 4.11 (t, J = 1.8 Hz, 4H, CpH), 
3.99 (t, J = 1.8 Hz, 4H, CpH), 3.98 (s, 10H, CpH), 3.38 (s, 4H, FcCH2), 2.90 (t, J = 6.7 Hz, 1H, 
CH2), 2.32 (t, J = 6.7 Hz, 1H, CH2), 1.43 (p, J = 6.7 Hz, 1H, CH2). 13C NMR (126 MHz, C6D6) δ 
84.3 (CpC), 70.3 (CpCH), 68.9 (CpCH), 68.2 (CpCH), 53.2 (CH2), 49.5 (CH2), 49.3 (CH2), 27.2 






General procedure F was followed using 46 (1.88 g, 6.4 mmol), 87 (522 mg, 3.8 mmol), 
sodium tris(acetoxy)borohydride (4.74 g, 22.4 mmol), and THF (20 mL), eluting with 
petrol/EtOAc/Et3N (80:20:5) to yield the title compound as an orange oil (1.55 g, 74%). 
IR ν (cm-1) 3087, 2940, 2812, 2090. 1H NMR (500 MHz, C6D6) δ 4.16 (t, J = 1.9 Hz, 4H, CpH), 
4.08 (t, J = 1.9 Hz, 4H, CpH), 3.99 (d, J = 1.9 Hz, 4H, CpH), 3.71 (t, J = 1.9 Hz, 4H, CpH), 3.38 (s, 
4H, FcCH2), 2.90 (t, J = 6.6 Hz, 2H, CH2), 2.29 (t, J = 6.6 Hz, 2H, CH2), 1.45 (p, J = 6.6 Hz, 2H, 
CH2). 13C NMR (126 MHz, C6D6) δ 85.9 (CpC), 78.7 (CpC), 72.9 (CpCH), 71.0 (CpCH), 70.7 
(CpCH), 67.9 (CpCH), 52.2 (FcCH2), 49.5 (CH2), 49.5 (CH2), 27.2 (CH2). HRMS (ESI) calculated 
for C25H27Br2Fe2N4 [M+H]+: m/z 654.9275, found 654.9326. 
3-azido-N,N-bis((1’-trimethylstannyl)ferrocenylmethyl)propan-1-amine 100 
 
General procedure F was followed 97 (1.13 g, 3 mmol), 87 (244 mg, 1.8 mmol), sodium 
tris(acetoxy)borohydride (2.22 g, 10.5 mmol), and THF (10 mL), eluting with 
petrol/EtOAc/Et3N (80:20:5) to yield the title compound as an orange oil (749 mg, 60%). 
IR ν (cm-1) 3081, 2930, 2834, 2093. 1H NMR (500 MHz, C6D6) δ 4.20 (t, J = 1.8 Hz, 4H, CpH), 
4.13 (t, J = 1.8 Hz, 4H, CpH), 4.02 (t, J = 1.8 Hz, 4H, CpH), 3.93 (t, J = 1.8 Hz, 4H, CpH), 3.42 (s, 
4H, FcCH2), 2.92 (t, J = 6.7 Hz, 2H, CH2), 2.33 (t, J = 6.7 Hz, 2H, CH2), 1.47 (p, J = 6.7 Hz, 2H, 
CH2), 0.27 (s, 12H, 6 x SnCH3). 13C NMR (126 MHz, C6D6) δ 84.1 (CpC), 75.0 (CpCH), 71.8 
(CpCH), 70.4 (CpCH), 69.1 (CpC), 68.2 (CpCH), 53.4 (FcCH2), 49.5 (CH2), 49.4(CH2), 27.2 







General procedure F was followed using 91 (2.22 g, 8.9 mmol), 87 (726 mg, 5.34 mmol), 
sodium tris(acetoxy)borohydride (6.59 g, 31.1 mmol), and THF (35 mL), eluting with 
petrol/EtOAc/Et3N (80:20:5) to yield the title compound as an orange oil (891 mg, 18%). 
IR ν (cm-1) 3089, 2975, 2882, 2089. 1H NMR (500 MHz, C6D6) δ 4.13 (t, J = 1.9 Hz, 4H (CpH), 
4.11 (t, J = 1.9 Hz, 4H, CpH), 3.99 (t, J = 1.9 Hz, 4H, CpH), 3.67 (t, J = 1.9 Hz, 4H, CpH), 3.39 (s, 
4H, FcCH2), 2.89 (t, J = 6.7 Hz, 2H, CH2), 2.30 (t, J = 6.7 Hz, 2H, CH2), 1.44 (p, J = 6.7 Hz, 2H, 
CH2). 13C NMR (126 MHz, C6D6) δ 85.8 (CpC), 72.5 (CpCH), 70.4 (CpCH), 68.7 (CpCH), 67.6 
(CpC), 66.9 (CpCH), 52.3 (FcCH2), 49.5 (CH2), 49.5 (CH2), 27.2 (CH2). HRMS (ESI) calculated 
for C25H26Cl2Fe2N4Na [M+Na]+: m/z 587.0127, found 587.0126. 
3-azido-N,N-bis((1’,2’,3’,4’,5’-pentamethyl)ferrocenylmethyl)propan-1-amine 102 
 
General procedure F was followed using 95 (1.80 g, 6.3 mmol), 87 (514 g, 3.8 mmol), sodium 
tris(acetoxy)borohydride (4.67 g, 22.1 mmol), and THF (20 mL) petrol/EtOAc/Et3N 
(90:10:5) to yield the title compound as an orange oil (875 mg, 43%). 
IR ν (cm-1) 3086, 2981, 2941, 2875, 2092. 1H NMR (300 MHz, C6D6) δ 3.66 (t, J = 1.8 Hz, 4H, 
CpH), 3.62 (t, J = 1.8 Hz, 4H, CpH), 3.34 (s, 4H, FcCH2), 2.93 (t, J = 6.7 Hz, 2H, CH2), 2.37 (t, J = 
6.7 Hz, 2H, CH2), 1.80 (s, 30H, 10 x CH3), 1.52 (p, J = 6.7 Hz, 2H, CH2). 13C NMR (75 MHz, C6D6) 
δ 83.2 (CpC), 80.4 (CpC), 73.1 (CpCH), 72.7 (CpCH), 52.5 (FcCH2), 49.9 (CH2), 49.8 (CH2), 27.7 







To a stirred solution of 47 (561 mg, 1.6 mmol) in CH2Cl2 (5 mL) and H2O (2.5 mL) was added 
p-toluenesulfonic acid (631 mg, 1.8 mmol) and the solution was allowed to stir at rt for 30 
minutes. The red solution was quenched with NaHCO3(sat.)(aq.) (20 mL) and the aqueous layer 
was extracted with CH2Cl2 (3 x 10 mL). The combined organics were dried over MgSO4, 
filtered, and concentrated in vacuo to give the crude aldehyde. 
The crude aldehyde was dissolved in anhydrous THF (5 mL) and treated with 87 (130 mg, 
0.96 mmol) and allowed to stir at rt for 10 minutes. To the solution was added sodium 
tris(acetoxy)borohydride (1.19 g, 5.6 mmol) portionwise and the reaction was allowed to 
stir at rt overnight. The reaction was quenched with NaHCO3(sat.)(aq.) (30 mL) and the aqueous 
layer was extracted with Et2O (3 x 20 mL). The combined organics were dried over MgSO4, 
filtered, and concentrated in vacuo, then the crude oil was purified via silica gel 
chromatography eluting with petrol/EtOAc/Et3N (80:20:5) to yield the title compound as 
an orange oil (380 mg, 70%). 
IR ν (cm-1) 3087, 2926, 2815, 2089. 1H NMR (500 MHz, C6D6) δ 4.18 (t, J = 1.8 Hz, 4H, CpH), 
4.14 (t, J = 1.8 Hz, 4H, CpH), 4.04 (t, J = 1.8 Hz, 4H, CpH), 3.92 (t, J = 1.8 Hz, 4H, CpH), 3.46 (s, 
4H, FcCH2), 2.91 (t, J = 6.7 Hz, 2H, CH2), 2.30 (t, J = 6.7 Hz, 2H, CH2), 1.89 (s, 6H, CH3), 1.47 (p, 
J = 6.7 Hz, 2H, CH2). 13C NMR (126 MHz, C6D6) δ 84.8 (CpC), 74.4 (CpCH), 71.4 (CpCH), 69.7 
(CpCH), 69.2 (CpCH), 68.5 (CpC), 52.3 (FcCH2), 49.1 (CH2), 49.0 (CH2), 26.8 (CH2), 9.1 (CH3). 










To a stirred solution of ferrocene (6.00 g, 32.2 mmol) and potassium tert-butoxide (448 mg, 
4.0 mmol) in anhydrous THF (280 mL) at -78 °C was added t-BuLi (1.7 M in pentane) (38 
mL, 64.4 mmol) dropwise over 20 minutes via pressure equalising funnel, forming an 
orange precipitate, and the suspension was allowed to stir for 90 minutes at -78 °C. After 
this time the suspension was treated with hexachloroethane (11.44 g, 48.5 mmol) in 
anhydrous THF (20 mL) dropwise, and once addition was complete was allowed to stir for 
30 minutes at -78 °C. The dark orange solution was warmed to rt and quenched by the 
addition of H2O (250 mL), and the aqueous layer was extracted with EtOAc (3 x 100 mL). 
The combined organics were concentrated to 200 mL, and washed with 0.2 M FeCl3(aq.) (4 x 
100 mL), H2O (3 x 100 mL), and brine(sat.) (100 mL). The organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo to yield the title compound as an amorphous orange solid 
(4.22 g, 60%). 
MP 63–64 ° C. 1H NMR (500 MHz, C6D6) δ 4.20 (t, J = 1.9 Hz, 2H, CpH), 4.00 (s, 5H, CpH), 3.68 







To a solution of phosphorous oxychloride (5.06 mL, 54.4 mmol) and N-methylformanilide 
(10.25 mL, 83.2 mmol) was added 90 (7.03 g, 32.0 mmol). The slurry was stirred at rt for 1 
hour, then heated to 70 °C for 2 hours. The slurry was cooled to rt and quenched by the 
addition of NaOAc (32 g) in H2O (200 mL) and allowed to stir overnight. The biphasic 
mixture was filtered through celite and washed with CHCl3 (2.5 L) until the washings ran 
clear. The aqueous layer was extracted with CHCl3 (3 x 50 mL), and the combined organics 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude red oil was purified 
twice via flash chromatography, eluting with petroleum ether/ EtOAc (9:1) to yield the title 
compound as a 4:1 ratio of inseparable 1,2-, and 1,1’- regioisomers, as a red solid (2.22 g, 
27%). 
MP 56–58 °C. 1H NMR (500 MHz, C6D6) δ 9.78 (s, 1H, CHO), 4.50 (s, 2H, CpH), 4.07 (s, 2H, 
CpH), 4.05 (s, 2H, CpH), 3.56 (s, 2H, CpH). 13C NMR (126 MHz, C6D6) δ 191.8 (CHO), 92.9 






To a round bottom flask under argon was added freshly cracked cyclopentadiene (1.66 mL, 
19.8 mmol) and treated with 2.5 M n-butyllithium (8.72 mL,21.8 mmol) dropwise at -78 °C 
and was allowed to warm to rt and stirred for 1 hour. The white slurry was treated with 
methyl formate (1.81 mL, 29.7 mmol) and allowed to stir at rt for 4 hours to give a deep red 
colour. 
2 hours after initial reaction, to a stirred solution of 1,2,3,4,5-pentamethylcyclopentadiene 
(3.4 mL, 21.8 mmol) in THF (100 mL) under argon at -78 °C was added 2.5 M n-butyllithium 
(8.72 mL, 21.8 mmol) dropwise and was allowed to warm to rt and stirred for 2 hours. 
3 hours after initial reaction, a suspension of FeCl2 (2.5 g, 19.8 mmol) in THF (100 mL) was 
vigorously stirred in the dark for 1 hour. 
4 hours after initial reaction, to the iron chloride suspension was added the LiCp* via 
cannula transfer with argon pressure and the mixture was allowed to stir at rt for 1 hour. 5 
hours after initial reaction, the LiCp was added to the LiCp* + FeCl2 mixture via cannula 
transfer and was allowed to stir at rt for 90 minutes. 
The solution was concentrated in vacuo and redissolved in 1:1 Et2O/Hexane. The solution 
was filtered through celite until the washings ran clear. The solution was concentrated in 
vacuo and purified via silica gel chromatography, eluting with petroleum ether/EtOAc (9:1) 
to yield the title compound as a red solid (1.89 g, 34%). 
MP 60–62 °C. 1H NMR (300 MHz, C6D6) δ 9.73 (s, 1H, CHO), 4.11 (t, J = 1.8 Hz, 2H, CpH), 3.78 
(t, J = 1.8 Hz, 2H, CpH), 1.62 (s, 15H, 5 x CH3). 13C NMR (75 MHz, C6D6) δ 192.5 (CO), 81.9 







To a stirred solution of 96 (1.55 g, 3.6 mmol) in CH2Cl2 (10 mL) and H2O (5 mL) was added 
p-toluenesulfonic acid (681 mg, 3.96 mmol) and the reaction was allowed to stir for 30 
minutes. The reaction was poured into NaHCO3(sat.)(aq.) and the aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL). The combined organics were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude oil was purified via silica gel chromatography eluting with 
petroleum ether/EtOAc (9:1) to yield the title compound as a red oil (1.15 g, 85%). 
IR ν (cm-1) 3085, 2978, 2909, 2818, 1679. 1H NMR (500 MHz, C6D6) δ 9.87 (s, 1H, CHO), 4.53 
(s, 2H, CpH), 4.16 (s, 2H, CpH), 4.12 (s, 2H, CpH), 3.88 (s, 2H, CpH), 0.19 (s, 9H, 3 x CH3). 13C 
NMR (126 MHz, C6D6) δ 191.9 (CHO), 80.3 (CpC), 75.7 (CpCH), 72.7 (CpCH), 72.3 (CpCH), 
71.1 (CpC), 69.6 (CpCH), -8.9 (3 x CH3). HRMS (ESI) calculated for C14H18FeOSnNa [M+Na]+: 
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Crystal data and structure refinement for 70 
Identification code    e15cfg1 
Empirical formula    C28 H35 Fe2 N O 
Formula weight    513.27 
Temperature     150(2) K 
Wavelength     0.71073 Å 
Crystal system     Monoclinic 
Space group     P 21/n 
Unit cell dimensions    a = 11.2994(3) Å   α= 90°. 
b = 16.8718(5) Å  β= 98.365(3)°.  
c = 12.6013(4) Å   = 90°. 
Volume     2376.77(12) Å3 
Z      4 
Density (calculated)   1.434 Mg/m3 
Absorption coefficient   1.241 mm-1 
F(000)     1080 
Crystal size    0.500 x 0.350 x 0.060 mm3 
Theta range for data collection  3.484 to 29.339°. 
Index ranges     -15<=h<=12, -21<=k<=17, -14<=l<=16 
Reflections collected    18871 
Independent reflections   5612 [R(int) = 0.0301] 
Completeness to theta = 25.242°  99.7 % 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   1.00000 and 0.85628 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters  5612 / 0 / 293 
Goodness-of-fit on F2    1.031 
Final R indices [I>2sigma(I)]   R1 = 0.0316, wR2 = 0.0623 
R indices (all data)    R1 = 0.0458, wR2 = 0.0668 
Extinction coefficient    n/a 





Crystal data and structure refinement for 73 
Identification code   k15cgf5 
Empirical formula    C28 H33 Br2 Fe2 N O 
Formula weight    671.07 
Temperature     150(2) K 
Wavelength    0.71073 Å 
Crystal system    Monoclinic 
Space group     P21/n 
Unit cell dimensions    a = 12.41410(10) Å  α= 90°. 
b = 16.8699(2) Å  β= 99.5089(5)°. 
c = 12.80360(10) Å γ = 90°. 
Volume     2644.55(4) Å3 
Z      4 
Density (calculated)    1.685 Mg/m3 
Absorption coefficient    4.141 mm-1 
F(000)      1352 
Crystal size     0.500 x 0.300 x 0.200 mm3 
Theta range for data collection  3.212 to 30.019°. 
Index ranges     -17<=h<=17, -23<=k<=23, -18<=l<=18 
Reflections collected    55114 
Independent reflections  7696 [R(int) = 0.0621] 
Completeness to theta = 25.242°  99.6 % 
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmission   0.455 and 0.229 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters  7696 / 1 / 311 
Goodness-of-fit on F2    1.029 
Final R indices [I>2sigma(I)]   R1 = 0.0345, wR2 = 0.0836 
R indices (all data)   R1 = 0.0465, wR2 = 0.0900 
Extinction coefficient    n/a 





Crystal data and structure refinement for 72 
Identification code    k15cgf3 
Empirical formula   C28 H35 N O Ru2 
Formula weight    603.71 
Temperature     150(2) K 
Wavelength     0.71073 Å 
Crystal system     Triclinic 
Space group    P-1 
Unit cell dimensions   a = 10.31700(10) Å α= 105.4920(6)°. 
b = 11.00000(10) Å  β= 98.2650(6)°. 
c = 11.0550(2) Å γ = 99.1990(6)°. 
Volume     1170.32(3) Å3 
Z      2 
Density (calculated)    1.713 Mg/m3 
Absorption coefficient    1.312 mm-1 
F(000)      612 
Crystal size     0.350 x 0.250 x 0.200 mm3 
Theta range for data collection  3.073 to 30.029°. 
Index ranges     -14<=h<=14, -15<=k<=14, -15<=l<=15 
Reflections collected    26807 
Independent reflections   6812 [R(int) = 0.0494] 
Completeness to theta = 25.242°  99.8 % 
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   0.773 and 0.687 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  6812 / 0 / 293 
Goodness-of-fit on F2    1.106 
Final R indices [I>2sigma(I)]   R1 = 0.0325, wR2 = 0.0686 
R indices (all data)    R1 = 0.0442, wR2 = 0.0738 
Extinction coefficient    n/a 















































































































































HPLC-MS Traces of S1 nuclease digestions 
CT-6 
Digest to 113 
HRMS (ESI) calculated for C36H40Fe2N6O8P [M-H]-: m/z 827.1350, found 827.1364. 
 
CT-dC 
Digest to 112 
HRMS (ESI) calculated for C37H46Fe2N4O7P [M-H]-: m/z 801.1809, found 801.1813. 
 
